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ABSTRACT 
 
Cryptococcosis is one of the leading causes of the deaths among AIDS patients.  
The high mortality rates of cryptococcosis are mainly due to inadequate information of 
its major causative agent Cryptococcus neoformans and the limitations of current 
therapies.   
Cryptococcus neoformans is an unconventional dimorphic fungus that can grow 
either as a yeast or in a filamentous form.  To study this dimorphism that is critical to the 
pathogenicity of many fungi, we constructed the congenic a and  strains for XL280(α), 
a strain with robust ability to undergo the yeast-hyphal transition.  We compared the 
congenic strains in different in vivo models and found they are equivalent in virulence.  
Furthermore, deletion or overexpression of a known transcription factor Znf2 in XL280 
abolished or enhanced filamentation and biofilm formation, consistent with its 
established role.  Therefore, the congenic strains provide a new resource for the study of 
morphogenesis and the related virulence of Cryptococcus.  
Meanwhile, we searched for novel antifungals by screening of a clinical 
compound library.  Two hits from the screen, the antibiotic polymyxin B and the 
antidepressant sertraline are all potently fungicidal against Cryptococcus.  Polymyxin B 
works synergistically with the azoles both in vitro and in vivo, thus it may serve as an 
adjunctive therapy with fluconazole in clinic.  Our investigation on sertraline has 
implicated its unique advantage in treating cryptococcal infections since it is able to 
traverse the blood brain barrier and reduce the fungal burden in brains.  We further 
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examined the fungal target of sertraline and found that this compound inhibits the fungal 
protein synthesis. 
Taken together, the studies in this thesis facilitate further research on the 
pathogenesis of Cryptococcus and provide new antifungal drug candidates with clinical 
value. 
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CHAPTER I  
INTRODUCTION AND LITERATURE REVIEW 
 
As a result of the expansion of the immunocompromised population, invasive 
infections caused by opportunistic pathogenic fungi have become a severe threat to 
public health since the 1980s.  The three primary invasive mycoses, aspergillosis, 
candidiasis, and cryptococcosis caused by fungal species of Aspergillus, Candida, and 
Cryptococcus respectively, have mortality rates ranging from 10 to 90% (1-4).  The 
basidiomycetous yeast Cryptococcus neoformans is the major causative agents of 
cryptococcal meningoencephalitis, one of the leading causes of deaths among the AIDS 
patients (4).  According to the estimation from the Centers for Disease Control, over one 
million new cases of cryptococcosis are documented annually, and more than 0.6 million 
deaths are related to Cryptococcus infection worldwide (4).   
In contrast to many pathogenic microbes that are always associated with the host, 
Cryptococcus is a free living organism in the environment.  It is ubiquitous and people 
are exposed to this microbe since childhood.  Therefore it is unlikely to control the 
disease by preventing human exposure to this pathogen.  Therefore, a comprehensive 
understanding of mechanisms of fungal pathogenesis would provide a powerful platform 
to develop effective strategies for the prevention or the treatment of the disease.  
Cryptococcus has a defined sexual cycle, and several congenic pair strains with different 
genetic backgrounds had been developed (5-7), which enable the various genetic 
analyses on this organism.  The genome of several Cryptococcus strains with different 
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genetic background have been sequenced (8); and the partial genome deletion set in H99 
background with ~1100 genes disrupted is now available (9).  With these useful genetic 
tools, researchers have gained some substantial insight into its physiology and related 
pathogenicity.  The first section of this chapter reviews the life cycle, the infectious route 
and the virulence related factors of Cryptococcus. 
Cryptococcus tends to cross the blood brain barrier (BBB) and invade the central 
nervous system (CNS) during systemic infections, leading to the fatal meningitis (10).  
As the BBB dramatically blocks a vast number of compounds that can approach the 
brain, this neurotropic trait grants Cryptococcus a natural protection against most of the 
antifungals, which are already extremely limited in number.  Moreover, few 
immunomodulation methods such as application of IFN-γ as adjunctive therapy have 
showen positive therapeutic effect in preclinical or clinical trials (11).  Furthermore, 
there is still no vaccination to protect people from Cryptococcus infection.  Thus there is 
urgent need of new therapeutic methods to treat the disease.  The second part of this 
chapter reviewed current immunotherapy and chemotherapy methods against systemic 
cryptococcosis, as well as the progress in the development of novel antifungal 
compounds. 
 
1.1. The mechanisms of fungal virulence in Cryptococcus 
After first isolation from patients in 1894 (10), Cryptococcus has been studied for 
over a century.  Up to date, the Cryptococcus genus contains 37 recognized species, 
among which only two sibling species, Cryptococcus neoformans and Cryptococcus 
 3 
 
gattii, are the main causative agents of invasive mycosis.  According to the result of 
serological test and DNA fingerprint patterns, C. neoformans can be further classified 
into two subspecies including four serotypes: C. neoformans (further classified as 
serotype A var. grubii and serotype D var. neoformans) and C. gattii (further classified 
as serotype B and C) (12, 13).  C. gattii was reported to be closely associated with gum 
and eucalyptus trees and the infections caused by C. gattii were primarily found in 
immunocompetent people in Australia where eucalyptus trees are native (14).  However, 
most of the isolates from the recent epidemic outbreak of cryptococcosis in Vancouver 
Island and the Pacific Northwest of the United States among immunocompetent people 
also belong to this species (15), suggesting the expansion of geographical range for C. 
gattii.  C. neoformans, on the other hand, is frequently isolated from soil contaminated 
with pigeon guano (16).  C. neoformans is responsible for the vast majority of the 
clinical cryptococcosis cases worldwide, specifically areas where AIDS is prevalent, 
such as sub-Saharan African (4).  Although serotype A of C. neoformans is 
predominantly sampled from patients and responsible for over 90% of the 
cryptococcosis worldwide (17-20), the two serotypes in general share similar life cycles 
and virulence factors, which will be discussed in the following sections. 
1.1.1. Life cycle and sexual reproduction  
Before 1960s, Cryptococcus neoformans was considered strictly locked in the 
yeast form with only asexual reproduction (21).  Later studies have demonstrated that 
Cryptococcus has a defined bipolar mating system that is controlled by a single mating 
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type locus with two opposite alleles, a and α; and Cryptococcus is capable of undergoing 
a morphotype transition from the yeast to the filamentous form during mating (21).   
The mating event in Cryptococcus is usually triggered by nutritional limitation 
and other environmental stimuli, such as desiccation or inositol from plants (16, 22).  As 
the upper panel of Fig. 1 shown, the haploid a and α cells recognize each other by 
sensing the presence of α and a peptide pheromones, respectively, and fuse to form 
heterokaryon cells (23, 24).  This further leads to the development of dikaryon hyphae, 
where the two parental nuclei remain separate and migrate coordinately via the clamp 
connections between adjacent hyphal compartments during filamentous elongation (23, 
24).  The tips of aerial hyphae will enlarge and form basidia, where the two nuclei fuse 
and further undergo a single meiotic event to generate four haploid nuclei followed by 
multiple rounds of mitosis to form four chains of basidiospores (23, 25).  The 
basidiospores are more tolerant to the harsh conditions and will geminate under suitable 
environment (26).  Spores are also considered the infectious particles of Cryptococcus.  
The size of spores (1 ~ 2 μm) is smaller than normal yeast cells (3 ~ 5 μm), which 
renders them easier to disperse and lodge at the alveoli of the lungs (26, 27).   
The a-α mating process results in an equal proportion of a and α spores.  
However, both clinical and environmental isolates of Cryptococcus tend to highly tilt 
towards the α (>99%), despite the fact that there is no advantage of α mating type stains 
in either germination or stress resistance (10).  This conundrum is at least partially 
attributed to the complexity of its mating behavior: besides the traditional bisexual 
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mating, some haploid Cryptococcus strains are also able to undergo monokaryotic 
fruiting, a self-filamentation event followed by sporulation (28-30).   
 
 
 
Figure 1  The life cycle of Cryptococcus   
The upper part describes the process of bisexual mating that involves partners of the 
opposite mating types (a and α), and the lower part shows the process of unisexual 
mating that occurs with itself or involves partners of the same mating type.  
 
 
Monokaryotic fruiting was considered as an asexual event due to the lack of the 
opposite mating partner in the process.  Therefore, it is striking that high frequency of 
genetic recombination and ploidy change during fruiting was observed (30).  In addition, 
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mutation of the meiosis-specific factor Dmc1 or Spo11 severely hampers sporulation and 
the germination rate of spores (30).  Taken together, the evidence suggests that 
monokaryotic fruiting is a novel form of sexual reproduction – unisexual mating – in 
Cryptococcus.   
In contrast to the bisexual mating, which requires the opposite mating partners, 
unisexual mating only involves cells of one mating type (Fig. 1 lower part).  In response 
to similar environmental stimuli for bisexual mating, haploid cells undergo 
diploidization by either endoduplication or nuclear fusion after cell fusion of two cells 
with same mating type (24).  The single nucleus will not be transferred during the 
development of hyphae, which will remain monokaryotic until the formation of the 
basidium.  The diploid nucleus undergoes meiosis in basidium to form four recombinant 
haploid basidiospores (23).  The benefit of unisexual mating is obvious: it provides 
Cryptococcus an alternative resource to create genetic diversity, which grants the species 
advantage in survival in changing environment.   
Notably, the efficiency of both bisexual and unisexual mating varies a lot among 
different subspecies of Cryptococcus.  For bisexual mating, although observed in all 
serotypes of Cryptococcus, Serotype D in general is robust in mating (31); and most C. 
gattii isolates (serotype B & C) from diverse sources are sterile under laboratory 
conditions (32).  Unisexual mating has only been observed under laboratory conditions 
among some serotype D strains, and the frequency of unisexual mating among a isolates 
is much less than that of α isolates (29, 30).  However, homozygous of mating type locus 
has been detected among natural isolates of Cryptococcus (33), which could potentially 
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serve as intermediate during unisexual mating; and genetic recombination has been 
equally detected in the a-α mixed and solo α populations (34).  Population genetic 
studies also suggest that some of the natural diploid serotype A strains are derived from 
the fusion of two distinct α mating type strains (35).  Such evidence strongly implicates 
the presence of unisexual mating of Cryptococcus in nature.  Moreover, although C. 
gattii strains were thought to be sterile in general, the highly virulent isolates from the 
cryptococcosis outbreak on Vancouver Island can mate robustly; and a diploid α mating 
type strain was identified, suggesting the origin of the hypervirulent strain might be 
derived from unisexual mating (15). 
It is necessary to point out that there is no evidence of either bisexual or 
unisexual mating behavior during cryptococcal infection.  In fact, in vivo conditions of a 
mammalian host (e.g. the high body temperature), are prohibitory to the yeast-hyphae 
transition that is associated with mating.  Thus mating is less likely to occur directly in 
response to the selective pressures from the host.  Since this free-living organism infects 
humans by accident, it is plausible that mating provides an essential platform for 
generating diverse traits to combat with environmental pressures, which may include 
one(s) that is/are also crucial to the development of infection in host.  This speculation 
has been supported by a similar regulon of gene expression profile when Cryptococcus 
interacts with Acanthamoeba castellanii or macrophage from a recent comparative 
transcriptome analysis (36).  In addition, some classic virulence factors of Cryptococcus, 
such as capsule or melanin, play a protective role against multiple stresses in 
environment, which will be reviewed in the next section. 
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1.1.2. Infection cycles and virulence factors 
1.1.2.1. Infection cycles 
In natural conditions, Cryptococcus is usually associated with soil contaminated 
by bird excreta (C. neoformans) or with some tree species (C. gattii) (37).  The infection 
of Cryptococcus can occur in human and other domestic or wild animals such as cats, 
dogs, koalas, mice, etc (10).  Spores and desiccated yeast cells of Cryptococcus may 
serve as air-borne infectious particles and be inhaled by the host, leading to the primary 
pulmonary infection.  There is no evidence indicating the transmission of this pathogen 
from human to human (10).  This facultative pathogen can be engulfed by alveolar 
macrophage or other local phagocytes.  Most immunocompetent individuals are able to 
clear the infection via efficient phagocytosis or suppress fungal growth to maintain it in 
a latent status (10).  Serologic studies suggest that the majority of people in areas where 
Cryptococcus is endemic have been exposed to this fungus since childhood; and the 
fungal cells are able to remain latent in lungs for decades (38).  However, under certain 
conditions, especially when the host immune system is compromised by HIV infection 
or certain chemotherapy, newly inhaled or latent fungal cells can replicate either 
extracellularly or even within the phagocytes and eventually escape the local 
sequestration.  The dissemination of cryptococcal cells via blood circulation further 
results in the infections in other organs, which usually includes the central nervous 
system and leads to fatal meningoencephalitis.   
The high rate of CNS invasion associated with Cryptococcus infection makes it 
distinct from other fungal pathogens.  This remarkable neurotropism of Cryptococcus 
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could be related to the enrichment of inositol in the brain, given that this fungus has 
developed a complicated inositol acquisition system and is capable to utilize inositol as 
the sole nutrition source (39). The favor of inositol by Cryptococcus can also be 
observed in environment since Cryptococcus is frequently isolated from plants with high 
inositol levels (22).  Meanwhile, the highly selective permeability formed by the tight 
junctions around the capillaries of BBB may play a dual role during infection: on the one 
hand, BBB prevents CNS from the damage by most neurotoxic molecules or infectious 
microbes; on the other hand, BBB also blocks the vast majority of antimicrobial 
compounds from reaching to the established infections in CNS.   
Investigators have speculated that Cryptococcus traverses across BBB by 
different mechanisms: direct invasion, the “Trojan Horse” strategy by which the yeast 
migrates into CNS within host macrophages, or both (40).  Some factors of 
Cryptococcus, including phospholipase B1, urease, and a recently identified 
metalloprotease, have been suggested to help this fungus penetrate BBB (41-43).  A 
bioimaging study shows that a urease-dependent crossing of BBB is always followed by 
a sudden stop of the fungal cells at the brain capillaries, which indicates the preparation 
of penetration (44).  Meanwhile, the “Trojan Horse” theory is supported by some 
indirect evidences that when infected by macrophages containing Cryptococcus cells 
intravenously, the murine host would develop meningitis faster, and that in the 
meningeal vasculature the fungal cells are found always associated with phagocytes (45, 
46).  A very recent study also suggests that a high rate of engulfment of Cryptococcus by 
macrophage in vitro is correlated with high brain fungal burden (47).  This study 
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indicates the positive role of macrophage in promoting the CNS invasion of fungal cells.  
In this thesis, we discovered a reduction of brain fungal burden due to the transcription 
factor Znf2 controlled morphological transition in Cryptococcus.  Our data suggest a 
new mechanism related to the fungal cell invasion to CNS. 
A primary question during the study of the pathogenesis of Cryptococcus is, how 
could an environmental organism become a major human pathogen (40)?  Although 
Cryptococcus is not naturally associated with human or other mammalian hosts, some of 
its endogenous traits may also have facilitated the establishment of infection in 
mammals.  For instance, the polysaccharides capsule and the dark melanin pigment are 
the two representative virulence factors which are critical in combating with both 
environmental stress and host defense. 
1.1.2.2. Capsule 
Cryptococcus is the only encapsulated fungal pathogen.  The polysaccharides, 
which are mainly composed of glucuronoxylomannan (GXM) and (GalXM), attach to 
the α-glucan of the fungal cell wall and form a highly negatively charged layer around 
the cell surface (10).  Capsule is produced constitutively, yet the production is drastically 
induced during infection (10).  A series of studies have revealed that capsule protects 
fungal cells from desiccation or natural predators, such as amoebae or nematodes (48-
50).  Moreover, high temperature, high level of CO2, serum, and other in vivo cues such 
as neutral to alkaline pH induces the formation of a much more robust layer of capsule.  
Mutants with defective capsule are always of low virulence (51-53).  Both the intact 
capsule coat and the shed capsule components promote the virulence of Cryptococcus.  
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The increase in the capsule size confers resistance to phagocytosis (54).  Furthermore, 
capsule is able to quench the cytotoxic free radicals and protect the fungal cells from 
lysosome digestion (55).  This extra layer on cell surface also conceals the antigenic 
components of Cryptococcus and prevents the recognition by the immune system.  In 
addition, the polysaccharides component, either within the intact capsule or on shedding, 
actively suppress the host immune response by inducing the production of IL-10, which 
has a broad suppressive effect on the immune system (56). Changes of the structure of 
capsule alter the ability of Cryptococcus to penetrate CNS (57).  Therefore, capsule 
promotes the virulence of Cryptococcus via protection from host stress and 
immunomodulation effect.  Interestingly, we found that capsule renders the fungal cells 
more susceptible to a potential antifungal candidate, polymyxin B, and this part will be 
discussed in Chapter III. 
1.1.2.3. Melanin 
Melanin is another well-characterized virulence factor of Cryptococcus.  This 
cell wall-associated dark pigment protects fungal cells from environmental damages, 
such as ultraviolet (UV) light, oxidizing agents and ionizing radiation (10).  Melanin 
contributes to the virulence of many pathogenic fungi (e.g. Aspergillus fumigatus, 
Paracoccidioides brasiliensis, and Cryptococcus) (58).  Cryptococcal melanin 
modulates the immune function by decreasing the rate of phagocytosis and/or altering 
the level of inflammatory cytokine production (59, 60).  Melanin is associated with the 
dissemination of Cryptococcus as the deletion of LAC1, a laccase gene in the 
biosynthesis pathway of melanin, restricts the fungal cells in the lungs in a murine 
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inhalation model of cryptococcosis (61).  In addition, melanin may contribute to the 
antifungal drug resistance by binding the compound, consequently reducing the drug 
concentration and decreasing the cell wall permeability (62).   
1.1.2.4. Mating type locus  
Besides the classical virulence factors discussed above, α mating type locus is 
also considered to be related to the pathogenesis of Cryptococcus.  This point of view up 
for debate since it is difficult to specify the contribution of virulence from an individual 
gene in the mating type locus.  Analyses of genomic sequence show an unusual 
complicated mating type locus (>100kb) of Cryptococcus.  The mating type locus 
contains around 20 genes encoding pheromones and some components of pheromone 
sensing pathway (63).  A few of the genes in mating type locus such as the p21-activated 
kinase Ste20 and transcription factor Ste12 have some impact on virulence (64).  
However, most of these genes are dispensable for virulence (65, 66).  In addition, there 
is a uniformly increased expression pattern of genes in mating type locus during the 
early stage of phagocytosis (67).   
Meanwhile, mating type locus has been proved to be a quantitative trait locus and 
the α allele significantly promotes unisexual mating (68).  It is proposed that the 
enhanced ability of unisexual mating and the production of spores among α isolates 
contributes to the predominance of the α mating type in both the environmental and the 
clinical isolates.  Meanwhile, higher frequencies of genetic recombination among α 
strains than a strains also increase the possibility to generate more α progeny with 
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infectious potential.  Therefore, this enhanced level of unisexual mating associated with 
the α mating type locus may indirectly contribute to the virulence of Cryptococcus. 
In addition, whether the mating type locus has an allelic affect on the virulence is 
still under debating.  This question will be further studied via a newly developed 
congenic pair strains of Cryptococcus in Chapter II. 
1.1.3. Morphogenesis and virulence 
The morphological switch between yeast and hyphae is commonly observed 
among pathogenic fungi and closely related to virulence.  For instance, the classic 
dimorphic fungi Histoplasma capsulatum and Blastomyces dermatitidis undergo 
morphological transition in response to the environmental temperature changes: The 
filamentous form is found in nature where the temperature is low, while the yeast form is 
always associated with infection in the host where the temperature is high(69, 70).  By 
contrast, the hyphal formation of Candida albicans is always related to infection and 
tissue tropism in vivo (71).  These morphological changes have crucial impacts on the 
fungal virulence in many steps of host-pathogen interactions such as adherence, tissue 
tropism, dissemination, and resistance to antimicrobial immune response (72-74).  It is 
worth to note that in addition to the physical aspects of morphogenesis, alterations in cell 
surface molecules during morphogenesis could change the interaction between the 
pathogen and the host, and consequently shape the outcome of fungal infections. 
Although comparisons of cryptococcal strains indicate a wide range in their 
capabilities to undergo filamentation, intensive research in the past four decades on the 
pathogenesis of Cryptococcus has been focused on the yeast isolates and without much 
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consideration of other morphotypes because yeast form is predominantly observed in 
vivo.  Recently, a series of studies have demonstrated that Cryptococcus species could 
undergo different types of morphological transition.  These morphotypes include giant 
cells that are strongly anti-phagocytic (75-77) and filamentous cells (pseudohyphae or 
hyphae) (28, 78-80), both of which impact virulence.  Interestingly, the pseudohypha or 
the hypha form of Cryptococcus attributes negatively on disease development and 
induces a protective response from the host (81-83).  This is consistent with earlier 
studies in 1960s and 1970s that purified filaments inoculated via various routes (e.g., 
intraperitoneally, intravenously, or intracranially) were found to be either avirulent or 
significantly attenuated in virulence compared to yeast cells purified from the same 
strains (28, 79, 82, 84-86).  Moreover, animals inoculated with filaments develop 
immunity against cryptococcosis (83, 87).  It was proposed that the reduced virulence 
associated with pseudohyphae or hyphae of Cryptococcus is due to stronger host 
immune responses elicited by this morphotype.  Thus, understanding the molecular 
mechanism of morphotype transition and virulence will help identify novel antifungal 
targets or means to modulate host immune response against cryptococcosis.   
The most common occurrence associated with hypha formation in Cryptococcus 
is during mating, either bisexual or unisexual mating.  However, the key components in 
the mating signaling pathway have no or minimal direct influence on virulence.  This is 
not unexpected since the host relevant conditions (aqueous environment, high 
temperatures, and high levels of CO2) are drastically contrary to mating-inducing 
conditions (desiccation, low temperature, and low levels of CO2).  A key regulator of 
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morphogenesis in Cryptococcus, the transcription factor Znf2, has been identified 
recently (66, 81).  Deletion of ZNF2 locks cryptococcal cells in the yeast phase and the 
constitutive expression of ZNF2 strongly promotes filamentation even in mating-
suppressive conditions, indicating that the regulation of filamentation is independent of 
the mating signaling pathway (81).  Moreover, the constitutive expression of ZNF2 
abolishes the fatality caused by cryptococcal infection in murine models (81).  Therefore, 
Znf2 bridges the sex-independent morphotype transition and fungal pathogenicity.  
Further microarray study suggests that the 23% of genes differentially expressed in the 
znf2Δ mutant encode secretory proteins.  Consistently, overexpression of ZNF2 strongly 
promotes cell aggregation, suggesting that the alteration of cell surface could potentially 
change the interaction between the host and the pathogen.  Cfl1, one of the secretory 
proteins regulated by Znf2, not only influences the virulence of Cryptococcus but also 
serves as a paracrinal signal promoting filamentation and biofilm formation (81, 88).  
Notably, the deletion of CFL1 cannot abolish hyphal formation or cell aggregation 
elicited by Znf2 (88).  These studies revealed the complexity of regulation of 
morphogenesis and morphotype transition-related virulence in Cryptococcus.   
1.1.4. Summary and thesis research 
In this section, the life cycle, infection cycle and virulence related factors of 
Cryptococcus have been reviewed.  The Cryptococcus species are free living organisms 
that ubiquitously exist in the environment.  Given this nature, the environmental cues, 
rather than host relevant factors are likely to be the main selective pressure that drives 
the evolution of this organism.  The major virulence factors such as capsule and melanin 
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all possess significant values in combating with harsh environmental conditions or 
natural predators.  The sophisticated mating system of Cryptococcus suggests that the 
impact of genetic diversities created by mating, particularly the unique unisexual mating, 
on fungal virulence is more profound.  The yeast-hyphal transition of Cryptococcus also 
possesses its own value during the infection.  The morphotype transition associated cell 
surface modification has uncovered a set of adhesive proteins as well as other factors 
that potentially could serve as a new reservoir for vaccine or adjuvant candidates.   
Both unisexual mating and morphology associated pathogenicity are primarily 
deciphered recently.  Their significance elicits research interests on further 
characterization of the molecular mechanisms.  However, several classic reference 
strains of Cryptococcus like B3501/JEC21 (serotype D) or H99 (serotype A), are not 
capable of undergoing unisexual mating and are restricted in the yeast morphology.  
Therefore, genetics sources related to these strains, such as congenic strains or knock-out 
mutant collections, are not suitable for the study on unisexual mating or morphotype 
transition, which impedes the investigation on these fields.   
Congenic pair strains are genetically identical in genome except the opposite 
mating type locus.  They are essential source for genetic analysis of the molecular 
mechanism of fungal virulence of Cryptococcus.  Previously a sibling strain of JEC21, 
XL280, was generated and found to be able to undergo self filamentation and unisexual 
mating (30).  This strain could serve as another standard stain for the study on the 
mechanism of unisexual mating as well as morphotype transition.  In order to fully 
utilize this strain in the future research, in Chapter II we generated the congenic strains 
 17 
 
of XL280 by backcrossing.  This chapter also includes virulence analyses of mating type 
locus and the impact of Znf2 on XL280 background. 
  
1.2. Current therapeutic options against systemic cryptococcosis 
As reviewed in the first section, cryptococcosis is one of leading cause of death 
among AIDS patients in Africa.  The emergence of highly virulent isolates in the 
outbreak of cryptococcosis in Northwest Pacific area sets another alert to the public 
health.  The high mortality rate of cryptococcal meningitis ranges from 10% to 70% 
even with antifungal therapy (4).  This unsatisfied outcome is largely due to the 
inadequate source of either immunotherapy or chemotherapy.  The following content 
will review current immunotherapy and chemotherapy of cryptococcal infections, as 
well as the progress on the exploration of new antifungals. 
1.2.1. Immunotherapy of cryptococcosis 
Research on most of immunomodulation strategies against cryptococcal infection 
could not provide promising evidence to support clinical application.  Due to the lack of 
understanding on the host-pathogen interactions, especially the dominant antigens of 
Cryptococcus, there is no vaccine commercially available or even in clinical trial (89).  
Preclinical and clinical studies suggest an ambiguous role of passive immunization with 
monoclonal antibody against capsule component: depending on the different dosage of 
antibody or host parameters, the antibody mediated effect may be protective, non-
protective, or even disease exacerbation (90-92).  A series of studies described the 
benefit of a radioimmunotherapy treatment for cryptococcosis, which is to use 
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radiolabelled monoclonal antibody to locate and deliver cytotoxic radiation to the 
infectious site (93).  This method has been shown to result in a prolonged survival as 
well as fungal burden reduction on a murine model of cryptococcosis (93).  Although 
further study suggests a relative mild side effect of this method (94), the influence of 
radioactive agent in vivo requires further examination.  The most promising clinical trial 
of immunotherapy is from a clinical phase II study where adjuvant recombinant IFN-γ1b 
is applied on HIV-associated cryptococcal meningitis patients, and yields a higher rate of 
negative cerebrospinal fluid culture comparing with the control group (11).  Taken 
together, the immunotherapies against cryptococcal infections require further 
investigation with better understanding of host-pathogen interactions.   
1.2.2. Antifungal compounds for treating systemic fungal infection 
Chemotherapy is the most widely-used treatment for cryptococcal infections in 
clinic.  Sadly, the arsenal of current antifungal compounds is extremely limited in 
number, especially comparing with that of compounds available to bacterial infections.  
Only three classes of compounds – polyenes (amphotericin B), azoles (triazoles, 
particularly fluconazole), and echinocandins (caspofungin) - are applied in the treatment 
of systemic fungal infections.  The emergence of drug resistance with the wide-spread 
use of antifungals further exacerbates the problem.  Currently, the standard regimen for 
AIDS-related cryptococcal meningitis starts with a two-week induction treatment of 
amphotericin B, either alone or in combination with flucytosine, followed by a 
consolidation and a lifelong maintenance antifungal therapy with fluconazole (95).   
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1.2.2.1. Amphotericin B 
Amphotericin B was discovered in 1950s as the first classified antifungal 
compound for treatment of systemic fungal infection (96).  It is natural product 
derivative from the actinomycetes Streptomyces nodosus (97).  The compound directly 
binds to ergosterol, the primary sterol on fungal membrane (analogous to cholesterol in 
mammalian cells) (97).  The integrity of fungal membrane is disrupted, leading to the 
leakage of ions such as potassium and sodium and eventually cell death (98).  
Amphotericin B is applied as the primary treatment for invasive mycoses for over 50 
years mostly due to its potent fungicidal effect toward a broad spectrum of pathogenic 
fungi such as Cryptococcus and Candida species.  Resistance to amphotericin B is rarely 
observed among Cryptococcus isolates.  However, the application of amphotericin B is 
hampered by its limitations.  Firstly, amphotericin B is still able to bind cholesterol with 
lower affinity in mammalian cell membrane.  It cause strong nephrotoxicity that may 
lead to renal insufficiency and other acute toxicity including nausea, vomiting, rigors, 
and fever (99).  Although a liposomal form of amphotericin B would partly reduce the 
side effects (100), this compound is still preferred only as the induction treatment.  
Secondly, the poor aqueous solubility of amphotericin B sharply limits the delivering 
methods.  Trials with methods other than intravenous administration all failed to achieve 
equivalent efficacy (101).  Therefore amphotericin B is not suitable for outpatient 
treatment and is restricted to hospital setting.  Thirdly, amphotericin B is non-permissive 
to CNS where cryptococcal cells tend to infect.  Due to this poor penetration of BBB, 
negative brain culture after the induction therapy often cannot be achieved in many 
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patients (95, 102), and 20-60% of AIDS patients experience relapse without maintenance 
therapy (103).  These deficiencies of amphotericin B restrict it only in induction therapy 
to treat cryptococcal meningitis. 
1.2.2.2. Fluconazole 
Fluconazole, as well as other triazoles, targets the cytochrome P450 enzyme 14α-
demethylase in the ergosterol synthesis pathway (104, 105).  There are four triazole 
antifungal compounds that are clinically available: fluconazole, itraconazole, 
voriconazole, and posaconazole, among which fluconazole is the first and most widely-
used one.  Fluconazole is introduced to clinic in the early 1990s and is mostly favored in 
prophylactic, therapeutic, and maintenance application to treat cryptococcal meningitis 
(3, 95, 106, 107).  It is well-tolerant in patients and efficiently penetrates CNS.  In fact, 
fluconazole and voriconazole (another triazole compound) are the only two clinical 
available agents that can penetrate BBB and be solely used to treat the CNS cryptococcal 
infection (108, 109).  However, the fungistatic nature of fluconazole significantly 
compromises its application.  In the study of this thesis, we find some environmental and 
clinical isolates of Cryptococcus is intrinsically resistant to fluconazole; and the long-
term fluconazole therapy on AIDS patients creates selective pressure for the pathogen to 
develop resistance (110-113).  According to a recent report, fluconazole resistance 
occurs to around 30 percent of cryptococcosis patients who have never been exposed to 
this compound before treatment (114).  Several molecular mechanisms attribute to the 
fluconazole resistance in various fungal species, including enhanced expression of the 
multidrug transporters (115, 116), point mutations and the related high expression level 
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of the 14α-demethylase encoding gene (117), and increased drug efflux by positive 
regulation of efflux pump genes (118, 119).  Some non-genetic factors such as biofilm 
formation also promote the drug resistance against azoles (120, 121).  Among these 
diverse mechanisms, the intrinsic heteroresistance is most commonly observed in 
Cryptococcus (122).  Heteroresistance describes the emergence of a fluconazole resistant 
minor subpopulation.  It results from a transient duplication of whole chromosomes 
harboring the fluconazole resistance relevant genes (123, 124).  Although several newly 
commercialized triazoles such as voriconazole and posaconazole display dramatic 
enhanced potency against many fungal species (125), they still have the same fungal 
target and maintain the fungistatic nature. 
1.2.2.3. Echinocandins 
Echinocandins are a class of newest developed antifungals.  They targets the 
fungal cell wall integrity by inhibition of the β-glucan (major cell wall component) 
synthase Fks1 (126).  Caspofungin is the first commercialized compound in this class of 
antifungals (126).  Although potent against candidiasis and aspergillosis, echinocandins 
demonstrate no clinical activity against cryptococcosis (126-128).  Interestingly, the 
FKS1 homolog gene in Cryptococcus is essential and the enzymatic activity of the 
encoding product is inhibited by echinocandins in vitro (129, 130).  Therefore, the 
resistance of Cryptococcus against echinocandins is less likely due to the altered 
sensitivity of β-glucan synthase.  It is possible that other factors of Cryptococcus, such 
as capsule or melanin, may restrict the access of the compound to the intact cryptococcal 
cells.  
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1.2.2.4. The combination of antifungals during therapy 
As the variety of compounds for the treatment of invasive mycoses is extremely 
limited, people seek different drug combinations to increase the potency as well as the 
diversity of antifungal treatment.  One successful example of this strategy is the 
combination of amphotericin B and flucytosine as the induction treatment for 
cryptococcal meningitis.  Either amphotericin B or 5-flucytosine has its own advantage 
and severe deficiency: amphotericin B is highly potent against Cryptococcus but poor at 
CNS penetration (131); 5-flucytosine inhibits the fungal DNA or RNA synthesis and 
frequently induces drug resistance in fungi when used as monotherapy, yet it penetrates 
well in most body sites including CNS (132).  Therefore, amphotericin B and flucytosine 
complements each other when combined.  Notably, antagonistic effect has also been 
observed among commonly prescribed antifungals.  For instance, fluconazole and 
caspofungin are the two most widely used compounds in treating infections caused by 
Candida albicans, however, the combination of them tends to be antagonistic especially 
to the Candida albicans biofilms (133).  This antagonism could happen at either 
simultaneous or sequential administration of the two compounds (134), which further 
compound the outcome of clinical treatment.  Therefore, for a novel antifungal candidate, 
it is necessary to test the drug combination effect with current frequently used antifungal 
compounds. 
In the Chapter III and Chapter IV of this thesis, beside the evaluation of the 
efficacy of the two antifungal candidates by themselves, we further discussed the effect 
of their combination with fluconazole, which is the most frequently and long-term used 
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antifungal.  Our data indicate different scenarios of the two compounds working together 
with fluconazole. 
1.2.3. Novel antifungal development 
As the limitation of clinically available antifungals greatly hampers the efficacy 
of current treatment against cryptococcosis as well as other invasive mycoses, there is 
critical need of developing new antifungals with various drug targets and higher potency.   
Investigation on the de novo synthesis of novel antifungal drug as well as screen 
of new natural product derivatives  has made much progress: An arylamidine derivative 
T2307 that causes the fungal mitochondria membrane collapse shows high efficacy in 
vitro and in vivo on Candida spp. and is now on clinical trial (135-138); E1210, an 
isoxazole derivative that targets the biosynthesis of the Glycosylphosphatidylinositol 
(GPI)-anchored protein on fungal cell wall, displays a broad antifungal activity in vitro 
as well as in animal models via oral delivery (139, 140); Occidiofungin, a natural 
derivative from Burkholderia contaminans, is also broadly fungicidal by induction of 
strong apoptosis of cells with no obvious toxicity in an animal model (141-143).   
These preclinical results are encouraging in that these compounds are broadly 
potent against many fungal species.  More important, they suggest a diverged new set of 
fungal drug targets that are different from the current ones.  Thus the value of the 
research on these compounds is not simply restricted in the development of antifungal 
candidates.  They also provide new perspectives in future screening of chemical 
compound or natural product libraries.  However, the final clinical application of them 
remains questionable.  Because of the uncertainty of many features such as the body 
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tolerance or potential side effects, these novel compounds have to pass through strict 
tests and clinical trials to be final distributed, the process of which could select off most 
of the candidates and also take long period of time.  For instance, it took around 30 years 
for caspofungin to progress from bench to bedside (144).   
By contrast, drug repositioning, which is to discover the antifungal activity of 
drugs with other known functions, represents another strategy of searching new 
antifungals.  This strategy has unique advantages in acceleration of the application of 
new drug candidates, since there are well-established pharmaceutical and safety 
information of these compounds from previous studies.  Many successful examples of 
drug repositioning have been documented in various medical areas, such as to apply the 
antifungal itraconazole on therapy for non-small-cell lung cancer (145) and to use the 
antihypertensive compound minoxidil to prevent hair loss (146).  Several reports of 
antifungal drug repositioning have drawn research attention.  Cyclosporin A and FK-506 
are calcineurin inhibitors and serve as immunosuppressant in clinical use.  They also 
have been demonstrated to possess antifungal activity especially together with 
fluconazole (147).  Another example is the estrogen receptor antagonist tamoxifen that is 
for the breast cancer therapy.  In a murine model of candidiasis tamoxifen reduces the 
fungal burden in kidney and its antifungal activity has been attributed to the inhibition of 
calmodulin (148).  Recently, several in vitro and in vivo screens on alternative animal 
models have suggested the potential antifungal activity of over one hundred off-patent 
medication drugs (149, 150).  These discoveries of drug repositioning greatly facilitate 
the search of new antifungals. 
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1.2.4. Summary and thesis research 
Due to the lack of effective immunotherapy, the control of cryptococcosis purely 
relies on only a few unsatisfied antifungals: amphotericin B is used strictly during 
induction treatment due to its high toxicity and poor CNS penetration; fluconazole is 
able to access CNS but its potency is hampered by its fungistatic nature; and the newest 
antifungal echinocandins are not effective to Cryptococcus.  The emergence of drug 
resistance in clinic further compromises the efficacy of antifungals.  The limitations of 
current therapies against systemic cryptococcal infections have greatly undermined the 
outcome of treatment.   
Trials on novel antifungal compound development, including de novo synthesis, 
screen of natural products, and the drug repositioning all have made encouraging 
progress.  In order to find new compounds that can be used in clinical application, we 
employed the drug repositioning strategy and screened the Johns Hopkins Clinical 
Compound Library, which contains 1,514 FDA or foreign governmental agencies 
approved drugs.  In the screen, we have identified two repositioning candidates: the 
antibacterial polymyxin B and the antidepressant sertraline.  In Chapter III and IV, the 
antifungal activities of the two drugs have been evaluated both in vitro and in vivo.  Our 
data support their potential clinical value as antifungals.  Further studies also suggested 
new mechanisms of the antifungal activity of these compounds. 
 
 26 
 
CHAPTER II  
CONGENIC STRAINS OF THE FILAMENTOUS FORM OF CRYPTOCOCCUS 
NEOFORMANS FOR THE STUDY OF VIRULENCE TRAITS* 
 
2.1. Introduction 
To analyze the molecular mechanism of the virulence of Cryptococcus, 
researchers have developed a series of genetic tools including several congenic strains, 
which are genetically identical except the mating type locus (MAT). The first and widely 
used Cryptococcus congenic strains, JEC21α/JEC20a, were constructed in the 1990s and 
sequenced in the early 2000s (5, 8).  They were derived from two serotype D progenitor 
strains, NIH433 (a) and NIH12 (α) (151) (Fig. 2).  Both can cause fatalities in mice, with 
NIH12 displaying a higher level of virulence (10).  However, JEC21α/JEC20a often fails 
to cause mortality in infected mice, even with a high infection dose (1x107 cells/animal) 
and a long study period (152, 153).  Two other related serotype D congenic pairs, 
KN3501α/a and KN433α/a (Fig. 2), also exhibit low levels of virulence in an 
intravenous infection model of murine cryptococcosis (6). Studying cryptococcal 
virulence with these serotype D congenic pairs often requires long study periods (40 ~ 
>100 days), the unnatural intravenous inoculation, and relatively high infection doses 
(1x106 ~1x107 cells/mouse) (5, 6, 153, 154). 
                                                 
* This material has been published in this or similar form in Infection and Immunity and is used here with 
permission of American Society for Microbiology. 
Zhai B, Zhu P, Foyle D, Upadhyay S, Idnurm A, and Lin X. (2013) Congenic strains of the filamentous 
form of Cryptococcus neoformans for studies of fungal morphogenesis and virulence. Infect Immun 81(7): 
2626-2637. 
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The construction of the H99 congenic pair strains (KN99α/a) facilitated genetic 
analyses in the serotype A background.  Examination of cryptococcal virulence with 
H99-derived strains permits lower inocula (1x103 ~1x105), shorter study periods (≤ 40 
days), and the more natural inhalation route of infection (7, 153, 155).  However, rapid 
progression of the disease in H99-infected mice may present a challenge to detect a 
potential protective effect on animal survival of some drugs, including the commonly 
used antifungal fluconazole. Thus it would be valuable to have a well-characterized 
strain with a modestly lower virulence than H99. 
One general deficiency of current available congenic pair strains is that they are 
lack of the ability to develop hyphae in most culture conditions and undergo unisexual 
mating.  Although NIH12 is highly self-filamentous, none of the derived congenic pair 
strains undergo fruiting except stochastic fruiting observed in JEC21α (Fig. 2).  
Nonetheless, B3502a derived from a cross between NIH433 and NIH12 is self-
filamentous, and so are many progeny derived from a cross between B3501α and 
B3502a (68).  However, a congenic pair in a self-filamentous genetic background has 
not been constructed because of the technical challenges of dissecting spores generated 
from the bisexual mating rather than from fruiting (151). 
The congenic pair strains also facilitate the study on the direct influence of 
mating type locus on the virulence of Cryptococcus.  The results are varied by strain 
backgrounds: in serotype D strains, JEC21α is more virulent than its congenic pair strain 
JEC20a (5, 153), and KN433α is also more virulent than KN433a (6), while there was 
no difference in virulence levels between the congenic KN3501α and KN3501a strains 
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(6); in serotype A strain, KN99α and KN99a exhibit no difference in virulence when 
they infect mice individually via inhalation route, but KN99α appears to be more 
efficient in colonizing the brain during coinfection with a mixture of a-α cells (6, 7, 156); 
in a recent study on the congenic strains of C. gattii, AIR265α and AIR265a are 
similarly virulent in mouse models, and neither of the mating types confers any 
competitive advantages during in vitro coculture or during a-α coinfection in mice, 
regardless of the route of inoculation (intranasal or intravenous) (157).  One plausible 
reason to account for the observed differences between strains is that various genetic 
background of strains may contain factors located outside the mating type locus involved 
in controlling both virulence and mating behavior.   
In this chapter, we used a series of backcrosses to generate a pair of congenic α 
and a strains in the highly self-filamentous XL280 background. We characterized the 
behaviors of the congenic strains in vitro and in two mouse models of cryptococcosis, 
and further examined the impact of mating type on virulence and tissue tropism during 
a-α co-infection.  Furthermore, we tested the function of a known regulator, Znf2, in the 
XL280 background in cellular and colony development and the impact on fungal 
virulence.  This new strain set fills a missing resource for exploring morphology and 
pathogenesis in C. neoformans. 
  
 29 
 
 
 
Figure 2  Crossing strategies used to generate the congenic strains XL280a and 
XL280α in this study and their relationship with other C. neoformans congenic 
pairs 
NIH12 is a clinical isolate and NIH433 is an environmental isolate (5, 151).  B3501 and 
B3502 were generated from a cross between NIH12 and NIH433 and they were used to 
generate the first congenic pair JEC21 and JEC20 in 1992 (5, 151).  Two other congenic 
pairs in the genetic background of NIH433 and B3501 were generated in 2005 (6).  
XL280p was generated previously by crossing B3501 and B3502 and was found to be 
hyper-filamentous under a variety of nutrient limiting solid media (68). Based on Next 
Generation Sequencing analysis, the genome sequence of XL280 is 81% identical with 
JEC21 (158).  *: B3502 is near isogenic with JEC20 based on two previous studies (6, 
159). 
 
 
2.2. Material and methods 
2.2.1. Strains, crossing, and isolation of meiotic progeny 
Strains XL280p (α) and JEC20 (a) were used as the starting parental strains for 
crosses made in this study.  XL280p was generated previously from a cross between two 
serotype D strains B3501 (α) and B3502 (a) (68).  JEC20a is congenic with the 
sequenced strain JEC21α (151).  Strains were maintained on yeast extract-peptone-
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dextrose (YPD) medium. For long-term storage, strains were saved in 15% glycerol 
stock at −80°C.  Crosses were set up by mixing yeast cells of α and a mating partners 
together on V8 agar plates (5% V8 juice, 0.5 g/liter KH2PO4, 4% agar, with pH adjusted 
to 7 with KOH).  Because self-filamentation during the fruiting process on V8 media 
initiates later than the dikaryotic filamentation during a-α bisexual mating and because 
sporulation during fruiting is much less efficient, we chose to dissect the spores 
generated within 3 to 7 days to avoid complications due to sporulation generated from 
fruiting.  Filaments formed on the edges and tops of the mated yeast colonies, and 
basidiospores were transferred to YPD plates.  Spores were micromanipulated with a 
dissecting microscope, and their mating type was determined by successful mating of 
their derived colonies with either JEC20a or JEC21α.  The mating type of a few 
randomly selected progeny was also tested by the presence or absence of the mating 
type-specific genes STE20α and STE20a as previously described (35).  The results 
obtained by both approaches were consistent. 
2.2.2. Molecular markers 
The PCR-restriction fragment length polymorphism (RFLP) molecular markers 
used in this study were originally designed based on single nucleotide polymorphisms 
(SNPs) identified between B3501α and B3502a (nearly isogenic with JEC20a) (68, 159).  
Thirteen pairs of primers selected to include one on most chromosomes of C. 
neoformans were tested on strains JEC20a and XL280p (Table 1).  Eight of the 
combinations were different between these two parental strains, while five were identical, 
consistent with the close relationship between these two strains.  These eight markers 
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were also used to test the final congenic pair, XL280α and XL280a. The PCR amplicons 
were digested with the appropriate restriction enzymes, and fragments were resolved on 
1.4% agarose–1× Tris-acetate-EDTA gels. 
 
 
Table 1  RFLP markers used in comparing the parental strains XL280p and 
JEC20a 
 
Marker 
name 
Chromosome Primer sequences (5’-3’) Polymorphic 
Hind28 1 
GGTGTGCTACATCTCTTGGTTG 
No TCATCATGTCTCATGCAGCTTAC 
Eco23 2 
TATTTAGGTATGGCCGATTGTG 
No TGCCCAACTCTCTTCCTATTTC 
Pst19 3 
AACCTCGTGGAGTCTTTGTCC 
Yes CTGGATCATGGCTAGATGATTG 
Hind8 3 
CTTGATGCTCTTTATGGGGAAG 
Yes TGTGCCAAGGTTATGGAGATG 
Hind33 4 
AGTCACTCTGACACCTCAGTCG 
Yes CTTACTTGAAGACTCCCGTTCG 
Hind10 4 
CGGTATGTCAATGCTCTCAATC 
No TTTCTCCACCTCTGGAAACAAC 
Hind34 5 
AGTCCTCCTCTCCGGGTATTC 
Yes AGAGCAATGACCCTGTCCAC 
Hind13 6 GTGATCATGCAGAACTTGGTGT Yes CCGAGATGTCGAAGAAGAAGAT 
Hind19 7 or 8 GCCACTCTTCATTCTTCCTCTG Yes TCAACGCCTTCTTCTTCTTCTC 
Hind25 7 or 11 TCATAGTCTCGGCGTATGTCTC No ATGGGTTGGCTCTGTTTGTC 
Hind11 10 ATACGACATACAAGGAGGGTCTG Yes TGATTGACCTGCACAGAGAAAC 
Hind9 12 GGATTCGGCGTTCTATACAGTC Yes TTGCTGATTCAAGTTGTTGCTC 
Hind15 13 GCTATGTGCCTACTGCTACTGG No CCGACTCTGCTTCTCATACTTG 
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2.2.3. Pulsed-field gel electrophoresis 
Chromosomal DNA was profiled by contour-clamped homogeneous electrical 
field (CHEF) electrophoresis. The conditions for preparation of chromosomal DNA and 
its resolution followed methods described previously (159).  DNA was separated in a 
CHEF-DR III system (Bio-Rad) using the following conditions: block 1 was 75 to 150 s 
of switching with 4 V/cm at 12°C for 24 h, followed by block 2, which was 200 to 400 s 
of switching with 4 V/cm at 12°C for 24 h.  
2.2.4. In vitro phenotypic assays of the congenic and the parental strains 
Yeast cells were grown on YPD medium overnight and washed three times with 
water.  Cells were suspended in distilled water, and the cell density was determined by 
measuring the optical density at 600 nm.  Then cells were 10× serially diluted.  To 
characterize capsule production, equal numbers of C. neoformans cells were transferred 
to Dulbecco's modified Eagle's medium (DMEM) (Invitrogen, CA) and grown for 3 days 
at 37°C under 5% CO2.  The appearance of a mucoid colony indicates capsule 
production.  The capsule was visualized under light microscopy as a white halo 
surrounding the yeast cell in India ink due to the exclusion of ink particles.  To examine 
melanin production, cells were spotted onto melanin-inducing medium containing L-
dihydroxyphenylalanine (L-DOPA) (100 mg/liter) and incubated at 22°C in the dark for 
6 days.  Melanization was observed as the colonies developed a brown color.  To 
analyze growth on a minimal medium, cells were spotted onto yeast nitrogen base (YNB) 
medium.  To analyze resistance to osmotic and oxidative stresses, cells were grown on 
YNB medium supplemented with 1 M of NaCl or 1 mM H2O2, respectively.   
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2.2.5. The segregation of znf2 mutations in the XL280 strain background 
The ZNF2 gene, encoding a zinc finger transcription factor that controls 
filamentation and biofilm formation, was replaced by the nourseothricin 
acetyltransferase (NAT) marker gene (66).  The ZNF2oe strain was generated by 
expressing ZNF2 under the control of the promoter of the GPD1 gene linked with the 
G418 resistance marker gene in the znf2Δ mutant background.  These mutants in the 
XL280p (α) background were crossed with XL280a to isolate the mutations in the 
MATa background.  Dissected progeny were examined for their mating type by crossing 
with JEC21α or JEC20a on V8 medium: their resistance to the drug NAT and/or G418 
by growing them on plates containing YPD plus NAT plus G418 (YPD+NAT/G418 
plates), their ability to undergo self-filamentation on V8 medium, and their ability to 
form a complex colony morphology on YNB medium (81).  The ratios of these 
phenotypes in the progeny indicated Mendelian segregation of the mating type and each 
drug resistance marker. It also indicated the linkage between Znf2 mutations and their 
corresponding phenotypes. 
2.2.6. Virulence assays in two mouse models of cryptococcosis 
The animal models of systemic cryptococcosis were induced by two routes: 
intravenous and intranasal infection.  In each infection model, 9 or 10 8- to 10-week-old 
female A/J mice (Jackson Laboratory) were infected by each Cryptococcus strain and 
were considered one group.  All animals per group were used for the survival study, and 
five or six animals per group were used to examine the fungal burden.  For the 
intravenous infection, each mouse was challenged with 1.0 × 106 fungal cells suspended 
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in 50 μl of saline.  For the intranasal infection, animals were first sedated with ketamine 
and xylazine, and then 1.0 × 106 fungal cells (or 5 × 105 and 5 × 106 cells for the pilot 
experiment) suspended in 50 μl of saline were slowly inoculated into the left nostril of 
sedated animals.  After infection, animals were weighed daily and monitored twice a day 
for disease progression, including weight loss, gait changes, labored breathing, or fur 
ruffling.  Moribund mice were sacrificed, and their organs were dissected.  For the 
intranasal infection model, the lungs, brain, spleen, and the left kidney from terminated 
mice were harvested.  For the intravenous infection model, the brain, spleen, and the left 
kidney were harvested.  The dissected organs were homogenized in 2 ml of cold 
phosphate-buffered saline (PBS) buffer using an IKA* Ultra-Turrax T18 homogenizer 
with the same setting for each type of organ.  The tissue suspensions were serially 
diluted (10×), plated onto YNB agar medium, and incubated at 30°C for 2 days such that 
the colonies became visible to count CFU. 
For the examination of the impact of znf2 mutation in the XL280 background on 
cryptococcal virulence, animals were infected by the wild type, the znf2Δ mutant, and 
the ZNF2oe strain intranasally with the inoculum of 1.0 × 106 fungal cells per animal as 
described above.  Because the PGPD1-ZNF2 strain exhibits heterogeneity in cell 
morphology and its population is a mixture of yeast cells and filamentous cells, only 
cells in the yeast form were used for animal inoculation to obtain an accurate inoculation 
and to avoid potential problems caused by differences in cell types at initial infection.  
The PGPD1-ZNF2 strain culture with a mixed morphotype was centrifuged briefly at a 
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low speed to allow the enrichment of yeast cells on the top.  The top layer was then 
centrifuged again at a higher speed, and yeast cells were collected for infection. 
2.2.7. Examination of cellular morphology in vitro and during infection 
To examine cell morphology under culture conditions that are relevant to host 
physiology, strains XL280α, XL280a, and the mixture of equal numbers of XL280α and 
XL280a cells were inoculated into fetal bovine serum and RPMI liquid medium with a 
final cell density of 1 × 105 cells/ml.  Cells cultured in rich YPD liquid medium under 
the same condition were used as controls.  The cells were incubated at 37°C under 5% 
CO2.  Photographs of the cells were taken after 3 days of incubation. 
To examine cellular morphology of XL280 during infection, animals were 
infected with XL280 at the dose of 5 × 105 cells per mouse intranasally as described 
above. Moribund mice were sacrificed, and lungs, brains, and kidneys dissected from the 
sacrificed animals were fixed in 10% formalin, embedded in paraffin, sectioned at a 
thickness of 5 μm, and stained with Gomori methenamine silver (GMS).  Fungal cell 
morphology was then examined microscopically. 
2.2.8. In vitro growth competition assay between the congenic a and α strains 
The congenic strains XL280a and XL280α were grown in YPD liquid medium at 
30°C overnight and then washed three times with sterile water.  The cell density of the 
suspension of each strain was determined based on hemocytometer counting.  XL280a 
and XL280α cells of equal numbers were then mixed and inoculated into liquid DMEM 
to the final concentration of 1 × 105 cells/ml.  The initial inocula were confirmed by 
plating the XL280a and XL280α cell suspension prior to the mixing onto YNB medium, 
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and their CFU were counted after colonies became visible.  The a-α coculture in liquid 
DMEM was incubated at 37°C under 5% CO2.  Aliquots of the in vitro coculture were 
removed at days 3 and 9 of incubation and plated onto YNB plates with serial dilutions. 
Single colonies were randomly picked and examined for their mating type through 
crossing with reference strains JEC20a and JEC21α separately on V8 juice agar medium 
at 22°C in the dark.  These single colonies by themselves were included as the negative 
control.  The crosses were examined after 2 to 3 days.  Crosses with abundant hyphal 
formation and sporulation compared to the tested colony alone were scored as 
successfully mating with the reference strain. 
2.2.9. Congenic a and α coinfection in two mouse models of cryptococcosis 
Mice were challenged with a 1:1 ratio of XL280a and XL280α cells (1 × 106 
total fungal cells per animal) intranasally or intravenously.  The a and α cell numbers of 
the initial mixed inocula were confirmed by measuring the CFU of serial dilutions.  The 
ratio of a to α cells in the original inocula was confirmed based on the CFU of a and α 
cell suspensions prior to the mixing.  The organs of sacrificed mice were dissected and 
processed as described earlier.  To determine the ratio of the a to α cells in various 
organs, single colonies recovered from each organ dissected from terminated animals 
were scored for their mating type by crossing with the reference strains JEC20a and 
JEC21α as described above.  In total, more than 9,000 matings were performed and 
screened to examine the mating type distribution in different organs. 
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2.2.10. Statistical analysis 
Statistical significance of the survival data between different groups was assessed 
by the Gehan-Breslow Wilcoxon test.  The one-way analysis of variance (ANOVA) tests 
were used in the fungal burden studies.  Fisher's exact test was used to analyze the 
distribution of the a and α isolates during the in vitro coculture competition.  All 
statistical analyses were performed using the Graphpad Prism 5 program, with P values 
lower than 0.05 considered statistically significant. 
 
2.3. Results 
2.3.1. Generation of a congenic pair of strains in a C. neoformans filamentous 
background by a series of backcrossing 
We chose to use XL280 as the genetic background to generate a pair of congenic 
α and a strains that can undergo self-filamentation and unisexual mating for the 
following three reasons. (i) XL280 was an α progeny isolated from a cross between the 
non-filamentous B3501 and a filamentous B3502 strain (30, 68) (Fig. 2).  It is one of the 
most robust fruiting strains examined and it can self-filament on a variety of nutrient-
poor media (68).  (ii) A genetic map and the genome sequences for XL280’s parental 
strains B3501 and B3502 (near isogenic with JEC20a) are available (8, 151).  The 
genome of XL280 itself has been sequenced (158).  (iii) In the past few years since its 
creation, XL280 has already been used by several laboratories in a variety of studies (30, 
66, 68, 81, 160, 161).  Here we refer to this strain as XL280p to distinguish it from the 
congenic pair strains that will be described later.  
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Figure 3  The pedigree of the congenic pair strains XL280α and XL280a  
The progeny with the a mating type from a cross was selected at random and used for 
the next backcross with XL280p. The series of backcrosses gave rise to the congenic pair 
strains XL280α and XL280a. 
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Figure 4  Enhanced self-filemantation is associated with the mating type locus 
All progeny generated in the ten backcrosses (generation J) were examined for self-
filamentation on V8 juice agar medium at 22°C in the dark.  The parental XL280p strain 
was also cultured under the same condition for comparison. All the isolates examined 
produced filaments as robustly as the parental XL280p strain. By comparison, all the a 
isolates filamented relatively poorly, with strain to strain variations. 
 
 
We selected JEC20a as the donor for the a mating type locus for the congenic a 
strain because sequences of its mating type locus are available.  Furthermore, JEC20a is 
closely related to XL280p and the contribution of this particularly mating type allele in 
virulence has been tested in three other strain backgrounds (Fig. 2).  A progeny with an a 
mating type from a cross between XL280p and JEC20a was selected at random and then 
backcrossed to XL280p.  After additional 9 rounds of backcrosses between a randomly 
selected a progeny with XL280p, we obtained the strain pair XL280a (AIJ18) and 
XL280 (AIJ9) (Fig. 2; Fig. 3).  During backcrossing, we noticed that in multiple 
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generations  progeny in general underwent relatively more robust fruiting than a 
progeny (Fig. 4).  This observation is consistent with the previous study showing that the 
mating type allele is one of the most significant quantitative trait loci associated with 
enhanced self-filamentation (68).   
XL280p and JEC20a are siblings from crosses between B3501 and B3502. 
Hence, XL280p and JEC20a already share a large proportion of their genetic material 
based on their pedigrees (5, 151).  A comparison of the genome sequences of XL280p 
and JEC21α indicates that their genomes are 81% identical (158).  Thus after the cross 
between XL280p and JEC20a and 9 backcrosses to XL280p, in theory both XL280a and 
XL280 should be 99.98% identical to the parental strain XL280p, with the exception of 
mating type locus difference in XL280a. Consistently, when the 8 polymorphic markers 
between XL280p and JEC20a were tested on XL280 and XL280a, all their alleles were 
identical with XL280p (Fig. 5A), indicating that the genetic material from XL280p has 
been successfully incorporated into the congenic pair strains during the bisexual a-α 
backcrosses (a x XL280p). A comparison of the chromosomal profiles of these strains 
using CHEF gel analysis indicates identical chromosomal profiles between XL280p and 
the congenic pair of strains (Fig. 5B).  These results suggest no gross chromosomal re-
arrangement or insertions or deletions of large regions during the backcrosses.  The 
results are consistent with the stable phenotypes and genotypes observed in the related 
serotype D strains previously generated (Fig. 2). Thus XL280 and XL280a are 
considered congenic, differing at the mating type locus.  
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Figure 5  Genetic typing of the XL280 congenic pair strains   
(A)  After ten backcrosses, both congenic strains XL280 and XL280a (a) contain 
all the alleles from XL280p (X) rather than JEC20a (J). The molecular marker 
segregation indicates that genetic materials from XL280p were transferred to the 
congenic pairs during backcrosses.  DNA regions of the four strains were amplified by 
PCR, the products digested with the diagnostic restriction enzyme, and fragments 
resolved on agarose gels.  M = the Invitrogen 1 Kb+ markers, with a subset of sizes 
indicated in kilobase pairs. (B) CHEF analyses of chromosomal DNA from the congenic 
pair strains XL280 and XL280a (a), XL280p (X), and JEC20a (J) indicate identical 
chromosomal profiles between the congenic pair and XL280p. The MATa donor JEC20a 
shows a different chromosomal profile.  
 
 
We further examined the phenotypes of the congenic pair strains XL280 and 
XL280a in vitro.  As shown in Fig. 6, the congenic pair strains and their parental strains 
XL280p and JEC20a are all prototrophic, capable of growing on minimum YNB media.  
All the strains grew well and produced capsule visible under light microscope when 
incubated on DME medium at 37°C under 5% CO2, a condition that is relevant to the 
host physiology.  All strains produced melanin on L-DOPA medium and showed a 
similar level of resistance towards NaCl and H2O2.  Thus, no drastic difference was 
detected among the strains in respect to these in vitro phenotypes.  One apparent 
exception is their ability to undergo morphological switch. JEC20a is non-filamentous; 
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XL280a produces filaments profusely; and XL280α and XL280p are much more robust 
in self-filamentation (Fig. 6). 
 
 
 
Figure 6  In vitro phenotypic assays of the parental strains XL280p and JEC20a, 
and the two congenic strains XL280and XL280a  
Yeast cells of each strain were grown in liquid YPD medium overnight and serial 
dilutions (10-fold) of cells were spotted onto different media. Cells were grown on 
minimal YNB medium at 22°C for 3 days as a control for growth (first column from the 
left); cells were grown on DME medium at 37°C under 5% CO2 to assay growth under 
host-relevant conditions (2nd column) and capsule production (images below); cells were 
grown on the L-DOPA medium at 22°C for 6 days (3rd column) to assay melanin 
production (brown pigment); cells were grown on YNB supplemented with 1 M NaCl or 
with 1 mM H2O2 to assay resistance to osmotic stress (4
th column) or oxidative stress 
(last column). Self-filamentation of these strains on the L-DOPA medium is shown 
below. 
 
 
2.3.2. XL280p is virulent to mice and it grows as yeast during infection 
We performed pilot experiments to determine if XL280p is virulent to mice. We 
tested XL280p in the inhalation model with two infection doses (5x105 and 5x106 CFUs 
per animal) in two independent experiments and monitored animal survival for 40 days 
after the infections.  As shown in the Fig. 7A, most animals succumbed to XL280p 
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infection within 40 days post infection in both pilot experiments and the 10x difference 
in inoculum did not appear to have any drastic effect on animal survival.  This is similar 
to what has been observed in the serotype A strain H99, where lowering the infection 
inoculum by 100 fold results in only a short delay in causing mortality in mice both in 
the inhalation infection model and in the intravenous infection model .    
 
 
 
Figure 7  XL280p is virulent in the inhalation infection model of murine 
cryptococcosis and it grows as yeasts during infection  
(A) Each mouse was inoculated intranasally with 5x105 or 5x106 fungal cells of 
XL280p, and animal survival was monitored for 40 days.  (B) Mice were inoculated with 
5x105 fungal cells intranasally. Lungs, brains, and kidneys were dissected from 
sacrificed moribund mice, fixed, and processed for GMS staining to reveal fungal cell 
morphology in the organs (shown in black). 
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Although XL280p and its congenic pair strains have been observed to grow as 
yeast in various liquid media and in rich solid media (Fig. 6 and Fig. 8), these strains can 
grow in the filamentous form on solid substrates in vitro under a variety of nutrient-
limiting conditions (Fig. 6) (68).  To ascertain the cell morphology of XL280p during 
infection, we performed histological examination of the lungs (the initial site of 
infection), kidneys (a dissemination site), and brains (the site of fatal infection) of the 
XL280p-infected mice.  As shown in Fig. 7B, XL280p was in the yeast form in all the 
organs examined.  Thus, like most clinical isolates, XL280p does not generate hyphae in 
vivo, where it grows as yeast. 
 
 
 
Figure 8  The congenic strains maintained yeast growth when cultured under in 
vitro conditions that are relevant to host physiology   
Strains XL280α, XL280a, and the mixture of equal number of XL280α and XL280a 
were inoculated into fetal bovine serum, RPMI medium, or YPD medium with the final 
cell density of 1 × 105 cells/ml.  The cells were incubated at 37°C with 5% CO2. 
Photographs were taken after 3 days of incubation. All cells were in the yeast form and 
no filaments were observed. 
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2.3.3. The congenic pair strains show similar levels of virulence in two mouse models 
of cryptococcosis 
To examine the virulence of the congenic strains, we used the well-established 
inhalation and intravenous infection models of murine cryptococcosis.  We chose to use 
the intermediate inoculum of 1x106 fungal cells per animal for both models and included 
XL280p in the comparative virulence assays to determine if the virulence potential of the 
congenic pair differs from their background parental strain.  The congenic pair strains 
and XL280p caused 100% fatalities in infected mice within 6 days after being introduced 
into animals intravenously (Fig. 9B), and ~90-100% animal mortality rates within 40 
days post infection after being introduced into animals via the respiratory route (Fig. 
9B).  The XL280 congenic strains are thus much more virulent compared to other 
serotype D reference strains, which typically require 30-100 days at a similar or higher 
dose to cause significant mortality in mice even when these strains are introduced to 
animals intravenously (5, 6, 153).     
At the inoculum used in these experiments, we did not observe any difference in 
animal mortality caused by the parental strain XL280p and the congenic strains XL280α 
and XL280a in either the inhalation infection model (Fig. 9A) or the intravenous 
infection model (Fig. 9B).  The comparable virulence exhibited by the congenic XL280α 
and XL280a strains in these two animal models excludes the mating type locus as one 
major factor influencing cryptococcal overall virulence in this genetic background under 
the tested conditions.  The high similarity between XL280p and XL280α both in vitro 
and in vivo is consistent with the predicted isogenicity between these two strains. 
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Figure 9  The congenic strains XL280and XL280a have equal virulence with each 
other and the parental XL280p strain individually or co-infected together   
(A) Mice were inoculated with 1x106 fungal cells intranasally and their survival was 
monitored for 40 days. There was no difference observed in survival among the strains. 
The p values were 0.833 (XL280p/XL280α), 0.252 (XL280p/XL280a), 0.984 
(XL280p/a+α), 0.075 (XL280α/XL280a), 0.754 (XL280α/a+α), and 0.053 
(XL280a/a+α). (B) Mice were inoculated with 1x106 fungal cells intravenously and 
there was no difference among these strains.  The p values were 0.317 
(XL280p/XL280α), 0.317 (XL280p/XL280a), 1 (XL280p/a+α), 1 (XL280α/XL280a), 
0.317 (XL280α/a+α), and 0.317 (XL280a/a+α).  
 
 
2.3.4. The a-α co-infection in the inhalation infection model of murine cryptococcosis  
One interesting phenomenon of the C. neoformans serotype A congenic pair 
strains KN99a and KN99α is that the α strain tends to dominate in brain during mixed a-
α co-infection in the inhalation infection model, even though KN99a and KN99α are 
equivalent in virulence when used in infection individually (7, 156).  No a-α co-infection 
experiment has been performed for other congenic pairs, except the recently constructed 
C. gattii AIR265α and AIR265a strains.  AIR265α and AIR265a are similar in virulence 
when tested individually in both the inhalation and the intravenous infection models of 
murine cryptococcosis (157).  Further, neither the α nor the a mating type allele confer 
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any apparent advantages in terms of mortality or neurotropism in the AIR265 
background during a-α co-infection in either model of murine cryptococcosis (157).  
Here, we tested the impact of potential interactions between a and α cells on 
virulence in the inhalation infection model using the co-infection of the congenic pair 
strains.  As shown in Fig. 9A, the XL280a and XL280α co-infection exhibited similar 
dynamics in causing animal fatality as either the a or the α strain infection alone in the 
inhalation infection model.  Next, we examined the distribution of the a and α mating 
type in various organs during a-α mixed co-infection. We chose the unmarked XL280a 
and XL280α strains for this experiment to preclude the addition of any potential 
variation by the introduction of genetic markers to the mating type locus, as was 
employed in the previous study (156).  We performed an in vitro control to determine if 
there is any proliferation advantage conferred by one mating type when the a and α cells 
are co-cultured together under a condition that is host physiologically relevant.  We 
inoculated a mixture of a and α cells into the mammalian cell culture medium DME at 
37°C under 5% CO2 with the 1:1 ratio (51.5% a versus 48.5% α, n=822).  The a/α ratio 
in the co-culture was measured again after 3 days and 9 days of incubation.  At day 3 
post inoculation, there was 44.2% a and 55.8% α (n=95); at day 9 post inoculation, there 
was 46.5% a and 53.5% α (n=127).  Thus the a/α ratio maintained a 1:1 level in the co-
culture and there was no statistically significant difference among the time points 
examined (p = 0.273).  Therefore, neither the a nor the α mating type allele appears to 
confer any apparent growth advantage in the co-culture under this in vitro condition.  
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We then examined the mating type distribution in eight terminated animals 
infected by the a-α mixture (Fig. 10A).  We randomly picked ~ 96 colonies from each of 
the 32 organs (lungs, brains, kidneys, and spleens of the 8 animals) and determined their 
mating type.  We could not perform as many tests for some spleens due to the low 
numbers of fungal cells recovered (Fig. 10B).  As shown in Fig. 10A, there were 
uniformly more α cells than a cells recovered from lungs of all eight animals examined. 
The median percentile for α cells in the lungs was ~76% and for a cells 24%.  This 
uniform over-representation of α cells in the lungs during a-α co-infection likely reflects 
the better proliferation of α cells in the lungs, as there was higher lung fungal burden in 
animals infected by α cells alone than those infected by a cells alone at the time of 
termination (Fig. 10B).  In contrast to the uniform over-representation of α cells in the 
lungs during the co-infection, there was no consistent pattern of mating type distribution 
in other organs.  In the brain, a and α were roughly equal in 3 out of 8 mice, while a 
dominating in 4 mice and α dominating in 1 mouse.  In the kidney, there was an even 
split between α and a, with the a dominating in 4 mice and α dominating in the 
remaining 4 mice.  A similar even split between a and α was also observed in the spleen. 
The different pattern of the a and α distribution in these organs during a-α co-infection is 
consistent with the organ fungal burden.  Here, animals infected by the α strain showed a 
higher fungal burden in the lungs, but their fungal burdens in the brain, kidney, and 
spleen showed no statistically significant difference from those infected by a or the a-α 
mixture (Fig. 10B).  It is not clear why higher proliferation of α in the lungs did not 
cause higher fungal burden in other organs and why over-representation of the α mating 
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type in the lungs during the co-infection did not generate any obvious ripple effect in 
other organs since these organs were infected after extrapulmonary dissemination. 
 
 
 
Figure 10  The mating type distribution during a-α co-infection in the inhalation 
infection model of cryptococcosis   
(A) Animals were challenged with the mixture of a-α fungal cells (1x106/animal) by 
inhalation.  At the time of termination, lungs, brains, kidneys, and spleens from eight 
animals per group were dissected and homogenized. The mating type of randomly 
picked Cryptococcus cells recovered from each organ was determined.  (B) Animals 
were challenged with 1x106 fungal cells (α, a, or the a-α mixture) intranasally. At the 
time of termination, lungs, brains, kidneys, and spleens from five animals per group 
were dissected and homogenized. Serial dilutions of the homogenized tissue were plated 
and colony forming units (CFUs) were used to determine the organ fungal burden. The 
short lines indicate the median. The fungal burden of these groups was statistically 
different in the lungs (p = 0.001). No statistically significant difference was found 
among the groups in the brain (p = 0.973), the kidney (p = 0.110), or the spleen (p = 
0.575).   
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2.3.5. The a-α co-infection in the intravenous infection model of murine cryptococcosis 
We further decided to examine the outcome of a-α co-infection in the 
intravenous infection model whereby the pulmonary infection is bypassed.  As shown in 
Fig. 9B, the a-α co-infection exhibited similar dynamics in causing animal fatality as the 
infection by either the a or the α strain alone in this intravenous infection model. Here 
we tested the mating type of fungal cells recovered from brains, kidneys, and spleens of 
seven mice infected by the a-α mixture (21 organs in total).  As shown in Fig. 11A, there 
were slightly more α cells than a cells in the brains in all seven mice examined.  A 
similar slightly higher representation of α was also uniformly observed in other two 
organs in all seven mice.  The median α : a ratio was 6 : 4 in the brain, 6 : 4  in the 
kidney, and 5.5 : 4.5 in the spleen.  It is not clear why the minor advantages in 
amplification of α cells during co-infection in this intravenous model did not cause any 
apparent differences in terms of virulence among the α, a, or the α+a infections (Fig. 
9B).  We speculate that rapid progression of the disease caused by these intravenous 
infections (death within 6 days after infection) could potentially render such modest 
advantages not important for the animal survival.  Consistent with this speculation, the 
fungal burdens in all organs examined at 5 days post inoculation were all high (typically 
~ 106 CFU/organ in the brain, kidney, and spleen) and there were no statistically 
significant differences among the α, a, or the a-α mixture group in this intravenous 
model used in this study (Fig. 11B).  Neither of the mating type alleles appeared to 
confer any apparent advantage in neurotropism during individual infection or co-
infection under the tested conditions (Fig. 11B).  
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Figure 11  The mating type distribution during a-α co-infection in the intravenous 
infection model of cryptococcosis  
(A) Animals were challenged with the mixture of a-α fungal cells (1x106) intravenously.  
At the time of termination, brains, kidneys, and spleens from seven animals per group 
were dissected and homogenized. The mating type of randomly picked Cryptococcus 
cells recovered from each organ was determined.  (B) Animals were challenged with 
1x106 fungal cells (α, a, or the a-α mixture) intravenously.  At DPI 5 and also the time of 
termination, brains, kidneys, and spleens from five animals per group were harvested. 
Serial dilutions of the homogenized tissue were plated and colony forming units (CFUs) 
were used to determine the organ fungal burden.  The short lines indicate the median. No 
statistically significant difference was found among the groups in the brain (p = 0.370), 
the kidney (p = 0.410), or the spleen (p = 0.070). 
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2.3.6. Znf2 is a common factor that governs morphogenesis and mediates fungal ability 
to cause diseases in the varieties of Cryptococcus neoformans   
As XL280 can easily undergo the yeast- filament morphological transition on its 
own under appropriate culture conditions, XL280 could be particularly useful in 
facilitating the research into the factors that control morphogenesis and virulence in 
Cryptococcus.  As discussed in the first chapter, the morphotype-associated 
pathogenicity has been observed in C. neoformans (23, 66, 81, 162).     
We then decided to examine a known factor that controls morphogenesis to 
assess its impact on virulence in the XL280 background.  We chose to investigate the 
zinc finger transcription factor Znf2, as it was previously demonstrated to govern the 
yeast to filament transition in C. neoformans (66, 81).  In addition, this regulator governs 
the formation of complex colony morphology (biofilm) through its control of the 
expression of multiple cell surface proteins, including the adhesion protein Cfl1 (81).   
To examine the role of Znf2 in the morphotype transition in the XL280 
background, we inoculated yeast cells of the wild-type strain, the znf2Δ mutant, and the 
ZNF2
oe
 strain (PGPD1-ZNF2 in the znf2Δ mutant background) on YPD, YNB, and V8 
media and examined their self-filamentation.  As expected, the wild type strain did not 
filament on the rich YPD medium, produced rudimentary filaments on the YNB 
medium, and generated robust filamentation on the V8 juice media (Fig. 12A).  The 
deletion of ZNF2 abolished the ability of XL280 to produce any filaments under all 
conditions, while the overexpression of ZNF2 conferred more robust filamentation on 
both YNB and V8 media and enabled XL280 to produce some filaments in the otherwise 
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suppressive conditions of the YPD medium (Fig. 12A).  Thus, Znf2 directs self-
filamentation in the XL280 background.  It has been shown previously that filamentation 
during bisexual mating between znf2Δ mutant with a wild-type partner is significantly 
reduced due to a dose effect, and mating hypha production is completely abolished in 
crosses involving both znf2Δ mutant partners in the JEC21α/JEC20a or the 
KN99α/KN99a background (66).  A similar phenotype was also observed when ZNF2 
was disrupted in XL280 (Fig. 12C).  Disruption of ZNF2 in both partners in the XL280 
background also completely eliminated mating hyphae production (data not shown). 
Taken together, Znf2 is required for filamentation derived from either monokaryotic 
fruiting (self-filamentation) or from a-α bisexual matings.  In addition to its fundamental 
role in filamentation, Znf2 also controls biofilm formation in XL280 as indicated by the 
increasingly complex colony morphology with increased ZNF2 expression (the znf2Δ 
mutant < wild type < the ZNF2oe strain) (Fig. 12B). This phenotype is consistent with 
previous observations made in the serotype A H99 background (81). 
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Figure 12  Znf2 controls filamentation and the formation of complex colony 
morphology in XL280 background   
(A) The wild type, the znf2Δ mutant, and the ZNF2oe strain with the inoculum were 
cultured on complete YPD medium, minimum YNB medium, and V8 juice medium at 
22°C in the dark for 2 days.   Photographs of the colony edge were shown to display 
filamentation (fluffy edge) or yeast cells (smooth edge). (B) The wild type, the znf2Δ 
mutant, and the ZNF2oe strain with the inoculum were cultured on YPD and YNB media 
at 22°C in the dark for 4 days.  The wrinkled colony indicates the complex colony 
morphology. (C) The non-filamentous strain JEC20a was mated with the wild type, the 
znf2Δ mutant, and the ZNF2oe α strains on V8 juice agar medium. The mating mixtures 
were cultured at 22°C in the dark for 9 days before the photographs were taken. The 
white fluffy phenotype reflects aerial hyphal production in the mating colony. The 
culture of the wild type, the znf2Δ mutant, and the ZNF2oe α strains without a mating 
partner is shown below for comparison. 
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Previously we showed that the expression level of Znf2 is inversely linked to the 
ability of strain H99 to cause fatal diseases in the inhalation model of murine 
cryptococcosis.  That is, the ZNF2oe strain in H99 background was completely avirulent 
while the znf2Δ mutant was slightly more virulent than the wild-type H99 strain (66, 81). 
Here we tested wild type, the znf2Δ mutant, and the ZNF2oe strain in the XL280 
background in the inhalation model of murine cryptococcosis to assess the role of this 
regulator in virulence.  As shown in Fig. 13A, the overexpression of ZNF2 resulted in a 
significant attenuation in virulence.  However, the reduction in virulence of the ZNF2oe 
strain is not as dramatic in XL280 compared to that in H99 (66, 81).  We could not 
detect any statistically significant difference between the wild type and the znf2Δ 
mutant.  This result is not unexpected given that the znf2Δ mutant is only slightly more 
virulent than the wild type in the H99 background and the effect of Znf2 mutations on 
virulence in XL280 might be less drastic. 
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Figure 13  Znf2 mediates the fungal ability to cause fatal diseases in the murine 
inhalation model of cryptococcosis 
(A) Mice were inoculated with 1x106 fungal cells intranasally and the survival was 
monitored for 40 days. There was no statistically significant difference between the wild 
type and the znf2Δ mutant.  The p value was 0.07 for WT/znf2Δ, and <0.001 for 
WT/ZNF2oe and ZNF2oe/znf2Δ. (B) Mice were inoculated with 1x106 fungal cells 
intranasally. At the time of termination, lungs, brains, kidneys, and spleens from six 
animals per group were dissected and homogenized. Serial dilutions of the homogenized 
tissue were plated and colony forming units were used to determine the organ fungal 
burden. The short lines indicate the median. No colonies were recovered from a few 
dissected organs even with all the suspended tissue plated.  Because the Y-axis is log10 
of the CFU, “n/a”, not applicable, was used to show them as zero on the bottom of the 
Y-axis. The fungal burdens among the wild type, the znf2Δ mutant, and the ZNF2oe 
strain were statistically different in the lungs (p < 0.001) and the brain (p = 0.004). There 
was no statistically significant difference in the kidney (p = 0.874) or in the spleen (p = 
0.442). 
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The ZNF2oe strain in the H99 background is avirulent and it did not disseminate 
to the brain tissue at the early stage of infection in the inhalation infection model of 
murine cryptococcosis.  However, it was not clear if the absence of brain fungal burden 
was an indirect effect due to the low fungal burden in the lungs or it reflects defective 
extrapulmonary dissemination of the ZNF2oe strain to the brain.  Here we examined the 
fungal burden of the lungs, brains, kidneys, and spleens of the mice infected by the wild-
type strain, the znf2Δ mutant, and the ZNF2oe strain in the XL280 background at the time 
of their termination.  As shown in Fig. 13B, the fungal burden in the lungs was high in 
mice infected by all the strains, with the ZNF2oe strain more than 10 fold higher than the 
wild-type strain or the znf2Δ mutant.  By contrast, the presence of the ZNF2oe strain in 
the brain was about 100 fold lower with larger variations (median ~105 CFU/organ) than 
the wild type while the znf2Δ mutant showed a slightly higher fungal burden in the brain 
(>107 CFU/organ) (Fig. 13B).  The lower burden of the ZNF2oe strain in the brain was 
unlikely a result of poor dissemination from the lungs, as there was no difference 
observed among all the strains in the kidney and the spleen (Fig. 13B).  The results 
suggest that Znf2 might have a role in interfering with extrapulmonary dissemination to 
the brain specifically.  Further investigation is needed to examine the role of Znf2 and its 
downstream factors in mediating cryptococcal neurotropism during infection.  
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2.4. Discussion 
XL280 was derived from a clinical isolate NIH12 that can also undergo robust 
monokaryotic fruiting.  The related congenic pairs constructed previously were 
purposely made in genetic backgrounds that do not self-filament or do so poorly. Among 
these congenic pairs, the pair JEC21α/JEC20a has been used most widely.  However, all 
the serotype D congenic strains, including JEC21α/JEC20a, display low levels of 
virulence in mouse models.  Investigating fungal virulence in these backgrounds requires 
high inocula and often intravenous inoculation (151).  Here we found that the animal 
survival curves produced by XL280 and its congenic pair strains with an inoculum of 
1x106 in both the inhalation and the intravenous infection models are similar to what we 
and others observe for the serotype A strain H99 with an inoculum of 1x105 (7). 
Although there is no direct comparison to other serotype D strains, XL280 congenic pair 
strains are likely much more virulent than their related serotype D strains in murine 
models (6, 65, 153, 154).  Based on the pedigree of these serotype D congenic pairs (Fig. 
2), JEC21α/JEC20a, KN3501α/a, and XL280α/a in theory should all harbor 
approximately 50% of the overall genetic background derived from each of the NIH12 
and NIH433 genomes. The differences between these pairs in terms of morphogenesis 
and virulence likely derive from allelic combinations generated by recombination events 
during meiosis.  
We noticed a different pattern of fungal proliferation in various organs in the 
inhalation model and the intravenous model of murine cryptococcosis at time of animal 
termination.  The high fungal burden observed in the lungs in the inhalation model is 
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expected, so is the preferential proliferation in the brain over other organs (e.g. kidney or 
spleen) in this model given the well-known neurotropism of cryptococcal infections 
(Fig. 10B).  In sharp contrast, the fungal presence in all organs examined was uniformly 
high in the intravenous infection model and there was no apparent tissue tropism (Fig. 
11B).  These observations indicate that the neurotropism of cryptococcal infections is 
apparent upon extra-pulmonary dissemination, but not with direct infusion of fungal 
cells into the blood.  Further supporting evidence of the difference of these two models 
comes from the study of the mating type distribution in various organs during a-α co-
infection.  When mixed a and α cells were introduced into animals intravenously, there 
was non-discriminating slightly higher representation of α in all organs and in all 
animals examined, likely reflecting slightly better proliferation of the α cells in vivo.  By 
contrast, although α uniformly dominated the lungs in all animals when mixed a and α 
cells were introduced into animals through the respiratory tract, a and α showed equal 
predominance in the kidney and the spleen, whereas a might even have a slightly better 
chance than α in dominating the brain. Thus, extrapulmonary dissemination appears to 
be a critical step in determining cryptococcal tissue tropism.  
It is possible that for Cryptococcus cells to disseminate successfully from lungs, 
specific alterations in their cells, such as cell morphology (size and shape) and cell 
surface composition, might have to happen (76, 77, 81, 163).  These alterations might 
render a higher affinity of these Cryptococcus cells to the brain.  For instance, it is 
known that capsule structure differs at different stages of infection and in different 
organs, and capsule and cell size change during organ invasion (45, 54, 57).  It is 
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conceivable then that certain changes associated with pulmonary extrusion may better 
assist cryptococcal invasion of the brain.  Alternatively, Cryptococcus can disseminate 
through a Trojan horse mechanism and its neurotropism could be derived indirectly from 
the affinity between the host cells hijacked by Cryptococcus and the brain.  For instance, 
monocytes have been shown to assist in cryptococcal dissemination and brain invasion 
(46).  The identification of cryptococcal factors and host factors that affect cryptococcal 
neurotropism could help in testing these hypotheses.  
XL280 congenic pair strains might be adept in regulating cell size in response to 
host factors.  We noticed, for example, that their cell sizes increased when cells were 
incubated in serum at 37°C under 5% CO2 (Fig. 8).  It is known that cell size regulation 
is important for cryptococcal virulence (76, 77, 163) and it is not clear if this or other 
traits of XL280 contribute to its heightened virulence compared to other related serotype 
D strains.  We also noticed that the XL280-infected mice more often showed apparent 
neurological disorders when they became moribund, while the H99-infected mice more 
often displayed severe pulmonary stress.  In accordance with this observation, the fungal 
burden in lungs is typically one order higher than that in the brain in H99-infected mice 
(156, 164).  In contrast, the fungal burden in the brain is at the same order as that in the 
lungs in XL280-infected mice (Fig. 10B and Fig. 11B). For comparison, the 
Cryptococcus gattii reference strain R265 predominantly amplifies in the lungs and very 
little in the brain (157, 164).  Further investigation into the molecular mechanisms 
underlying the strain or serotype-specific differences in neurotropism is warranted.  It is 
also interesting to note that overexpression of ZNF2 in XL280 led to drastically lower 
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fungal burden in the brain even though it was present at higher numbers in the lungs and 
comparable levels in the kidney and spleen as the wild type (Fig. 13B).  This reduced 
brain fungal burden of ZNF2 overexpression stain is consistent with previously observed 
in a virulence analysis with ZNF2 overexpression stain in H99 background (81).  Thus, 
Znf2 may play a role in interfering with cryptococcal dissemination specifically to the 
brain after pulmonary extrusion.  Given that Znf2 is a transcription factor and its regulon 
is highly enriched with cell surface proteins (81), it would be interesting to examine 
surface molecules altered by Znf2 and to investigate their roles in cryptococcal tissue 
tropism in the future.   
In conclusion, the congenic α/a strains constructed in the genetic background of 
the highly filamentous strain XL280 are highly virulent, making them a preferred system 
for both cryptococcal morphogenesis and virulence studies and enabling the uses of this 
species complex to understand the genetic basis for dimorphic transitions in pathogenic 
fungi. 
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CHAPTER III  
THE ANTIBIOTIC POLYMYXIN B EXERTS POTENT ANTIFUNGAL ACTIVITY 
WITH AZOLES* 
 
3.1.Introduction 
Polymyxin B is composed of a cationic cyclic polypeptide and a long 
hydrophobic lipid tail.  It was initially discovered in 1940s and approved by FDA for 
treating gram-negative infections (165).  Due to the nephrotoxicity and neurotoxicity, its 
parenteral use was gradually stopped since 1970s (166, 167).  However, recent studies 
have suggested a much milder toxicity associated with polymyxin B (168).  Currently 
polymyxin B is applied clinically for the treatment on multidrug-resistant Gram-negative 
infections (169, 170). 
This cationic molecule perturbs the stability of the outer membrane of gram-
negative bacteria via a neutralizing effect on the negative-charged lipopolysaccharide 
(LPS) (171).  The insertion of polymyxin B into the membrane increases the 
permeability of the bacteria and further results in the cell lysis (171).  In parallel, 
Cryptococcus possesses a unique polysaccharide capsule layer which is highly negative-
charged on the cell surface (172).  The cryptococcal cells may also succumb to 
                                                 
* This material has been published in this or similar form in International Journal of Antimicrobial Agents 
and Journal of Antimicrobial Chemotherapy, and is used here with permission of Elsevier B.V. on behalf 
of the International Society of Chemotherapy and Oxford University Press on behalf of the British Society 
for Antimicrobial Chemotherapy, respectively. 
Zhai B and Lin X (2013) Evaluation of the anticryptococcal activity of the antibiotic polymyxin B in vitro 
and in vivo. Int J Antimicrob Agents 41(3):250-254. 
Zhai B*, Zhou H*, Yang L, Zhang J, Jung K, Giam CZ, Xiang X, and Lin X. (2010) Polymyxin B, in 
combination with fluconazole, exerts a potent fungicidal effect. J Antimicrob Chemother 65(5):931-938. 
 63 
 
polymyxin B as a result of a similar electrostatic interaction.  This speculation is 
supported by this study in that among the pathogenic fungi tested, Cryptococcus is 
particularly sensitive to polymyxin B.  In addition, the antifungal activity of other 
cationic peptide antibiotics, such as colistin and omiganan, has been reported (173, 174).  
Since polymyxin B is not able to penetrate the blood brain barrier, we hypothesized that 
to apply polymyxin B together with other antifungals, such as fluconazole, to control the 
systemic fungal infections.  
The serum concentrations of polymyxin B in clinic are about 6.25~50 mg/L 
(175), which are below the in vitro inhibitory concentrations against most fungal 
pathogens but fall within the range of those of Cryptococcus isolates.  We then decided 
to evaluate the in vivo efficacy of polymyxin B in two murine models of cryptococcosis.  
Naturally, hosts inhale cryptococcal cells from the environment.  The fungal cells are 
either cleared in the lungs or they establish latent infections (16).  When the immune 
system of the host is compromised (e.g. HIV infection), cryptococcal cells can activate, 
disseminate from lungs, and eventually cause the fatal systemic cryptococcosis (16).  In 
the inhalation model, the animals are inoculated intranasally with Cryptococcus cells, 
which is analogous to the natural route of infection.  These animals develop primarily 
pulmonary infections.  In the intravenous model, the animals are infected intravenously 
with fungal cells to represent disseminated cryptococcosis.  Although the poor 
penetration of polymyxin B to the central nervous system may limit its effect on brain 
infections, our data on the tissue fungal burden of the lung and the kidney suggest a 
modest efficacy of this compound against systemic cryptococcal infections. 
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3.2. Material and methods 
3.2.1. Strains and media 
The strains used in this chapter and in the next chapter are listed in Table 2.  All 
yeast strains were maintained on Yeast Peptone Dextrose (YPD) medium.  For the initial 
drug screening experiments, the Aspergillus nidulans strain R21 was grown on YAG 
medium (0.5% yeast extract, 2% agar and 2% glucose).  Time course assays were 
performed using PBS buffer or RPMI 1640 medium buffered with MOPS 
(morpholinepropanesulfonic acid). 
 
 
Table 2  Strain information 
 
Strains Species Reference 
H99 Cryptococcus neoformans (7) 
C45 Cryptococcus neoformans (155) 
A7-35-23 Cryptococcus neoformans (155) 
C23 Cryptococcus neoformans (155) 
Bt31 Cryptococcus neoformans (176) 
Bt81 Cryptococcus neoformans (176) 
92BC2-45 Cryptococcus neoformans (177) 
92BC1-52 Cryptococcus neoformans (177) 
98BC1-86 Cryptococcus neoformans (177) 
A2-102-5 Cryptococcus neoformans (155) 
123.96 Cryptococcus neoformans (178) 
Bt50 Cryptococcus neoformans (176) 
163.99 Cryptococcus neoformans (178) 
UA 1993 Cryptococcus neoformans (153) 
JEC21 Cryptococcus neoformans (5) 
3-10 Cryptococcus neoformans (155) 
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Table 2 Continued 
 
Strains Species Reference 
3-17 Cryptococcus neoformans (155) 
93BC2-52 Cryptococcus neoformans (177) 
99BC1-40 Cryptococcus neoformans (177) 
UA 491 Cryptococcus neoformans (153) 
XL1495 Cryptococcus neoformans (154) 
UM4 Cryptococcus neoformans (179) 
92C Cryptococcus neoformans (179) 
VPCI 87 Cryptococcus gattii from Duke University Medical Center 
BY4742 Saccharomyces cerevisiae (180) 
SC5314 Candida albicans from Duke University Medical Center 
PAT2ISO3 Candida glabrata from Duke University Medical Center 
DUMC132.
91 
Candida krusei from Duke University Medical Center 
MMRL1594 Candida parapsilosis from Duke University Medical Center 
MMRL2017 Candida tropicalis from Duke University Medical Center 
2-367 Candida lusitaniae from Duke University Medical Center 
FGSC2489 Neurospora crassa from Fungal Genetics Stock Center 
 
 
3.2.2. Compounds and animals 
For in vitro studies, Polymyxin B sulfate was dissolved in water at a stock 
concentration of 20 mg/ml; fluconazole was dissolved in water at a stock concentration 
of 2mg/ml; and both of the two drugs were further diluted with PBS buffer or RPMI 
media to the indicated working concentrations.  For animal studies, polymyxin B was 
dissolved in 0.9% saline at a stock concentration of 20 mg/ml and diluted with 0.9% 
saline for injection.  Fluconazole was dissolved in 0.9% saline at 4 mg/ml.  Female A/J 
mice (6 to 8 weeks old) were purchased from Charles River (Wilmington, MA). 
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3.2.3. Screening of the clinical compound library 
The Johns Hopkins Clinical Compound Library (JHCCL version 1.0), a 
collection of 1514 FDA approved (1082) and Foreign Approved (432) Drugs (181), were 
screened for an inhibitory effect on A. nidulans colony growth. The library was 
assembled in a 96-well plate format with 25 μl aliquots of 10 mM stocks of drug in 
either water or DMSO.  An aliquot of 2 μl from each well was spotted onto YAG plate 
and approximately 1x105 spores of Aspergillus nidulans strain R21were point-inoculated 
onto the spots of original drug application.  The cells were incubated at 37oC for two 
days.  Drugs that either significantly or completely inhibited A. nidulans colony 
development were selected.  Selected drugs at 2 μM were tested again for inhibitory 
effect on A. nidulans in liquid medium.  A. nidulans spores (approximately 105) were 
inoculated into 500 μl of drug-containing liquid medium and incubated at 37oC for 
overnight in the 8-chambered Lab-Tek Borosilicate Coverglass System.  Eleven 
compounds that significantly inhibited colony growth of A. nidulans strain R21 at this 
concentration were identified.  
3.2.4. Disk diffusion halo assay for antifungal activity 
Briefly, yeast cells at cell density of approximately 5x106 were spread onto 
RPMI 1640 agar medium with L-glutamine and without sodium bicarbonate. The plates 
were allowed to solidify and dry.  Whatman paper disks (7mm) containing water, 
fluconazole, polymyxin B, and their combination at various concentrations were dried 
and placed on the solidified agar surface.  The cells were incubated for 24 to 48 hours at 
37°C in 5% CO2 to mimic the host environment. 
 67 
 
3.2.5. Microdilution assays for antifungal activity 
Microdilution assay was performed according to the CLSI standard except that 
the cells were incubated at 37°C in 5% CO2 to mimic the host environment.  Briefly, 
yeast cells at final concentration of approximately 1 × 103 per ml (or Aspergillus spores 
at final concentration of approximately 5 × 104 per ml) were inoculated in the RPMI 
1640 liquid medium with serial (2×) dilutions of each drug being tested.  The 
concentrations used in for polymyxin B and fluconazole were indicated in the text. Wells 
that contained no drugs or no yeast inoculation were included as positive and negative 
controls. The MIC100 of polymyxin B or the combination was defined as the lowest drug 
concentration that resulted in a 100% decrease in absorbance compared with that of the 
control in drug free medium. MIC90 of fluconazole was defined as the lowest drug 
concentration that resulted in a 90% decrease in absorbance compared with that of the 
control in drug free medium. MICs were read after incubation without agitation for 24 
hours for Candida strains and 48 hours for the Aspergillus, Rhizopus, or Cryptococcus 
isolates.  Fungicidal effect was examined by counting CFU of the suspension from each 
well after plating it onto YPD medium and incubated for 24 (for Candida strains) to 48 
hours (for Cryptococcus strains). MFC stands for minimal fungicidal concentration and 
was defined as at least 99% of cells were killed compared to the original inoculum. 
Synergistic or additive fungicidal effect between fluconazole and polymyxin B for each 
strain was calculated based on fractional fungicidal concentration index. FFC = 
[F]/MFCF + [P]/MFCP, where MFCF and MFCP are the MFCs of fluconazole and 
polymyxin B, respectively, and [F] and [P] are the concentrations at which fluconazole 
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and polymyxin B, in combination, are fungicidal. FFCs lower than 0.5 indicate 
synergistic interactions, FFCs between 0.5-1.0 indicate additive interactions, and FFCs 
between1.0-2.0 indicate indifferent interactions, and FFCs greater than 2.0 indicate 
antagonistic interactions (182). 
3.2.6. Generation of fluconazole resistant H99FR 
C. neoformans H99 reference strain was cultured in YNB liquid medium with 
fluconazole at an inhibitory but sublethal concentration of 2.4 μg/ml. The culture was 
maintained at 37°C with shaking. An aliquot of the culture was transferred to fresh YNB 
medium with fluconazole every other day and continued for 16 weeks. 
3.2.7. The effect of the polysaccharide capsule on the drug efficacy 
Time course assays were employed to evaluate the effect of polysaccharide 
capsule on the drug efficacy.  To induce the capsule production, H99 cells were cultured 
on RPMI agar media at 37ºC in 5% CO2.  To suppress the capsule production, H99 cells 
were cultured on YPD agar with addition of 1M NaCl at 30ºC in ambient air.  After three 
days of incubation, the cells grown under each condition were collected, washed, and 
suspended in PBS buffer to obtain a cell density between 1500 to 2000 cells/ml. The cell 
suspension was treated with polymyxin B (8 mg/L). The no drug treatment was used as 
the positive control. At different time points (0, 1, 2, 4, 6, 8 hours post inoculation), 
aliquots of cell suspensions were spread onto drug-free solid YPD medium to determine 
the number of viable cells by measuring the colony forming units (CFUs). 
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3.2.8. In vivo murine models of cryptococcosis 
The animal models of systemic cryptococcosis were induced by two infectious 
routes: intravenous infection and intranasal infection.  In each infection model, the mice 
were assigned into 4 treatment groups: control (0.9% saline), fluconazole, polymyxin B, 
and the drug combination.  Five animals per group were used for the fungal burden assay 
and ten animals per group were used for the survival study.  All the drugs were 
administrated intraperitoneally.  For the intravenous infection, each mouse was 
challenged with 1.0 x 104 H99 cells at Day 0. The drug treatment with fluconazole (10 
mg/kg/day), polymyxin B (2.5 mg/kg/day), or the drug combination started on Day 1 
and lasted for 5 consecutive days.  The mice were given drugs once every 24 hours. The 
mice were then sacrificed on Day 6 and their organs were harvested to be used for the 
determination of the tissue fungal burden.  For the intranasal infection, animals were first 
sedated with Ketamine and Xylazine, and then 1.0 x 105 H99 cells suspended in 50 µl of 
saline were slowly inoculated into the left nostril of sedated animals.  In the survival 
study, the drug treatment with fluconazole (16 mg/kg/day), polymyxin B (2.5 
mg/kg/day), or the drug combination was initiated at Day 2 and lasted for 5 consecutive 
days.  In the fungal burden study, the drug treatment with fluconazole (4 mg/kg/day), 
polymyxin B (2.5 mg/kg/day), or the drug combination was initiated at Day 10 and 
lasted for 3 consecutive days.  The mice were sacrificed one day (24 hours) after the last 
dose of treatment and their lungs were harvested.  The kidneys or lungs were 
homogenized in 2 ml of cold PBS buffer using an IKA* Ultra-Turrax T18 homogenizer 
with the same setting for each type of organ.  The cell suspensions were serial diluted 
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(10x), plated onto YPD agar, and incubated at 30°C for additional 2 days such that the 
colonies became visible in order to calculate CFUs.  Animals were weighed daily and 
monitored twice a day for disease progression and potential severe side effects, including 
weight loss, gait changes, labored breaths, or fur ruffling.  The animal experiments were 
performed according to the recommendations in the Guide for the Care and Use of 
Laboratory Animals of the National Institutes of Health. The protocol was approved by 
the Texas A&M University Institutional Animal Care and Use Committee (IACUC, 
Animal protocol permit number: 2011-22). 
3.2.9. Statistical analysis 
The one-way ANOVA tests in the fungal burden studies were performed using 
Graphpad Prism 5 program. The p values lower than 0.05 were considered significant. 
 
3.3. Results 
3.3.1. Drug screen suggested the anti-Aspergillus nidulans activity of polymyxin B 
The Johns Hopkins Clinical Compound Library (181), composed of 1514 
approved drugs was screened for anti-A. nidulans activity.  A. nidulans is a model 
filamentous fungus used widely in mycology research.  Twenty three drugs were found 
to either significantly or completely inhibit the colony growth of the A. nidulans strain 
R21 when 2 μl of the drugs from 10 mM stock were directly spotted onto each point 
inoculum containing approximately 1x105 spores (Fig. 14A).  Eleven compounds that 
significantly inhibited spore germination in liquid medium at a concentration of 2 μM 
were listed in Table 3 (Fig. 14B and C).  Not surprisingly, the majority of them were 
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known antifungals belonging to the azole family.  One antibiotic (polymyxin B sulfate) 
and three antiseptic compounds were also identified.  Because of our interest in 
compounds that have the potential to treat systemic fungal infections, only polymyxin B 
was chosen for further studies.  The effect of polymyxin B on A. nidulans is fungicidal. 
Both spores and pre-germinated germ tubes inhibited by polymyxin B failed to re-grow 
after transfer to fresh drug free medium (Fig. 14B-D). 
 
 
 
Figure 14  Polymyxin B inhibits the growth of A. nidulans (A-D) and A. fumigatus 
(E-H) 
(A) A portion of the drug-screening plate showing that 2 μl of 1 mM Polymyxin B 
sulfate, when applied to the spot of the plate (arrow), completely inhibited the growth of 
A. nidulans colony.  (B) Wild type A. nidulans in drug free medium. Bar, 5 m. (C) 
Polymyxin B at 2 μM (2.8 μg/ml) inhibited germination of A. nidulans. (D) A. nidulans 
conidia treated with 2 μM polymyxin B did not germinate when transferred to drug free 
medium.  (E) A. fumigatus spores in drug free medium. (F) Polymyxin B of 20 μM (28 
μg/ml) inhibited germination of the majority of A. fumigatus spores. (G) A. fumigatus 
conidia treated with 2 μM polymyxin B did not germinate when transferred to drug free 
medium.  (H) Pre-germinated germ tubes of A. fumigatus did not grow in the presence of 
polymyxin B at 20 μM. (I) Quantitative measurements of the effectiveness of polymyxin 
B at 20 M (28 μg/ml) or 40 M (56 μg/ml) in inhibiting the germination of A. 
fumigatus spores. Spores of A. fumigatus strain B5233 were incubated at 37oC for 9.5 
hours. 150 cells were counted for each treatment. The average and standard deviation 
based on three independent repeats are shown in the graph. 
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Table 3  Drugs that significantly inhibited A. nidulans spore germination at 2 μM 
 
Name Drug Type Usage 
Clotrimazole Antifungal Topical 
Econazole Antifungal Topical 
Oxiconazole nitrate Antifungal Topical 
Voriconazole Antifungal Systemic 
Butoconazole nitrate Antifungal Topical 
Miconazole Antifungal Topical 
Tioconazole Antifungal Topical 
Polymyxin B sulfate Antibiotic Topical and systemic 
Brilliant green Antiseptic Topical  
Cetylpyridinium bromide monohydrate Antiseptic Topical 
Methylbenzethonium chloride Antiseptic Topical 
 
 
3.3.2. Polymyxin B alone is fungicidal at relatively high concentrations 
We further tested the susceptibility to polymyxin B of the pathogenic filamentous 
fungi A. fumigatus and Rhizopus oryzae, and pathogenic yeasts including Cryptococcus 
neoformans, Candida albicans, Candida glabrata, Candida krusei, and Candida 
parapsilosis was examined using the standard microdilution assay.  Microscopic 
examination revealed that more than 80% A. fumigatus (B5233) spores did not germinate 
in the presence of polymyxin B at 28 μg/ml compared to no drug treatment control (Fig. 
14I).  Those spores also failed to grow even after the drug removal, consistent with the 
fungicidal effect of the drug (Fig. 14F-G).  Growth of pregerminated germ tubes also 
failed to grow in the presence of polymyxin B (Fig. 14H). However, some spores present 
in the population were resistant and were able to form hyphae in the presence of the drug 
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after an overnight incubation. Thus, as expected, both B5233 and Af293 isolates showed 
strong resistance to polymyxin B in the disk diffusion assay (data not shown) and the 
microdilution assay (MIC100 >1 mg/ml) based on visual examination.  In contrast, the R. 
oryzae strain 99-880 is more sensitive, with a MIC100 32 μg/ml. The pathogenic yeast 
strains tested also showed varied sensitivity to polymyxin B, with MIC100 ranging from 8 
to 256 ug/ml (Table 4, columns 1-2). This range is consistent with MICs reported in the 
literatures (183-185). Given that bacterial strains with MICs greater than 8 μg/ml are 
considered resistant (186), the relatively high MICs observed in these fungal species 
preclude the clinical use of polymyxin B as a monothereapy. 
3.3.3. In combination with fluconazole, polymyxin B at lower concentrations is 
fungicidal for all yeast strains tested 
Polymyxins act against Gram-negative bacteria by binding lipopolysaccharide 
(LPS) and anionic phospholipids in bacterial membrane, disrupting membrane integrity 
(171, 187, 188).  It is possible that polymyxin B binds fungal membrane in an analogous 
manner, but with lower efficiency because eukaryotic membrane has low membrane 
potentials, high levels of sterols, and higher contents of neutral lipid (171, 189, 190). The 
azole antifungals target the lanosterol 14α-demethylase Erg11 in the fungal ergosterol 
biosynthesis pathway (191).  It results in a reduced ergosterol level and altered 
membrane property (116, 192, 193). We reason that polymyxin B and azole antifungals 
may have synergistic interactions against fungi.  To test this hypothesis, the 
susceptibility of C. neoformans, C. albicans, C. glabrata, C. krusei, and C. parapsilosis 
strains to fluconazole, polymyxin B, and a combination of these two compounds was 
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analyzed by disk diffusion halo assay. As shown in Fig. 15B, the strains demonstrated 
varied sensitivity to fluconazole with the C. krusei strain DUMC132.91 and the C. 
parapsilosis strain MMRL1594 highly resistant. Polymyxin B alone at 20 μg per disk 
had no or minimal fungicidal activity against the strains tested (Fig. 15B).  Interestingly, 
when fluconazole was combined with polymyxin B, the halo surrounding the disk was 
significantly more clear (Fig. 15B), an indication of potential fungicidal activity. 
 
 
Table 4  Polymyxin B and fluconazole exhibit a synergistic fungicidal effect 
Yeast Strains 
MIC100 
PMB** 
MFC* 
PMB 
MIC90 
FLC** 
MFC 
FLC 
MFC 
PMB - FLC 
FFC 
index 
Cryptococcus 
neoformans H99α 
8 8 1 8 1 -   2 0.266 
Candida albicans 
SC5314 
128 >256 0.2 64 6 -   8 0.125 
Candida glabrata 
PAT2ISO3 
256 256 8 >64 25 - 15 0.236 
Candida krusei 
DUMC132.91 
32 32 64 64 8 - 10 0.160 
Candida parapsilosis 
MMRL1594 
128 256 >64 >64 10 - 10 0.078 
Saccharomyces 
cerevisiae BY4741 
32 64 4 16 2 -  4 0.252 
Filamentous Fungal 
Strains 
MIC100 
PMB 
MFC* 
PMB 
MIC90 
ICZ** 
MFC 
ICZ 
MFC 
PMB - ICZ 
FFC 
index 
Aspergillus fumigatus 
Af293 
>1000 >1000 0.4 12.8 12 - 1.6 0.137 
Rhizopus oryzae  
99-880 
32 32 0.4 1.6 4 - 0.4 0.375 
 
*: MFC is defined as the lowest concentration at which over 99% of the original 
inoculums cells were killed.  When fluconazole is used alone, MFC is not achieved 
sometimes in the dose range tested and is indicated by “>”.  
**: PMB: polymyxin B (susceptible breakpoint for bacteria is 2 or 4 μg/ml); FLC: 
fluconazole (susceptible breakpoint for yeasts is 8 μg/ml); ICZ: itraconazole (susceptible 
breakpoint for moulds is 1.0 μg/ml).  
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Figure 15  Synergistic interaction between fluconazole and polymyxin B against 
Candida and Cryptococcus 
Disks containing water, polymyxin B, fluconazole, and the drug combination were dried 
and placed on top of a lawn of yeast cells derived from the strains indicated. Cells were 
incubated for 24 hours (Candida species) or 48 hours (Cryptococcus).  Inhibition of 
fungal growth in regions surrounding the disk produces a halo. A completely clear halo 
indicates fungicidal activity.  (A) Disk diffusion halo assays of the C. albicans strain 
SC5314 demonstrate a clear halo when the disk used contained fluconazole and 
polymyxin B combination. (B) Microscopic observations reveal significant clearing of 
the zone of inhibition (halo) when fluconazole and polymyxin B were used in 
combination. The left corner of each image shows the edge of the disk. PMB stands for 
polymyxin B and FLC stands for fluconazole. 
 
 
Because the disk diffusion method was not quantitative in determining the 
susceptibility to polymyxin B due to the relatively large size of this molecule (30), the 
synergy of the drug combination was further examined using the microdilution assay.  
Cells from the microdilution assay after incubation with polymyxin B alone, fluconazole 
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alone, or the combination at various concentrations were also plated on drug-free 
medium for colony forming units (CFUs) to determine the minimal fungicidal 
concentration (MFC).  As shown in Table 4, the strains showed varied sensitivity to 
polymyxin B and fluconazole, and there is no apparent correlation between the 
sensitivity towards polymyxin B and the sensitivity towards fluconazole. Consistent with 
results from the disk diffusion assays, the C. krusei strain DUMC132.91 and the C. 
parapsilosis strain MMRL1594 are highly resistant to fluconazole (the susceptibility 
breakpoint for fluconazole is 8 μg/ml according the CLSI standard). The MFC of 
polymyxin B is similar to the MIC100 (column 2 and 3), supporting its fungicidal 
property.  Conversely, MFC of fluconazole can be much higher than the MIC90 (column 
4 and 5) and complete cell killing is often not achievable. This is in accord with its 
classification as a fungistatic drug.  A synergistic fungicidal interaction between 
polymyxin B and fluconazole was observed against all fungal strains tested (last two 
columns).  Similar synergistic interactions against the C. neoformans H99 strain were 
also observed for polymyxin B and itraconazole (another azole antifungal), and 
polymyxin B and amphotericin B combinations (data not shown).  
The susceptibility of the filamentous fungal (mould) pathogens A. fumigatus 
strain Af293 and R. oryzae strain 99-880 towards polymyxin B alone, itraconazole alone, 
and the drug combination was also examined using the microdilution assay.  
Itraconazole rather than fluconazole is often used in clinic to treat mould infections. As 
shown at the bottom of Table 4, a synergistic interaction between itraconazole and 
polymyxin B was also observed. 
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3.3.4. The combination of polymyxin B and fluconazole at clinically relevant 
concentrations is effective against Cryptococcus strains with varied fluconazole 
resistance 
The C. neoformans strain H99 is more sensitive to polymyxin B than the 
Candida strains tested (Table 4). To examine whether the sensitivity to polymyxin B and 
the high sensitivity to polymyxin B and fluconazole combination is specific to the H99 
strain or is general for Cryptococcus, additional clinical and environmental C. 
neoformans isolates that are genetically distinct were examined (16, 31, 155, 176) (Table 
4).  These strains belong to the three major C. neoformans molecular types VNI, VNII, 
or VNB and are of either a or  mating type (Table 5).  Despite the variations in 
sensitivity towards polymyxin or fluconazole, the combination of polymyxin B at 2 
μg/ml and fluconazole at 8 μg/ml was able to achieve greater than 99% cell killing for all 
strains tested except two strains Bt81 and A2-102-5 where 93-96% killing was achieved. 
Because the concentrations of either fluconazole (≤8 μg/ml) or polymyxin B (≤2 μg/ml) 
used are within the susceptible breakpoint for each agent according to the CLSI 
standards, the drug combination has the potential to be effective in vivo.  
As long-term fluconazole therapy is necessary for AIDS patients with 
cryptococcal meningitis, the emergence of azole resistance is becoming a grave concern.  
Here we have shown that natural Cryptococcus isolates with variable resistance to 
fluconazole (MIC90 ranging from 1-32 μg/ml) are all susceptible to the drug 
combination.  We also obtained a relatively fluconazole-resistant strain H99FR by 
culturing H99 in the presence of sublethal fluconazole for 16 weeks. The strain H99FR 
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showed a sixteen fold increase in MIC90 to fluconazole (Table 5) and significantly 
increased resistance to itraconazole (data not shown).  Again, a synergistic interaction 
against H99FR was observed between polymyxin B and fluconazole, and the 
combination of polymyxin B at 2 μg/ml and fluconazole at 8 μg/ml was again effective 
(Table 5).  Taken together, the results suggest that that this combination also is likely to 
be effective against infections caused by azole resistant Cryptococcus isolates. 
 
 
Table 5  In combination with fluconazole, polymyxin B at low concentrations 
effective against different Cryptococcus neoformans isolates 
 
Strains Genotype* Source* Virulence* 
MIC100 
PMB 
MFC 
PMB 
MIC90 
FLC 
MFC 
FLC 
MFC 
PMB-FLC 
H99 VNI (A1) C High 8 8 1 4 1 - 2 
C45 VNII C High 20 24 2 6 2 - 8 
A7-35-23 VNII E Low 16 20 4 >64 2 - 8 
C23 VNI (A1) C High 8 20 8 64 2 - 8 
Bt65 VNB (A15) C ― 12 12 8 12 2 - 8 
Bt31 VNB (A4) C ― 8 8 12 32 2 - 8 
Bt81 VNB (A15) C ― 24 32 12 >64 2 - 8 # 
Bt85 VNB (A21) C ― 8 8 12 >64 2 - 8 
A2-102-5 VNI (A2) E Low 10 10 16 32 2 - 8 # 
Bt70 VNB (A19) C ― 8 8 16 >64 2 - 8 
H99FR VNI (A1) L ― 5 6 16 48 2 - 8 
Bt50 VNB (A4) C ― 6 8 32 >64 2 - 8 
 
The highest concentration of fluconazole tested was 64 μg/ml. 
*: VNI, VNII, and VNB indicate C. neoformans three molecular types. A capital “A” 
followed by a number indicates further genotypic classification based on Amplified 
fragment length polymorphism (AFLP) genetic typing pattern.  C: clinical; E: 
environmental; L: laboratory.  The symbol “―”indicates no information available. 
#: the combination at the indicated concentrations achieved 93-96% rather than >99% 
killing. 
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3.3.5. Polymyxin B is fungicidal against both proliferative and non-proliferative 
cryptococcal cells in vitro 
To examine whether polymyxin B is fungicidal against both proliferative and 
non-proliferative cryptococcal cells, we performed a comparative time course assay of 
cell viability of H99 and XL280 strains in vitro treated with polymyxin B, fluconazole, 
or the drug combination.  We cultured the fungal cells in RPMI medium or suspended in 
PBS buffer to represent rapidly proliferative or quiescent cells, respectively.  As shown 
in Fig. 16, the survival curves of H99 and XL280 to the drug treatment displayed similar 
patterns.  In RPMI medium, the fungal cells with all of the drug treatments were cleared 
within the experimental period (Fig. 16A and B).  The number of viable H99 cells 
started to decrease within 6 hours in the presence of polymyxin B compared to the no-
drug control.  Similarly, viable XL280 cells started to decrease within 4 hours after 
being treated with polymyxin B.  The drug combination showed strongest effect on H99 
cells, indicating a synergistic interaction of the two drugs; whereas polymyxin B 
displayed a more dominant role in the drug combination in clearing XL280 cells.  
Similarly, the fungal cells of both strains in PBS buffer were completely cleared by 
polymyxin B (Fig. 16C and D).  These results indicate that polymyxin B is fungicidal 
and is potent against Cryptococcus cells irrespective of the cell growth status.  In 
contrast, fluconazole was effective in clearing rapidly proliferative cells incubated in the 
RPMI medium (Fig. 16A and B); but it did not show any effect on clearance of non-
proliferative fungal cells in the PBS buffer by itself (Fig. 16C and D).  Fluconazole also 
failed to enhance the potency of polymyxin B against cryptococcal cells in the PBS 
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buffer.  These results indicate that polymyxin B is fungicidal and is more potent than 
fluconazole against quiescent fungal cells. 
 
 
Figure 16  Polymyxin B is fungicidal against proliferative and quiescent 
Cryptococcus cells of the serotype A strain H99 and the serotype D strain XL280   
H99 cells were inoculated into RPMI media (A) or PBS buffer (C) and cultured without 
any drug (control) or in the presence of fluconazole (FLC; 8 mg/L), polymyxin B (PMB; 
16 mg/L), or a combination of these two drugs.  XL280 cells were inoculated into RPMI 
media (B) or PBS buffer (D) and cultured without any drug (control) or in the presence 
of fluconazole (FLC; 6 mg/L), polymyxin B (PMB; 10 mg/L), or a combination of these 
two drugs.  At the indicated time points, aliquots of cell suspensions were transferred 
and plated onto drug-free agar medium.  CFUs were measured after 2 more days of 
incubation.  
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3.3.6. The polysaccharide capsule of Cryptococcus facilitates the fungicidal activity of 
polymyxin B 
Given that isolates of Cryptococcus are much more susceptible to polymyxin B 
compared with isolates of Candida and Aspergillus spps., we hypothesize that 
differences in the cell surface composition may contribute to the difference in their 
susceptibility to polymyxin B.  The polysaccharide capsule is a prominent and unique 
structure present in Cryptococcus that is negatively charged (172).  Therefore, we 
suspect that the presence of the capsule may contribute to the hypersensitivity of this 
fungus to polymyxin B.  To test this hypothesis, we firstly compared the inhibitory 
concentration of polymyxin B against the acapsular cap59Δ mutant (53) with the wild-
type H99.  The cap59Δ mutant is more resistant to polymyxin B compared to H99, with 
a 20% higher MIC100 (MIC100 of cap59Δ is 10 mg/L and the MIC100 of the wild-type 
H99 is 8 mg/L).  This suggests that the lack of capsule confers the cryptococcal 
resistance against the stress caused by polymyxin B. 
 
 
 82 
 
 
Figure 17  The capsule enhances the susceptibility of Cryptococcus to polymyxin B 
The cells were examined by India ink staining.  The capsule excludes Indian ink and 
appears as a halo surrounding the yeast cell. The size of the halo reflects the size of the 
capsule.  (A) Capsule induced.  (B) Capsule suppressed.  Fungal cells previously grown 
at each condition were suspended in PBS buffer with addition of polymyxin B at the 
concentration of 8 mg/L.  At the indicated time points, aliquots of cell suspensions were 
transferred and plated onto drug-free agar medium to determine CFUs after 2 more days 
of incubation. 
 
 
As the mutation in the cap59Δ strain could result in other physiological changes 
in the fungal cells that may account for the drug resistance(194), we decided to test the 
effect of capsule on Cryptococcus sensitivity to polymyxin B by examining the drug 
sensitivity of wild-type H99 cells with different size of capsules.  We cultured the 
wildtype H99 cells under a capsule-inducing condition that is relevant to the host 
physiological condition (mammalian cell culture media with neutral pH, 37ºC, 5%CO2), 
and under a capsule-suppressing condition (YPD media with addition of a high 
concentration of salt).  The difference in capsule size of the H99 cells cultured under 
these two conditions was apparent after 3 days of incubation by India ink staining (Fig. 
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17A and B).  The cells grown at these conditions were then collected individually, 
washed, and suspended in PBS buffer.  The susceptibility of these cells to polymyxin B 
(8 mg/L) was measured by a time-course cell viability assay.  We chose to maintain the 
cells in the non-proliferative status in the PBS buffer during the assay to avoid potential 
complication of changes in capsule size during cell proliferation if RPMI media were 
used.  The survival rates of these fungal cells treated with polymyxin B were examined 
at different time points.  As shown in Fig. 17C, over 50% of the fungal cells with large 
capsule were cleared by polymyxin B within 2 hours; while it took more than 8 hours to 
reach a similar clearance level of the cells with no visible capsule.  Taken together, these 
results indicate that the capsule of Cryptococcus renders this fungus more susceptible to 
polymyxin B. 
3.3.7. Polymyxin B modestly reduces the kidney fungal burden in the intravenous 
infection models of systemic cryptococcosis 
In the in vivo study, we adopted a murine model of systemic cryptococcosis 
where animals were infected intravenously.  Our pilot experiments showed that the 
organ fungal burden displayed relatively low variations among individual animals in this 
model.  Previous studies on polymyxin B had defined a safe dose of 2.5 mg/kg/day or 
below (195); therefore we set all the polymyxin B treatments at this dose in our animal 
experiments.  As shown in Fig. 18, polymyxin B modestly reduced the tissue fungal 
burden in kidney, although the reduction is not statistically significant (p value = 0.058).  
Surprisingly, the drug combination did not show any synergistic effect.  We also 
performed the animal survival study using this model, but no significant difference was 
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observed among the groups (data not shown).  The rapid progression of the disease in 
this model might prevent us from observing any apparent effect of the drug treatments 
on animal survival as the animals succumbed to the cryptococcal infection within 7 days 
after inoculation even with the fluconazole therapy. 
 
 
 
Figure 18  Polymyxin B modestly reduces the fungal burden of kidney in a murine 
model of disseminated cryptococcosis   
Mice were challenged with H99 cells intravenously and treated with saline, polymyxin B 
(2.5 mg/kg/day), fluconazole (10 mg/kg/day), or the drug combination for 5 consecutive 
days and then sacrificed.  The fungal burden of the kidney was determined by 
calculating CFUs.  Polymyxin B alone was able to modestly reduce the fungal burden (p 
value = 0.058). However, there is no significant difference among the three drug 
treatment groups. 
 
 
3.3.8. Polymyxin B slightly prolongs the survival period of animals, reduces the fungal 
burden in the lungs, and works synergistically with fluconazole in an intranasal 
infection model 
We further tested the effect of these treatments in the murine inhalation model of 
cryptococcosis where the infect route reflects the natural route of cryptococcal infection.  
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We increased the dose of fluconazole from 10 mg/kg/day to 16 mg/kg/day to achieve a 
better protective result.  As shown in Fig. 19A, the treatment with polymyxin B or 
fluconazole modestly prolonged the survival of infected mice.  However, the drug 
combination did not show any apparent advantage in prolonging animal survival 
comparing to the treatments with single drug alone. 
We reasoned that the high dose of fluconazole, although by itself is more 
effective, may mask the potential synergistic effect between fluconazole and polymyxin 
B in vivo.  The modest differences in animal survival among these groups may also 
prevent us seeing the potential synergy between the drugs. Therefore, we reduced the 
dose of fluconazole to 4 mg/kg/day in the intranasal infection model and examined the 
lung fungal burden instead.  Lungs are the primary infectious site in this model.  As 
shown in Fig. 19B, the 3-day treatment with polymyxin B alone significantly reduced 
the lung fungal burden (p value < 0.05).  The fluconazole group did not show any 
protective effect, as expected with such low dose used.  However, the drug combination 
displayed a strong inhibitory effect on the fungal proliferation (p value < 0.001), 
indicating the synergy between fluconazole and polymyxin B.  Taken together, our data 
suggest that polymyxin B is effective in vivo against cryptococcal infections. 
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Figure 19  Polymyxin B is effective in reducing lung fungal burden and modestly 
prolongs animal survival in a murine model of pulmonary cryptococcosis  
Mice were challenged with H99 cells intranasally.  (A) The treatment started at Day 2 
and last for 5 consecutive days.  The survival of animals in each group was examined.  
(B) The lung of infected mice were dissected and homogenized after 3 days of drug 
treatment.  Polymyxin B alone is able to reduce the fungal burden in lung (p value < 
0.05) and the drug combination displays the best protection (p value < 0.001).  
 
 
3.4. Discussion 
Here we showed that through a screen of the clinical approved compound library, 
polymyxin B was identified to possess antifungal activity.  Moreover, the combination 
of polymyxin B and fluconazole at low concentrations are fungicidal against a variety of 
pathogenic fungal species and also relatively fluconazole resistant strains.  We found 
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that polymyxin B is particularly potent against Cryptococcus.  Therefore we further 
examined the efficacy of polymyxin B against Cryptococcus both in vitro and in vivo.  
Our results indicate that this combination could potentially be used to treat fungal 
infections, particularly cryptococcal infections, and to reduce the risk of the development 
of resistance to the popular azole antifungals.     
The antifungal property of the polymyxins and other cationic peptides antibiotics 
has been proposed by several groups recently (173, 174).  These studies suggested that 
the mechanisms of the antifungal property of these drugs are analogous to their 
antibacterial effect, that is, disruption of the integrity of membranes (cytoplasmic and/or 
vacuolar).  Due to the huge differences between the composition and structure of the 
eukaryotic and bacterial membrane (e.g. the presence or the absence of sterols in the 
membrane, the prevalence of negatively charged lipids etc.), fungi are in general more 
resistant to polymyxin B and other cationic antibiotics compared to Gram-negative 
bacteria.  However, Cryptococcus is more susceptible to polymyxin B than other tested 
fungal pathogens.  The evidence presented here suggests that the polysaccharide capsule 
of Cryptococcus may contribute to this hypersensitivity.  This unique negatively charged 
layer may enrich the effective concentration of cationic molecules in the 
microenvironment of the cell surface and render the Cryptococcus cells more susceptible 
to polymyxin B.   
Compared to the in vitro potency of polymyxin B, the in vivo efficacy of this 
drug against Cryptococcus is modest in our animal models.  One possible reason is the 
difference between the in vitro and the in vivo conditions.  The non-specific binding of 
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polymyxin B to proteins in serum or host tissues may decrease the effective 
concentration of the drug against Cryptococcus in vivo.  This is supported by previous 
studies showing that polymyxins lost approximately 50% of their activity in the presence 
of serum (195, 196).  Additionally, the animal models used in this study may diminish 
the observable effect of polymyxin B in vivo.  The A/J mouse is highly susceptible to 
cryptococcal infections, and the H99 strain is one of the most virulent clinical isolates 
(197).  The rapid progression of cryptococcosis in the models used here may 
underestimate the drug effect.  A better effect of polymyxin B might be expected on a 
more robust animal model, such as rat or rabbit, or when the animals are infected by a 
less virulent cryptococcal strain.  However, the fact that polymyxin B displayed a 
modest efficacy in vivo against Cryptococcus, especially in the clearance of tissue fungal 
burden, in the models used in this study suggests the potential of  polymyxin B as an 
option for the treatment of cryptococcosis.  Furthermore, polymyxin B could be used in 
topical and eye treatment to combat local fungal infections, where much higher doses of 
polymyxin B are often used to treat bacterial infections. 
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CHAPTER IV  
THE ANTIDEPRESSANT SERTRALINE PROVIDES A PROMISING 
THERAPEUTIC OPTION FOR NEUROTROPIC CRYPTOCOCCAL INFECTIONS* 
 
4.1.Introduction 
Sertraline belongs to the selective serotonin reuptake inhibitors; it is also the 
most frequently prescribed antidepressant.  Potential antifungal activity of this 
antidepressant was first observed in a clinical setting: three patients with premenstrual 
dysphoric disorder (PMDD) and recurrent vulvovaginal candidiasis (VVC) were treated 
with sertraline for their PMDD. Their clinical symptoms of VVC disappeared during the 
sertraline therapy but recurred after treatment was stopped (198).  Follow-up in vitro 
studies demonstrated that sertraline is fungicidal against Aspergillus and Candida with 
minimum inhibitory concentrations (MIC) ranging from 7 to >256 µg/ml (198, 199). 
Because the MICs of sertraline against these Aspergillus and Candida strains are much 
higher than the achievable serum concentrations of sertraline (55 to 250 ng/ml) under 
standard therapeutic regimens (200), the potential clinical value of sertraline in treating 
systemic infections caused by these fungi was considered low (201).   
The data presented in this study demonstrate that sertraline is particularly potent 
against Cryptococcus, with its fungicidal concentrations falling below 10µg/ml. 
Furthermore, previous pharmacokinetics studies of sertraline in rats and dogs indicate 
                                                 
* This material has been published in this or similar form in Antimicrobial Agents and Chemotherapy and 
is used here with permission of American Society for Microbiology. 
Zhai B, Wu C, Wang L, Sachs MS, and Lin X (2012) The antidepressant sertraline provides a promising 
therapeutic option for neurotropic cryptococcal infections. Antimicrob Agents Chemother 56(7):3758-
3766. 
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that sertraline concentrations in cerebrospinal fluid, brain, and some other organs are 20- 
to 40- fold higher than its serum concentration (202). Such levels could meet or exceed 
the MICs of sertraline against Cryptococcus isolates. In addition, abundant clinical data 
support the safety of long-term use of this antidepressant (203-205). Given its 
psychotropic nature and its potent fungicidal activity against Cryptococcus, we 
hypothesized that sertraline could be uniquely suitable in treating systemic 
cryptococcosis.  
The mechanism of action of sertraline on the mammalian nervous system has 
been well characterized: it blocks the 5-hydroxytryptamine (5-HT) transporter and 
inhibits the reuptake of 5-HT into the presynaptic cell (206). However, there is no 
conserved homolog of the 5-HT transporter in fungi.  Thus the underlying mechanisms 
responsible for the antifungal activity of sertraline remain mysterious.  One report 
attributed the antifungal activity of sertraline to a non-specific cytotoxicity due to its 
lipophilicity (201).  However, findings of two recent studies suggested membrane 
organization and vesicle-mediated transport as its antifungal targets (150, 207). 
Sertraline was also shown to possess antitumor activity (208-210). The antitumor 
activity was attributed to the inhibition of the initiation of protein synthesis through its 
effects on mTOR pathway (209). It is not clear if translation is also a target of sertraline 
in fungal cells as homologs of certain relevant factors important for translational 
regulation in mammals do not exist in fungi. In addition to antifungal and antitumor 
activities, sertraline has been shown to exert antiviral activity (211), antibacterial activity 
(212, 213), anti-parasite activity (214), and spermicidal activity (215). The anti-
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proliferative activity of sertraline against evolutionarily diverse organisms implicates its 
interference with some fundamental processes. Based on our genetic screen and in vitro 
translation assays using fungal cell extracts, we demonstrate here that sertraline indeed 
inhibits protein synthesis in fungi.  Thus, together with previous studies, our results 
indicate that the broad anti-proliferative activity of sertraline might be attributable to its 
interference with translation.  
 
4.2.Materials and methods 
4.2.1. Strains and media 
The strains used in this study are listed in Table 2.  All yeast strains were 
maintained on Yeast Peptone Dextrose (YPD) medium.  Drug disk diffusion assay or 
microdilution assay were performed using RPMI 1640 medium buffered with MOPS 
according to the standard protocol of CLSI. 
4.2.2. Compounds and animals  
Sertraline hydrochloride was dissolved in DMSO at a stock concentration of 20 
mg/ml. The drug was diluted with water or with appropriate media to the indicated 
working concentrations in the in vitro studies. For animal studies, sertraline was 
dissolved in 0.9 volume of water first and then 0.1 volume of 10x PBS stock solution 
was added. Fluconazole was dissolved at a stock concentration of 2mg/ml in water, and 
was diluted by water or appropriate media in the in vitro studies. Fluconazole was 
dissolved in 1x PBS buffer at 3mg/ml for the animal studies. Female A/J mice of 10-12 
 92 
 
weeks old were purchased from Charles River (Wilmington, MA). Drug solutions for 
animal studies were prepared freshly before daily injection.   
4.2.3. In vitro study of antifungal activity  
The drug disk diffusion assay was performed as described in Chapter III.  The 
microdilution assay was performed according to the CLSI standard except that cells 
were incubated at 37°C to mimic host conditions. The initial inocula of fungal cells 
ranged from 1500 to 2000 cells/ml. Drugs were added by calculating the desired dose as 
indicated. The minimum inhibitory concentrations (MICs) were defined by comparing 
the growth of the treated samples after 48 hours of incubation for Cryptococcus strains 
or 24 hours of incubation for Candida strains versus the no drug control via measuring 
the absorbance at 600nm. The minimum fungicidal concentrations (MFCs) were defined 
as at least 99% of cells were killed compared to the original inocula. The number of 
viable cells was determined by plating the suspension on drug free solid media and then 
measuring colony forming units (CFUs).  
The interaction between sertraline (SRT) and fluconazole (FLC) was quantified 
by the fractional fungicidal concentration index (FFCI) = [FLC]/MFCFLC + 
[SRT]/MFCSRT, where MFCFLC and MFCSRT were the concentration of fluconazole and 
sertraline used alone, respectively, and [FLC] and [SRT] were the concentrations at 
which fluconazole and sertraline, in combination, killed at least 99% of cells compared 
to the original inocula.  When MFC was not achieved (> was used in these cases), the 
concentration 2 × that of the highest concentration tested was used for the FFC index 
calculation. For the interaction of sertraline and fluconazole on Candida strains, the 
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status of cell proliferation were measured by the absorbance at 600nm and quantitatively 
displayed with color. 
4.2.4. In vivo model of systemic cryptococcosis 
Mice were assigned into 4 groups: control (PBS), fluconazole, sertraline, and the 
drug combination. All treatments, including the PBS control, were given 
intraperitoneally. The mice of the sertraline and the drug combination groups were 
treated with sertraline at the dose of 15 mg/kg/day for 7 days before Cryptococcus 
infection. All the mice were challenged with 1.0x104 H99 cells intravenously. The 
sertraline treatment continued. The fluconazole treatment at the dose of 15 mg/kg/day 
and the drug combination group was initiated after 24 hours of infection. All the drug 
treatment continued for three consecutive days after infection and the mice were 
sacrificed. Brains, kidneys, and spleens of mice were harvested and homogenized. 
Suspensions were serial diluted (10x), plated onto YPD agar, and incubated for another 
two days for the colonies to become visible in order to calculate CFU. Animals were 
weighed daily and monitored twice a day for disease progression and potential severe 
side effects, including weight loss, gait changes, labored breaths, or fur ruffling. The 
animal experiments were carried out in strict accordance with the recommendations in 
the Guide for the Care and Use of Laboratory Animals of the National Institutes of 
Health. The protocol was approved by the Texas A&M University Institutional Animal 
Care and Use Committee (IACUC, Animal protocol permit number: 2011-22). 
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4.2.5. Gene ontology analysis on the fungal target of sertraline 
The genome deletion mutant collection in 96-well plates were replicated onto 
RPMI agar medium, or RPMI agar medium with addition of 4 µg/ml or 6 µg/ml of 
sertraline, for the selection of sensitive and resistant strains, respectively.  After 2 days 
of incubation, about 300 strains with visually detectable differences in colony growth 
were selected (either more sensitive or more resistant).  These selected strains were 
streaked out for individual colonies and tested through two additional rounds to exclude 
issues of contamination during replication or storage.  In total, 89 resistant mutants and 
33 sensitive mutants were selected.   
4.2.6. Cell-free translation analysis 
Cryptococcus H99 cells from an overnight culture were inoculated into 2-liter 
YPD medium to the optical density of 0.05 (OD. 600).  The culture was incubated at 
30°C with shaking for approximately 10 more hours to reach the optical density of 2. At 
this stage, the cells were collected, washed, and resuspended for the preparation of yeast 
cell-free extract.  The resuspended cells were dripped directly into liquid nitrogen by 
using a sterile Pasteur pipette to form small ice beads.  Frozen cell beads were 
transferred into pre-chilled grinding vials of a SPEX SamplePrep 6850 Freezer/Mill and 
powdered in the liquid nitrogen-filled tub using a setting consisting of 10 minutes of pre-
cooling followed by three 2-min grind cycles with 1-min re-cooling between each cycle.  
The powdered cells were transferred to pre-chilled 50-mL polycarbonate centrifuge 
tubes, allowed to thaw on ice, and then centrifuged at 4°C for 15 min at 16,000 rpm in an 
SS34 rotor. The supernatant was carefully collected with a sterile Pasteur pipette, 
 95 
 
avoiding both the pellet and the fatty upper layer, and placed in a fresh 15 ml conical 
tube that was maintained on ice.  Small molecules were removed from the extract by 
chromatography through Sephadex G-25 superfine columns (216). 
Capped, polyadenylated RNA encoding the firefly luciferase was synthesized 
using T7 RNA polymerase from a pPQ101(216).  Uncapped RNA transcripts were also 
synthesized using the same procedure by omitting cap analog. The yield of RNA was 
quantified using ImageQuantTL software by comparison to standard markers with 
known masses using ethidium bromide-stained agarose gels. Gel images were acquired 
with a GE Typhoon Trio phosphorimager. 
The in vitro translation reaction mixtures (10 µl, programmed with 60 ng of 
template RNA) were incubated at 26°C for 40 min.  The reactions programmed in 
Cryptococcus extract contained 110 mM KOAc, 35 mM HEPES-KOH (pH 7.6), 2.6 mM 
Mg(OAc)2, and 10 µM of each amino acid. Translation reactions were stopped by 
adding passive lysis buffer (Promega) to final 1× concentration. Firefly luciferase 
activity was determined using the Luciferase Assay System (Promega), and measured 
with a Perkin Elmer Victor3V multilabel counter. Where 5 µCi of [35S]Met (MP 
Biomedical, > 1000 Ci/mmol) was used to label the translation products, the translation 
reaction mixtures contained 10 µM of each amino acid except methionine. Translation 
reactions were stopped by adding SDS-PAGE loading buffer (Invitrogen) to final 1x 
concentration. [35S]Met-labeled translation products were analyzed on SDS-PAGE gels 
and visualized using a GE Typhoon Trio phosphorimager. 
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4.3. Results 
4.3.1. Sertraline is fungicidal against various Cryptococcus isolates in vitro 
During the drug screen described in the previous chapter, we found that sertraline 
exhibited a modest inhibitory effect on Aspergillus nidulans.  We investigated the 
activity of this antidepressant against Cryptococcus given the brain involvement of 
cryptococcal infections and the psychotropic property of this drug.  Sertraline displayed 
high potency against H99, a clinical and reference Cryptococcus strain. The MIC90 
against H99 is approximately 6µg/ml (Table 6), which is much lower than the reported 
MICs against many other fungal strains of Candida or Aspergillus species (198, 199). 
 
 
 
Figure 20  Sertraline is fungicidal against both proliferative and quiescent 
Cryptococcus cells  
(A): H99 cells were inoculated into RPMI media and cultured without any drug 
(control), or in the presence of fluconazole (FLC, 8 µg/ml), sertraline (SRT, 10µg/ml), or 
a combination of these two drugs. At the indicated time points, aliquots of cell 
suspensions were transferred and plated onto drug-free agar medium to determine CFU 
after two more days of incubation. Fungal cells proliferated rapidly in the absence of any 
drugs, but they were gradually cleared with any of the drug treatments. (B): H99 cells 
were inoculated into PBS buffer and cultured without any drug (control), or in the 
presence of fluconazole (8 µg/ml), sertraline (8 µg/ml), or a combination of these two 
drugs. At the indicated time points, aliquots of cell suspensions were transferred and 
plated on drug-free medium to determine CFU after two more days of incubation. 
Fungal cells in PBS maintained the viability during the tested period. 
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To determine whether sertraline is fungistatic or fungicidal, we performed a 
comparative time-course assay of cell viability in the presence of sertraline and the 
commonly used fungistatic drug fluconazole.  We cultured Cryptococcus H99 cells in 
RPMI medium or in PBS buffer to represent rapidly proliferative or quiescent cells, 
respectively.  These cells were treated with no drug, sertraline alone, fluconazole alone, 
or with a combination of sertraline and fluconazole.  At different time points, aliquots of 
cell suspensions were spread onto drug-free solid medium to determine the number of 
viable cells by measuring the colony forming units (CFU).  In RPMI medium, the 
number of viable cryptococcal cells started to decrease as early as 2 hours in the 
presence of sertraline compared to the no drug control; and there were no viable fungal 
cells in the presence of sertraline after 48 hours of incubation (Fig. 20A).  Sertraline was 
modestly more effective than fluconazole under this condition (Fig. 20A).  The drug 
combination showed the highest efficiency in clearing the yeast cells (Fig. 20A).   
Similarly, Cryptococcus cells in PBS buffer were rapidly cleared by sertraline 
(within 4 hours after inoculation), indicating that sertraline is fungicidal and is potent 
against H99 cells regardless whether cells are growing or not (Fig. 20B).  In sharp 
contrast, fluconazole showed no effect on the viability of the fungal cells in PBS buffer 
(Fig. 20B).  The lack of killing effect of fluconazole on quiescent fungal cells is 
consistent with the classification of fluconazole as a fungistatic drug: that is, it is 
effective in inhibiting fungal cell proliferation, but ineffective in destroying cells that are 
not actively growing. The fungicidal effect of sertraline is not specific to Cryptococcus, 
as sertraline also kills S. cerevisiae BY4742 cells regardless whether they were in RPMI 
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medium growing or in PBS buffer quiescent (Fig. 21).  These results indicate that 
sertraline is able to kill fungal cells independent of whether they are proliferating. 
 
 
Figure 21  Sertraline time-course study with S. cerevisiae  
Saccharomyces cerevisiae BY4742 cells were inoculated into RPMI media or PBS 
buffer with or without the addition of sertraline at the final concentration of 6µg/ml. At 
the indicated time points, aliquots of cell suspensions were plated onto drug-free 
medium to determine CFU. Sertraline cleared both proliferative and quiescent S. 
cerevisiae cells. 
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Table 6  Sertraline, alone or with fluconazole, is potent against diverse 
Cryptococcus isolates 
 
Strains 
Serotype  
(source) 
Geographic 
Origins 
MIC90 
SRT 
MFC 
SRT 
MIC90 
FLC 
MFC 
FLC 
MFC 
SRT – FLC 
FFCI 
H99 A (C) North America 6 10 1 8 2 – 2 0.45 
C45 A (C) North America 2 6 2 6 1 – 2 0.50 
A7-35-23 A (E) North America 3 10 4 >64 4 – 4 0.43 
C23 A (C) North America 5 8 8 64 2 – 8 0.38 
Bt31 A (C) Africa 4 8 12 32 4 – 8 0.63 
Bt81 A (C) Africa 5 8 12 >64   2 – 16 0.38 
92BC2-45 A (C) Europe 6 10 4 >64   6 – 32 0.85 
92BC1-52 A (C) Europe 3 8 3 64 2 – 4 0.31 
98BC1-86 A (C) Europe 5 8 2 32   2 – 16 0.75 
A2-102-5 A (E) North America 5 8 16 32 4 – 8 0.75 
123.96 A (C) North America 4 8 8 >64   4 – 16 0.63 
Bt50 A (C) Africa 6 10 16 >64   4 – 32 0.65 
163.99 A (C) North America 4 6 6 >64   2 – 32 0.58 
UA 1993 A (C) Europe 5 8 2 6 2 – 2 0.54 
JEC21 D (L) North America 2 6 1 4 1 – 2 0.83 
3-10 D (E) North America 3 10 4 >64 2 – 8 0.26 
3-17 D (E) North America 4 8 2 64 2 – 4 0.31 
93BC2-52 D (C) Europe 3 8 4 32 1 – 8 0.38 
99BC1-40 D (C) Europe 4 8 3 32 2 – 4 0.38 
UA 491 D (C) Europe 4 8 2 8 2 – 2 0.50 
XL1495 AD hybrid (L) North America 4 8 3 8 2 - 4 0.75 
UM4 AD hybrid (N) Europe 4 10 6 >64   4 – 16 0.53 
92C AD hybrid (N) Europe 4 10 4 >64   6 – 32 0.85 
VPCI 87 C. gattii (E) North America 4 10 6 64 2 – 8 0.33 
 
(C): clinical strain; (E): environmental strain; (L): laboratory strain; (N): not clear. 
MIC90 (µg/ml): drug concentration that resulted in a 90% decrease in absorbance. 
MFC (µg/ml): minimal fungicidal concentration, the lowest concentration at which at 
least 99% of cells were killed compared to the original inoculums. When fluconazole is 
used alone, MFC is indicated by “>”when is not achieved in the dose range tested.  
FFCI: fractional fungicidal concentration index. FFCIs < 0.5: synergistic, FFCIs between 
0.5-1.0: additive, FFCIs between 1.0-2.0: indifferent, FFCIs > 2.0: antagonistic. 
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To examine whether the susceptibility to sertraline is specific to the H99 strain or 
is a general trait of Cryptococcus, we further tested 23 genetically and phenotypically 
distinct Cryptococcus strains, including 13 serotype A (this serotype accounts for 95% of 
the clinical representation of cryptococcosis cases), 6 serotype D (serotype D represents 
fewer than 5% of clinical cases of cryptococcosis), 3 AD hybrid, and 1 C. gattii strain 
(Table 6).  These strains are clinical or environmental isolates originated from North 
America, Europe, or Africa.  The MICs of sertraline were determined by the 
microdilution assay according to the CLSI standard. Compared to the wide range of 
inhibitory concentrations of fluconazole (from 1 to >64 µg/ml), all of these strains are 
very sensitive to sertraline, with a surprisingly narrow spectrum of inhibitory 
concentrations (≤10 µg/ml) (Table 6).  Notably, there is no correlation between the level 
of susceptibility to fluconazole and to sertraline among these strains, indicating that there 
is no cross-resistance between sertraline and fluconazole. Thus, it is unlikely that these 
two drugs share common mechanisms of action. These results imply the general 
susceptibility of Cryptococcus to sertraline irrespective of their susceptibility level to 
fluconazole. 
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Figure 22  The synergy between sertraline and fluconazole in the disc diffusion 
assay against Cryptococcus isolates  
Disks containing water, fluconazole, sertraline, or the drug combination were air dried 
and then placed on top of a lawn of yeast cells derived from the strains indicated. Cells 
were incubated at 37°C for 48 hours. Inhibition of fungal growth in regions surrounding 
the disk produced a halo and the drug efficacy was determined by the size and the 
clearance of the halo. The drug combination demonstrated a better efficacy against all 
tested strains compared to single drugs alone. 
 
 
4.3.2. Sertraline interacts synergistically or additively with fluconazole against 
Cryptococcus in vitro 
As fluconazole is the most commonly used antifungal in cryptococcosis 
treatment, drugs that can act additively or synergistically with fluconazole are more 
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likely to be used clinically. In the time-course assay described above, we observed that 
the combination of sertraline and fluconazole accelerated the clearance of proliferative 
Cryptococcus cells (Fig. 20A). To determine the interaction between sertraline and 
fluconazole against Cryptococcus, we compared the susceptibility of the 24 isolates to a 
combination of these drugs with their susceptibility to each drug alone using the disk 
diffusion halo assay. For all the strains tested, halos formed near disks containing the 
drug combination were larger and clearer than those formed near disks containing either 
fluconazole or sertraline alone (Fig. 22). The results indicate possible synergistic or 
additive interactions between sertraline and fluconazole against Cryptococcus. 
We next quantified the interaction between sertraline and fluconazole against 
Cryptococcus by using a microdilution assay to determine the fractional fungicidal 
concentration index (FFCI). Sertraline increases the antifungal activity of fluconazole 
against all the tested Cryptococcus strains, demonstrating a synergistic (FFCI < 0.5) or 
additive (FFCI between 0.5-1.0) (182) effect between the two drugs (Table 6). This is 
consistent with the results obtained by the disk-diffusion method. Considering the 
divergence of genetic background of the tested strains, these observations suggest the 
possibility that the combination of sertraline and fluconazole could be more effectively 
clearing different Cryptococcus isolates in mammalian cryptococcosis. 
4.3.3. Sertraline alone or in combination with fluconazole displays antifungal activity 
in a murine model of systemic cryptococcosis 
As described earlier, sertraline exerts anti-Cryptococcus activity alone or in 
combination with fluconazole in vitro.  To determine the efficacy of sertraline or its 
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combination with fluconazole in vivo, we adopted a murine model of systemic 
cryptococcosis.  We chose the intravenous model of cryptococcosis here because our 
pilot experiments showed that organ fungal burden displayed relatively low variations 
among individual animals. To examine the drug efficacy in this model, we assigned mice 
into four groups: the control (PBS) group, fluconazole treatment group, sertraline 
treatment group, and the group receiving a drug combination.  Given that it takes at least 
5~7 days for sertraline to reach a steady state in the mouse brain (217), mice of the 
sertraline group and the drug combination group were given a 7-day pretreatment of 
sertraline prior to the infection by the Cryptococcus reference strain H99.  Based on 
previous studies, the serum level of sertraline in these animals was likely to be too low 
(55 to 250 ng/ml (200)) to exert any growth inhibitory effect on the fungal cells initially 
inoculated into the blood stream. Fluconazole treatment was initiated at one day post 
infection (DPI 1) in both the fluconazole alone treatment group and the drug 
combination treatment group. Such treatment was continued for three consecutive days. 
The animals were sacrificed at DPI 4; their brain, kidney, and spleen were homogenized 
and the fungal burdens of these organs were determined by measuring CFU. As shown 
in Fig. 23, the treatment with sertraline alone reduced the fungal burden in the brain (P 
value < 0.05), with its efficacy comparable with that of fluconazole. Sertraline also 
reduced fungal burden in kidney, while fluconazole showed no apparent effect. 
Sertraline appeared to have a modest effect on fungal burden in spleen but such effect 
was not statistically significant. The difference in the drug efficacy on the three organs 
examined may reflect variations of drug concentrations at these organs. Importantly, the 
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treatment with the combination of sertraline and fluconazole displayed the most potent 
efficacy in reducing fungal burden of all three organs examined (Fig. 23). Therefore, the 
data demonstrate that sertraline alone is efficacious against cryptococcosis and the 
combination of sertraline with fluconazole is a more effective treatment than either drug 
alone due to their strong synergy in vivo. 
 
 
 
 
 
Figure 23  Sertraline reduces the fungal burden alone or in combination with 
fluconazole in vivo  
Brains (A), kidneys (B) and spleens (C) of mice from different treatment groups were 
dissected and homogenized. The suspensions were diluted serially and the fungal burden 
was determined by calculating CFU. Sertraline alone significantly reduced the brain and 
the kidney fungal burden while the drug combination reduced the fungal burden 
significantly in all three organs. *: P value < 0.05; **: P value < 0.01; ***: P value < 
0.001. In brain, the drug combination displays higher potency comparing to either 
fluconazole or sertraline alone (both P values < 0.05). The efficacy of the drug 
combination is also superior to that of fluconazole alone in kidney (P value < 0.001), or 
that of sertraline alone in spleen (P value < 0.001). 
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4.3.4. Sertraline antagonizes the growth inhibitory effect of fluconazole against many 
Candida strains 
To examine if the potency of sertraline alone or in combination with fluconazole 
can be extended to Candida species, we tested the MICs of sertraline against six strains 
that represent six different Candida spp.: C. albicans SC5314, C. glabrata PAT2ISO3, 
C. krusei DUMC132.91, C. parapsilosis MMRL1594, C. tropicalis MMRL2017, and C. 
lusitaniae 2-367.  The MIC90s ranged from 12 to 24 µg/ml (Table 7), which are 
considerably higher than the MICs against Cryptococcus but are consistent with previous 
studies (198).  These MIC values are higher than the achievable blood or even organ 
levels of sertraline.   
 
 
Table 7  Sertraline is less potent against Candida strains 
 
Strains  MIC90 MIC100 
Candida albicans SC5314  32 48 
Candida glabrata PAT2ISO3
 
 12 16 
Candida krusei DUMC132.91
 
 12 16 
Candida parapsilosis MMRL1594
 
 24 24 
Candida tropicalis MMRL2017
 
 24 32 
Candida lusitaniae 2-367
 
 8 24 
 
MIC100: the lowest drug concentration that resulted in a 100% decrease in absorbance. 
Unit: µg/ml 
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In striking contrast to the results obtained with Cryptococcus, sertraline exerted a 
significant antagonistic impact on the inhibitory effect of fluconazole against the 
majority of the tested Candida stains in vitro (Fig. 24). For example, one-day incubation 
with fluconazole alone was able to effectively inhibit the growth of C. tropicalis 
MMRL2017 strain at a concentration of 1.0µg/ml.  However, with the addition of 
sertraline (1.0~6.0 µg/ml), fungal growth in the presence of fluconazole not only 
recovered but actually became more robust.  The spectrum of the concentrations at 
which sertraline exerts antagonistic effect with fluconazole, unfortunately falls in the 
clinically relevant range.  Similar antagonistic interactions between sertraline and 
fluconazole were also observed among three other Candida strains: C. albicans SC5314, 
C. glabrata PAT2ISO3, and C. parapsilosis MMRL1594 (Fig. 24). Sertraline did not 
decrease the inhibitory effect of fluconazole on C. lusitaniae 2-367 or on C. krusei 
DUMC132 (Fig. 24). Although synergistic or additive interactions between sertraline 
and fluconazole were reported in some Candida strains (150), antagonistic interactions 
between fluconazole and sertraline are commonly observed among Candida and 
Aspergillus strains (this study and (218)). 
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Figure 24  Antagonistic effects between sertraline and fluconazole among Candida 
strains  
Six Candida strains, C. albicans SC5314, C. glabrata PAT2ISO3, C. krusei 
DUMC132.91, C. parapsilosis MMRL1594, C. tropicalis MMRL2017, and C. 
lusitaniae 2-367 were incubated in RPMI media with indicated drug treatment. Gradient 
by columns: sertraline (µg/ml); gradient by rows: fluconazole (µg/ml). The scale of the 
fluconazole concentrations was determined based on the results from Chapter III. 
Growth was measured by absorbance at 600 nm after 24 hours of incubation. Green 
indicates fungal growth and black indicates the lack of fungal growth. 
 
 
4.3.5. Sertraline interferes with translation in fungal cells 
The broad anti-proliferative activity of sertraline against many organisms 
indicates that the mechanism underlying its fungicidal activity may involve some 
fundamental cellular processes.  To identify the potential fungal molecules and processes 
affected by sertraline, we screened the whole genome deletion collection of S. cerevisiae 
for sertraline-sensitive or sertraline-resistant mutants. This mutant collection set is 
composed of a non-essential gene deletion set in a haploid background and an essential 
gene deletion in a heterozygous diploid background (180). After one round of initial 
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screen and two rounds of additional screen to confirm the selected phenotype, 88 
resistant and 36 sensitive strains were identified. Gene ontology analyses indicate that 
these genes are enriched for those with roles in intracellular vesicle transport and 
membrane organization (Fig. 25), which is consistent with the findings of two recent 
studies of sertraline on yeast (150, 207). 
 
  
 
Figure 25  Gene ontology analysis of the S. cerevisiae genes involved in sertraline 
tolerance or susceptibility  
Gene ontology (GO) terms for annotated S. cerevisiae genes involved in sertraline 
resistance (A) or susceptibility (B) were extracted from the GO database and sorted into 
the immediate subcategories for molecular functions and biological processes. 
 
 
Interestingly, genes related to protein synthesis are highly enriched in the 
resistant group; and the most sensitive mutant selected from our screen was Δtif3, a 
strain in which an important translation initiation factor Tif3 was disrupted. Since 
previous studies in mammalian cells have indicated that sertraline inhibits translation 
initiation (209), these data indicated that it was possible that sertraline also disrupts 
translation in fungi. 
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4.3.6. Sertraline inhibits translation in a Cryptococcus cell-free system 
To determine the effect of sertraline on translation in Cryptococcus, we 
performed in vitro translation assays.  In these assays, the luciferase mRNA was used as 
the template and the translation machinery was provided by the cell extract obtained 
from C. neoformans strain H99. As expected, translation in these Cryptococcus cell 
extracts was synergistically dependent on the mRNA 5' terminal cap and 3' terminal 
poly(A) tail, as with Saccharomyces cell extract (Fig. 26A) and Neurospora crass cell 
extract (216, 219). This result verified that Cryptococcus in vitro translation system 
faithfully recapitulated the dependence of cap and poly(A) for translation. 
The effects of sertraline on translation of cap and poly(A) luciferase mRNA was 
assessed by two means: 1) the enzymatic activity of the luciferase produced by the in 
vitro translation, and 2) the level of [35S] methionine incorporation into the luciferase 
polypeptide produced. We found that sertraline inhibited the translation efficiency in a 
dose-dependent manner using both detection methods (Fig. 26B and C). Luciferase 
enzyme activity dropped 50% compared to the control when the concentration of 
sertraline was increased to 0.1 mM (30.6 µg/ml). No enzyme activity above background 
was detected in the presence of sertraline at 0.4 mM (122.4 µg/ml). The decrease in 
luciferase enzyme activity in the presence of sertraline was not due to direct interference 
of sertraline on the enzymatic activity of the synthesized luciferase, since addition of 
sertraline into the cell extract after translation was completed did not alter enzyme 
activity based on this measurement (Fig. 26B). The [35S] methionine incorporation assay 
showed that sertraline affected the yield of luciferase polypeptide synthesized in this cell 
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extract (Fig. 26C). Protein synthesis was also affected by sertraline in fungal extracts 
derived from the yeast S. cerevisiae and the filamentous fungus N. crassa, although 
higher concentrations of sertraline were required to achieve a similar level of inhibition 
(Fig. 27). In contrast, fluconazole, which is known to target the enzyme Erg11 in the 
ergosterol biosynthetic pathway, did not show any inhibitory effect on protein synthesis 
in a similar concentration range in such assays (Fig. 28). These data obtained in cell-free 
translation systems using fungal extracts show that sertraline interferes with fungal 
protein synthesis. 
 
 
 
Figure 26  Sertraline inhibits translation in a Cryptococcus cell-free system 
Cell-free translation system was prepared as described in Materials & Methods. (A): The 
translation of luciferase in both Cryptococcus and Saccharomyces cell free extracts is 
dependent on the mRNA 5' terminal cap, designated as C, and on the 3' terminal poly(A) 
tail, designated as A. The cap and poly(A) synergistically stimulate RNA translation in 
both cell free systems. (B) and (C): Water, the solvent (DMSO), or sertraline in stock 
solution was added into reactions to reach the indicated concentrations. Luciferase 
protein synthesis by the cell-free translation system was measured based on the relative 
light units arising from the enzymatic activity of luciferase (B), or the level of [35S] 
methionine incorporated into the synthesized luciferase polypeptide (C). Both 
measurements showed that sertraline inhibited translation in a dose-dependent manner. 
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Figure 27  Sertraline inhibits translation with the cell extract of S. cerevisiae or 
Neurospora crassa 
Luciferase protein synthesis by the cell-free translation system was measured based on 
the relative light units generated due to the enzymatic activity of luciferase. The cell 
extracts of S. cerevisiae (A) or N. crassa (B) were inhibited by sertraline in a dose-
dependent manner. The in vitro translation processes in both systems dropped sharply 
when the sertraline concentration was increased to 0.5mM. 
 
 
 
 
Figure 28  Fluconazole shows no apparent inhibition on protein synthesis in the in 
vitro translation assay 
The in vitro translation of luciferase in Cryptococcus cell extract was accomplished in 
the presence of fluconazole at indicated concentrations. No dramatic decrease of 
luciferase activity was observed even when the concentration of fluconazole reached 
1mM. 
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4.4. Discussion 
4.4.1. Sertraline offers a promising option for the therapy of cryptococcal meningitis 
Here we provide evidence for the potent anti-cryptococcal activity of the 
antidepressant sertraline both in vitro and in vivo. Given the difficulties in developing 
antifungal drugs de novo, recent studies have explored existing clinical compounds for 
potential use as antifungals (220).  Existing pharmaceutical and safety information 
concerning the use of these drugs in animals or in humans could greatly accelerate the 
investigation into their clinical use as antifungals.  Consistent with the safety profile of 
sertraline for long-term use in patients, we did not observe any severe side-effects due to 
sertraline administration during the treatment process in the animal studies presented 
here. Previous studies also showed the safety of sertraline administration in mice with a 
similar daily dose but for a much longer period of time (214). 
The discovery that sertraline has anti-cryptococcal activity offers the potential for 
an additional choice for treating cryptococcosis.  Our tests of 24 diverse Cryptococcus 
strains indicate a uniformly high sensitivity of this fungus to sertraline relative to other 
fungal species tested.  Compared to fluconazole, sertraline showed a much narrower 
range of inhibitory concentrations against these diverse Cryptococcus isolates (Table 6), 
suggesting a lower probability of naturally occurring resistance to sertraline in existing 
Cryptococcus populations.  The fungicidal nature of sertraline and its synergy with 
fluconazole against Cryptococcus as previously observed in vitro and in vivo in an insect 
model (150) and this study shown in a mammalian model, could potentially shorten the 
duration of anti-cryptococcal therapy, and reduce the risk of emerging drug-resistance.  
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During latent infection or during fluconazole treatment, Cryptococcus cells are likely 
dormant or grow slowly. Given that even dormant cells need transcription and 
translation (221), and that sertraline is capable of killing fungal cells under quiescent 
conditions, it is reasonable to speculate that sertraline might be useful to clear latent 
cryptococcal infections or to kill residual fungal cells unharmed by the fluconazole 
treatment.  This could be tested by further investigation. 
It is worth mentioning that we did not observe any difference in survival in any 
of the treatment groups (including the fluconazole treated groups).  This is consistent 
with the observation in Chapter III.  The A/J mouse used in this study is very susceptible 
to Cryptococcus infections and H99 is one of the most virulent clinical isolates of 
Cryptococcus (197).  We tried different inocula of the fungal cells (1x103, 1x104, and 
1x105 cells/mouse) in this intravenous infection model and found that a 10-fold decrease 
in inoculum prolonged survival for an additional 1- 2 days, and that infected mice all 
succumbed to the diseases within 8 days.  We speculate that better protection against 
cryptococcosis by sertraline or the drug combination might be observed in other animal 
models or in humans, or if cryptococcosis is caused by less virulent strains.  
Optimization of drug doses, the route and frequency of drug administration, and the 
duration of treatment warrant further investigation in order to assess the treatment 
outcomes. 
One of the most valuable aspects of sertraline as a potential anti-cryptococcal 
drug is its superior ability to accumulate in CNS relative to other antifungals.  This is 
particularly critical in the treatment of cryptococcosis given that Cryptococcus 
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preferentially proliferates in the brain. Consistent with our expectations, the in vivo study 
presented here supports the ability of sertraline in reducing brain fungal burden, either 
alone or in combination with fluconazole.  
Although sertraline demonstrates comparable efficacy against cryptococcosis as 
fluconazole based on the data presented here, the potential application of this drug to 
treat mycoses caused by fungal pathogens such as Candida or Aspergillus requires 
further investigation. The commonly observed antagonistic interaction between 
sertraline and fluconazole against Candida and Aspergillus strains is particularly 
concerning (this study and (218)). It is possible that specific chemical modification of 
sertraline could increase its efficacy against these other fungi and abolish its antagonistic 
interaction with fluconazole. Such modifications would increase its value in the battle 
against systemic mycoses. 
4.4.2. The antifungal mechanism of sertraline 
Sertraline displays extremely broad anti-proliferative activity against 
evolutionarily diverse organisms (117, 198, 199, 209, 211, 212, 215). Recent studies 
indicate the influence of sertraline on membrane stability or vesicle transport in fungi 
(150, 207). The results of our S. cerevisiae mutant screens are consistent with these 
discoveries. Our mutant screens and the in vitro translation assays also indicated protein 
synthesis as another process interfered by sertraline. Our finding regarding the inhibitory 
effect of sertraline on translation is consistent with a recent study on translation in tumor 
cells (209), even though the implicated mammalian factors in the mTOR pathway 
identified in that study, such as PDCD4 or REDD1, do not have obvious homologs in 
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fungi. Inhibition of translation could possibly cause changes in other processes, as 
molecules involved in protein trafficking and membrane proteins are also significantly 
enriched in our screen (Fig. 25).  Sertraline’s impact on translation might more acutely 
affect protein synthesis from specific transcripts in Cryptococcus important for growth 
such that it does not need to completely inhibit protein synthesis for its strong anti-
cryptococcal activity.  Thus, while sertraline inhibits mammalian protein synthesis, it 
may be that qualitative, not quantitative, differences in sertraline’s effects on fungal 
protein synthesis are crucial for sertraline’s anti-proliferative activity.   
The possibility of emergence of fungal resistance to sertraline seems low based 
on the following observations.  First, we noted during our genetic screen that S. 
cerevisiae gene deletion mutants selected for sertraline resistance showed only up to 
50% increase in MIC compared to the wildtype.  Second, our repeated attempts of UV 
mutagenesis of S. cerevisiae and C. neoformans failed to yield any sertraline-resistant 
strains with MICs greater than 14µg/ml.  Third, all natural Cryptococcus strains tested 
uniformly showed high sensitivity to sertraline.  Such observations are drastically 
different from what is known for azole drugs, as more than 10-100 fold difference in 
fluconazole susceptibility can be easily observed in both clinical and laboratory settings. 
This feature, although making it rather challenging to pinpoint the underlying fungicidal 
mechanisms of sertraline, could be advantageous for its clinical application, as the 
possibility of encountering sertraline-resistant Cryptococcus isolates and the risk of 
developing fungal resistance during therapy would be low. 
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CHAPTER V  
CONCLUSIONS AND FUTURE DIRECTIONS 
 
5.1. Summary of research 
The purpose of this research is to understand the pathogenesis of Cryptococcus 
and to explore novel antifungal drugs. 
5.1.1. Construct and characterize the congenic strains of the filamentous form of 
Cryptococcus neoformans 
We used a series of backcrosses to generate a pair of congenic α and a strains in 
the highly self-filamentous XL280 background.  We characterized the behaviors of the 
strains in vitro and in two mouse models of cryptococcosis.  Our data showed that the 
congenic strains are phenotypically similar under various conditions in vitro.  They are 
also nearly equivalent in virulence, as observed from the animal survival curve, fungal 
burden in organs, and the competitive growth during co-infection.  One obvious 
exception was better self-filamentation observed in the α strain.  Enhanced filamentation 
of the α strain is consistent with previous research showing that the mating type locus is 
a quantitative trait locus controlling self-filamentation and the α allele promotes 
filamentation (68).  Therefore, the difference in the mating type allele does not directly 
contribute to the difference in virulence in XL280 background. 
Meanwhile, we tested the function of a known master regulator of 
morphogenesis, Znf2, in the XL280 background.  We found that Znf2 plays predicted 
roles in filamentation and biofilm formation.  It also negatively regulated virulence as 
 117 
 
we expected.  The overexpression of Znf2 reduces the CNS penetration of cryptococcal 
cells, consistent with what we have observed in H99 background.  Our lab previously 
showed that Znf2 regulates a set of cell surface and secretory proteins, and studies on 
other fungal pathogens had demonstrated that the cell surface proteins are critical during 
the fungal invasion of brain (72, 222).  Therefore we speculate that the neurotropic 
activity of Cryptococcus is influenced by the altered expression level of Znf2 via the 
changing of cell surface composition or structure.   
As XL280 has been used in a variety of studies to investigate morphogenesis, 
sporulation, and cryptococcal interaction with various hosts since its generation on 2006 
(27, 30, 66, 68, 81, 160, 161), the congenic pair strains generated from this current study, 
in combination with its recently sequenced genome (158), will enable XL280 to be a 
useful model for future analysis of morphogenesis and virulence in C. neoformans. 
5.1.2. Repositioning of polymyxin B and sertraline as novel antifungals 
The benefits of research on existing clinical compounds that exert antifungal 
activity are attracting more attention in recent years.  The existing information 
concerning the pharmaceutical and safety of these drugs implicates a much shorter 
period of investigation before their potential clinical use as antifungals.  Through a 
screen of the Johns Hopkins Clinical Compound Library, we found that the antibiotic 
polymyxin B and the antidepressant sertraline possess antifungal activity.   
Polymyxin B alone is toxic to a variety of pathogenic fungi at relatively high 
inhibitory concentrations.  However, it is particularly potent against Cryptococcus.  Here 
we showed that the combination of polymyxin B and fluconazole (or itraconazole) at 
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low concentrations are fungicidal with a broad spectrum, including fluconazole-resistant 
strains.  We then confirmed this synergy between polymyxin B and fluconazole in a 
murine model of systemic cryptococcosis.  Further analysis suggested that the capsule of 
Cryptococcus renders the fungal cells hypersensitive towards polymyxin B.  This is in 
contrast to its usual protective role in various stress conditions.  However, polymyxin B 
frequently binds with proteins in serum and organs in a non-specific manner.  It also 
lacks the ability of CNS penetration.  In these cases, the efficacy of this drug against 
brain fungal infections may be modest.  Therefore polymyxin B could be more 
promising for treating infections other than brain, or for topical use.  
A more encouraging discovery is the potent anti-cryptococcal activity of 
sertraline.  Sertraline displays a much narrower range of inhibitory concentrations 
comparing with fluconazole.  It also interacts with fluconazole synergistically or 
additively against divergent Cryptococcus isolates.  These data suggested that 1) there is 
a low probability that Cryptococcus isolates are intrinsically resistant to sertraline; 2) the 
outcome of a combinational therapy with sertraline and fluconazole is likely to be 
synergistic.  More importantly, sertraline alone is fungicidal and is able to accumulate in 
CNS.  These are the two key features desirable for the ideal anti-cryptococcal drug.  The 
in vivo data further confirmed that the antifungal activity of sertraline is comparable with 
fluconazole in reducing fungal burden in the brain.  Sertraline also interacts 
synergistically with fluconazole in all the tested organs.  Our study is the first to 
demonstrate the anti-cryptococcal activity of sertraline, specifically in the central 
nervous system.  This discovery provides the key evidence that supports the clinical trial 
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of adjunctive sertraline for the treatment of HIV-associated cryptococcal meningitis 
(ClinicalTrials.gov Identifier: NCT01802385).  This is an essential step bridging 
laboratory findings and clinical application of the discovery. 
Several recent studies including ours have suggested that sertraline is a 
compound with pleiotropic effects in eukaryotic cells.  We found that sertraline inhibits 
protein synthesis, which is supported by the GO analysis of the screen results of 
Saccharomyces genome deletion set against sertraline and the in vitro translation assay.  
The GO analysis and a recent study on Saccharomyces also have suggested the potential 
influence of sertraline on membrane stability or vesicle transport in fungi.  The 
pleiotropic effects of sertraline may account for the extremely low incidence of 
resistance among various Cryptococcus isolates. 
 
5.2. Future directions 
5.2.1. Dissection of the relationship of fungal virulence and morphotype transition in 
Cryptococcus 
The yeast-hyphal transition is particularly critical in fungal virulence of many 
pathogenic fungi during the host-pathogen interaction (70, 73, 74).  We have observed a 
protective immune response in the host during the infection with a ZNF2 overexpression 
strain in the H99 background.  We would like to further characterize the factor(s) in 
Cryptococcus that mediate(s) this protection.  The research will have three directions: 1) 
the ongoing research suggests that Znf2 regulates the hyphal formation mainly via two 
parallel downstream factors, Cfl1 and Pum1.  We plan to further test the fungal virulence 
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influenced by the overexpression of ZNF2 in the absence of Cfl1 and Pum1.  This could 
help us to determine whether the attenuated virulence is related to the hyphal form of 
Cryptococcus per se.  2) The regulon of Znf2 contains factors that affect the cell wall 
composition.  Therefore we plan to examine the cell wall composition of the ZNF2 
overexpression strain.  We also plan to characterize the factor(s) that is (are) responsible 
for this cell wall remodeling and the consequent impact on virulence.  3) We have 
collected the serum from the animals that had developed protective immune response as 
a result of ZNF2 overexpression strain infection.  By proteomics assay of the serum, we 
would potentially find the immunogenic factors in the ZNF2 overexpression strain. 
Another potential impact of Znf2 on fungal virulence is the regulation of cell 
surface adherence by the altered expression of secretory/surface proteins.  These factors 
may involve in the initial adhesion in lungs and/or the invasion of CNS during 
cryptococcal infections.  Our data have shown a reduction of brain fungal burden of 
ZNF2 overexpression strains in different strain backgrounds.  We would like to further 
test the role of these proteins on the CNS penetration. 
5.2.2. Characterization of the fungal target of sertraline 
The clinical trial of sertraline in treating AIDS-related cryptococcosis is 
encouraging and it reinforces the value of drug repositioning strategy in antifungal 
development.  Further research on sertraline as an antifungal would be to determine its 
fungal target.  This potentially will provide new drug target(s) for the future 
investigation and help the development of a new compound with enhanced efficacy and 
low toxicity. 
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Although some evidence suggested that sertraline disturbs the membrane stability 
or vesicle transport in fungi, we favor the hypothesis that sertraline targets the protein 
synthesis process.  As reviewed in Chapter IV, sertraline displays a broad anti-
proliferative activity ranging from bacteria to higher eukaryotes (117, 198, 199, 209, 211, 
212, 215).  The protein synthesis is a fundamental process in organisms at different 
domains.  To further characterize the direct fungal target(s) of sertraline, a recently 
developed variomic library in the model yeast Saccharomyces cerevisiae would be 
helpful (223).  Comparing with the classic genome deletion set with the deletion of the 
whole ORF in each strain, this variomic library contains an average of ∼10,000 variant 
alleles for each ORF.  Therefore, this tool could help specify the drug target at amino 
acid residue level. 
5.2.3. New strategy of antifungal drug development   
Natural products and newly synthesized compounds from various screens, as 
well as the repositioning drugs are the main sources for searching for novel antifungals.  
Currently, nearly all the screens with different sets of natural products or chemical 
compounds aim to the essential process of fungal cells and consequently inhibit the 
fungal growth.  Growth inhibition potentially creates strong selective pressures and 
could drive the emergence of drug resistance (224).  An alternative direction of 
antifungal drug discovery is to target the virulence of fungi (224).  For instance, urease, 
phospholipase B1 or other cell surface proteins are potentially related to the capacity of 
the CNS penetration of cryptococcal cells.  Drug screens against these factors could 
discover compound(s) that prevent(s) the fungal cell dissemination.  This kind of 
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compounds would be particularly valuable for the prophylaxis of cryptococcal 
meningitis among people that are susceptible to the infection.   
 123 
 
REFERENCES 
 
 
1. Steinbach WJ & Stevens DA (2003) Review of newer antifungal and 
immunomodulatory strategies for invasive aspergillosis. Clin Infect Dis 37 Suppl 
3:S157-187. 
 
2. Filioti J, Spiroglou K, Panteliadis CP, & Roilides E (2007) Invasive candidiasis 
in pediatric intensive care patients: epidemiology, risk factors, management, and 
outcome. Intensive Care Med 33(7):1272-1283. 
 
3. Longley N, et al. (2008) Dose response effect of high-dose fluconazole for HIV-
associated cryptococcal meningitis in southwestern Uganda. Clin Infect Dis 
47(12):1556-1561. 
 
4. Park BJ, et al. (2009) Estimation of the current global burden of cryptococcal 
meningitis among persons living with HIV/AIDS. AIDS 23(4):525-530. 
 
5. Kwon-Chung KJ, Edman JC, & Wickes BL (1992) Genetic association of mating 
types and virulence in Cryptococcus neoformans. Infect Immun 60(2):602-605. 
 
6. Nielsen K, et al. (2005) Interaction between genetic background and the mating-
type locus in Cryptococcus neoformans virulence potential. Genetics 171(3):975-
983. 
 
7. Nielsen K, et al. (2003) Sexual cycle of Cryptococcus neoformans var. grubii and 
virulence of congenic a and alpha isolates. Infect Immun 71(9):4831-4841. 
 
8. Loftus BJ, et al. (2005) The genome of the basidiomycetous yeast and human 
pathogen Cryptococcus neoformans. Science 307(5713):1321-1324. 
 
9. Liu OW, et al. (2008) Systematic genetic analysis of virulence in the human 
fungal pathogen Cryptococcus neoformans. Cell 135(1):174-188. 
 
10. Heitman J & American Society for Microbiology. (2011) Cryptococcus : from 
human pathogen to model yeast (ASM Press, Washington, DC) pp xvii, 620 p. 
 
11. Pappas PG, et al. (2004) Recombinant interferon- gamma 1b as adjunctive 
therapy for AIDS-related acute cryptococcal meningitis. J Infect Dis 
189(12):2185-2191. 
 
 124 
 
12. Franzot SP, Salkin IF, & Casadevall A (1999) Cryptococcus neoformans var. 
grubii: separate varietal status for Cryptococcus neoformans serotype A isolates. 
J Clin Microbiol 37(3):838-840. 
 
13. Belay T, Cherniak R, O'Neill EB, & Kozel TR (1996) Serotyping of 
Cryptococcus neoformans by dot enzyme assay. J Clin Microbiol 34(2):466-470. 
 
14. Sorrell TC (2001) Cryptococcus neoformans variety gattii. Med Mycol 
39(2):155-168. 
 
15. Fraser JA, et al. (2005) Same-sex mating and the origin of the Vancouver Island 
Cryptococcus gattii outbreak. Nature 437(7063):1360-1364. 
 
16. Lin X & Heitman J (2006) The biology of the Cryptococcus neoformans species 
complex. Annu Rev Microbiol 60:69-105. 
 
17. Viviani MA, et al. (2006) Molecular analysis of 311 Cryptococcus neoformans 
isolates from a 30-month ECMM survey of cryptococcosis in Europe. FEMS 
Yeast Res 6(4):614-619. 
 
18. Liaw SJ, Wu HC, & Hsueh PR (2010) Microbiological characteristics of clinical 
isolates of Cryptococcus neoformans in Taiwan: serotypes, mating types, 
molecular types, virulence factors, and antifungal susceptibility. Clin Microbiol 
Infect 16(6):696-703. 
 
19. Escandon P, Sanchez A, Martinez M, Meyer W, & Castaneda E (2006) 
Molecular epidemiology of clinical and environmental isolates of the 
Cryptococcus neoformans species complex reveals a high genetic diversity and 
the presence of the molecular type VGII mating type a in Colombia. FEMS Yeast 
Res 6(4):625-635. 
 
20. Meyer W, et al. (1999) Molecular typing of global isolates of Cryptococcus 
neoformans var. neoformans by polymerase chain reaction fingerprinting and 
randomly amplified polymorphic DNA-a pilot study to standardize techniques on 
which to base a detailed epidemiological survey. Electrophoresis 20(8):1790-
1799. 
 
21. Hull CM & Heitman J (2002) Genetics of Cryptococcus neoformans. Annu Rev 
Genet 36:557-615. 
 
22. Xue C, Tada Y, Dong X, & Heitman J (2007) The human fungal pathogen 
Cryptococcus can complete its sexual cycle during a pathogenic association with 
plants. Cell Host & Microbe 1(4):263-273. 
 125 
 
23. Lin X (2009) Cryptococcus neoformans: morphogenesis, infection, and evolution 
Infect Genet Evol 9(4):401-416. 
 
24. Wang L & Lin X (2011) Mechanisms of unisexual mating in Cryptococcus 
neoformans. Fungal Genet Biol 48(7):651-660. 
 
25. Idnurm A (2010) A tetrad analysis of the basidiomycete fungus Cryptococcus 
neoformans. Genetics 185(1):153-163. 
 
26. Botts MR, Giles SS, Gates MA, Kozel TR, & Hull CM (2009) Isolation and 
characterization of Cryptococcus neoformans spores reveal a critical role for 
capsule biosynthesis genes in spore biogenesis. Eukaryot Cell 8(4):595-605. 
 
27. Velagapudi R, Hsueh YP, Geunes-Boyer S, Wright JR, & Heitman J (2009) 
Spores as infectious propagules of Cryptococcus neoformans. Infect Immun 
77(10):4345-4355. 
 
28. Shadomy HJ & Utz JP (1966) Preliminary studies on a hyphaforming mutant of 
Cryptococcus neoformans. Mycologia 58(3):383-390. 
 
29. Wickes BL, Mayorga ME, Edman U, & Edman JC (1996) Dimorphism and 
haploid fruiting in Cryptococcus neoformans: association with the alpha-mating 
type. Proc Natl Acad Sci U S A 93(14):7327-7331. 
 
30. Lin X, Hull CM, & Heitman J (2005) Sexual reproduction between partners of 
the same mating type in Cryptococcus neoformans. Nature 434(7036):1017-
1021. 
 
31. Litvintseva AP, et al. (2003) Evidence of sexual recombination among 
Cryptococcus neoformans serotype A isolates in sub-Saharan Africa. Eukaryot 
Cell 2(6):1162-1168. 
 
32. Halliday CL & Carter DA (2003) Clonal reproduction and limited dispersal in an 
environmental population of Cryptococcus neoformans var gattii isolates from 
Australia. J Clin Microbiol 41(2):703-711. 
 
33. Cogliati M, Esposto MC, Tortorano AM, & Viviani MA (2006) Cryptococcus 
neoformans population includes hybrid strains homozygous at mating-type locus. 
FEMS Yeast Res 6(4):608-613. 
 
34. Saul N, Krockenberger M, & Carter D (2008) Evidence of recombination in 
mixed-mating-type and alpha-only populations of Cryptococcus gattii sourced 
from single eucalyptus tree hollows. Eukaryot Cell 7(4):727-734. 
 126 
 
35. Lin X, et al. (2009) Diploids in the Cryptococcus neoformans serotype A 
population homozygous for the alpha mating type originate via unisexual mating. 
PLoS Pathog 5(1):e1000283. 
 
36. Derengowski Lda S, et al. (2013) The transcriptional response of Cryptococcus 
neoformans to ingestion by Acanthamoeba castellanii and macrophages provides 
insights into the evolutionary adaptation to the mammalian host. Eukaryot Cell 
12(5):761-774. 
 
37. Idnurm A, et al. (2005) Deciphering the model pathogenic fungus Cryptococcus 
neoformans. Nature reviews. Microbiology 3(10):753-764. 
 
38. Goldman DL, et al. (2001) Serologic evidence for Cryptococcus neoformans 
infection in early childhood. Pediatrics 107(5):E66. 
 
39. Xue C, et al. (2010) Role of an expanded inositol transporter repertoire in 
Cryptococcus neoformans sexual reproduction and virulence. mBio 1(1). 
 
40. Del Poeta M & Casadevall A (2012) Ten challenges on Cryptococcus and 
cryptococcosis. Mycopathologia 173(5-6):303-310. 
 
41. Olszewski MA, et al. (2004) Urease expression by Cryptococcus neoformans 
promotes microvascular sequestration, thereby enhancing central nervous system 
invasion. Am J Pathol 164(5):1761-1771. 
 
42. Maruvada R, et al. (2012) Cryptococcus neoformans phospholipase B1 activates 
host cell Rac1 for traversal across the blood-brain barrier. Cell Microbiol 
14(10):1544-1553. 
 
43. Liu TB, et al. (2013) Brain inositol is a novel stimulator for promoting 
Cryptococcus penetration of the blood-brain barrier. PLoS Pathog 
9(4):e1003247. 
 
44. Shi M, et al. (2010) Real-time imaging of trapping and urease-dependent 
transmigration of Cryptococcus neoformans in mouse brain. J Clin Invest 
120(5):1683-1693. 
 
45. Chretien F, et al. (2002) Pathogenesis of cerebral Cryptococcus neoformans 
infection after fungemia. J Infect Dis 186(4):522-530. 
 
46. Charlier C, et al. (2009) Evidence of a role for monocytes in dissemination and 
brain invasion by Cryptococcus neoformans. Infect Immun 77(1):120-127. 
 
 127 
 
47. Sabiiti W, et al. (2014) Efficient phagocytosis and laccase activity affect the 
outcome of HIV-associated cryptococcosis. J Clin Invest 124(5):2000-2008. 
 
48. Chrisman CJ, Albuquerque P, Guimaraes AJ, Nieves E, & Casadevall A (2011) 
Phospholipids trigger Cryptococcus neoformans capsular enlargement during 
interactions with amoebae and macrophages. PLoS Pathog 7(5):e1002047. 
 
49. Garcia-Rodas R, Casadevall A, Rodriguez-Tudela JL, Cuenca-Estrella M, & 
Zaragoza O (2011) Cryptococcus neoformans capsular enlargement and cellular 
gigantism during Galleria mellonella infection. PloS One 6(9):e24485. 
 
50. Steenbergen JN, Shuman HA, & Casadevall A (2001) Cryptococcus neoformans 
interactions with amoebae suggest an explanation for its virulence and 
intracellular pathogenic strategy in macrophages. Proc Natl Acad Sci U S A 
98(26):15245-15250. 
 
51. Chang YC, Penoyer LA, & Kwon-Chung KJ (1996) The second capsule gene of 
cryptococcus neoformans, CAP64, is essential for virulence. Infect Immun 
64(6):1977-1983. 
 
52. James PG, Cherniak R, Jones RG, Stortz CA, & Reiss E (1990) Cell-wall glucans 
of Cryptococcus neoformans Cap 67. Carbohydr Res 198(1):23-38. 
 
53. Chang YC & Kwon-Chung KJ (1994) Complementation of a capsule-deficient 
mutation of Cryptococcus neoformans restores its virulence. Mol Cel Biol 
14(7):4912-4919. 
 
54. Garcia-Hermoso D, Dromer F, & Janbon G (2004) Cryptococcus neoformans 
capsule structure evolution in vitro and during murine infection. Infect Immun 
72(6):3359-3365. 
 
55. Zaragoza O, et al. (2008) Capsule enlargement in Cryptococcus neoformans 
confers resistance to oxidative stress suggesting a mechanism for intracellular 
survival. Cell Microbiol 10(10):2043-2057. 
 
56. Vecchiarelli A, et al. (1996) Purified capsular polysaccharide of Cryptococcus 
neoformans induces interleukin-10 secretion by human monocytes. Infect Immun 
64(7):2846-2849. 
 
57. Charlier C, et al. (2005) Capsule structure changes associated with Cryptococcus 
neoformans crossing of the blood-brain barrier. Am J Pathol 166(2):421-432. 
 
58. Eisenman HC & Casadevall A (2012) Synthesis and assembly of fungal melanin. 
Appl Microbiol Biotechnol 93(3):931-940. 
 128 
 
59. Wang Y, Aisen P, & Casadevall A (1995) Cryptococcus neoformans melanin and 
virulence: mechanism of action. Infect Immun 63(8):3131-3136. 
 
60. Mednick AJ, Nosanchuk JD, & Casadevall A (2005) Melanization of 
Cryptococcus neoformans affects lung inflammatory responses during 
cryptococcal infection. Infect Immun 73(4):2012-2019. 
 
61. Salas SD, Bennett JE, Kwon-Chung KJ, Perfect JR, & Williamson PR (1996) 
Effect of the laccase gene CNLAC1, on virulence of Cryptococcus neoformans. J 
Exp Med 184(2):377-386. 
 
62. Ikeda R, Sugita T, Jacobson ES, & Shinoda T (2003) Effects of melanin upon 
susceptibility of Cryptococcus to antifungals. Microbiol Immunol 47(4):271-277. 
 
63. Fraser JA, et al. (2004) Convergent evolution of chromosomal sex-determining 
regions in the animal and fungal kingdoms. PLoS Biol 2(12):e384. 
 
64. Wang P, et al. (2002) Mating-type-specific and nonspecific PAK kinases play 
shared and divergent roles in Cryptococcus neoformans. Eukaryot Cell 1(2):257-
272. 
 
65. Davidson RC, Nichols CB, Cox GM, Perfect JR, & Heitman J (2003) A MAP 
kinase cascade composed of cell type specific and non-specific elements controls 
mating and differentiation of the fungal pathogen Cryptococcus neoformans. Mol 
Microbiol 49(2):469-485. 
 
66. Lin X, Jackson JC, Feretzaki M, Xue C, & Heitman J (2010) Transcription 
factors Mat2 and Znf2 operate cellular circuits orchestrating opposite- and same-
sex mating in Cryptococcus neoformans. PLoS Genet 6(5):e1000953. 
 
67. Fan W, Kraus PR, Boily MJ, & Heitman J (2005) Cryptococcus neoformans gene 
expression during murine macrophage infection. Eukaryot Cell 4(8):1420-1433. 
 
68. Lin X, Huang JC, Mitchell TG, & Heitman J (2006) Virulence attributes and 
hyphal growth of C. neoformans are quantitative traits and the MATalpha allele 
enhances filamentation. PLoS Genet 2(11):e187. 
 
69. Beyhan S, Gutierrez M, Voorhies M, & Sil A (2013) A temperature-responsive 
network links cell shape and virulence traits in a primary fungal pathogen. PLoS 
Biol 11(7):e1001614. 
 
70. Kane J (1984) Conversion of Blastomyces dermatitidis to the yeast form at 37 
degrees C and 26 degrees C. J Clin Microbiol 20(3):594-596. 
 129 
 
71. Whiteway M & Bachewich C (2007) Morphogenesis in Candida albicans. Annu 
Rev Microbiol 61:529-553. 
 
72. Liu Y & Filler SG (2011) Candida albicans Als3, a multifunctional adhesin and 
invasin. Eukaryot Cell 10(2):168-173. 
 
73. Jacobsen ID, et al. (2012) Candida albicans dimorphism as a therapeutic target. 
Expert Rev Anti Infect Ther 10(1):85-93. 
 
74. Rappleye CA & Goldman WE (2006) Defining virulence genes in the dimorphic 
fungi. Annu Rev Microbiol 60:281-303. 
 
75. Love GL, Boyd GD, & Greer DL (1985) Large Cryptococcus neoformans 
isolated from brain abscess. J Clin Microbiol 22(6):1068-1070. 
 
76. Okagaki LH, et al. (2010) Cryptococcal cell morphology affects host cell 
interactions and pathogenicity. PLoS Pathog 6(6):e1000953. 
 
77. Zaragoza O, et al. (2010) Fungal cell gigantism during mammalian infection. 
PLoS Pathog 6(6):e1000945. 
 
78. Freed ER, Duma RJ, Shadomy HJ, & Utz JP (1971) Meningoencephalitis due to 
hyphae-forming Cryptococcus neoformans. Am J Clin Pathol 55(1):30-33. 
 
79. Lurie HI & Shadomy HJ (1971) Morphological variations of a hypha-forming 
strain of Cryptococcus neoformans (Coward strain) in tissues of mice. 
Sabouraudia 9(1):10-14. 
 
80. Williamson JD, Silverman JF, Mallak CT, & Christie JD (1996) Atypical 
cytomorphologic appearance of Cryptococcus neoformans: a report of five cases. 
Acta cytologica 40(2):363-370. 
 
81. Wang L, Zhai B, & Lin X (2012) The link between morphotype transition and 
virulence in Cryptococcus neoformans. PLoS Pathog 8(6):e1002765. 
 
82. Neilson JB, Ivey MH, & Bulmer GS (1978) Cryptococcus neoformans: 
pseudohyphal forms surviving culture with Acanthamoeba polyphaga. Infect 
Immun 20(1):262-266. 
 
83. Fromtling RA, Blackstock R, Hall NK, & Bulmer GS (1979) Immunization of 
mice with an avirulent pseudohyphal form of Cryptococcus neoformans. 
Mycopathologia 68(3):179-181. 
 130 
 
84. Neilson JB, Fromtling RA, & Bulmer GS (1981) Pseudohyphal forms of 
Cryptococcus neoformans: decreased survival in vivo. Mycopathologia 73(1):57-
59. 
 
85. Shadomy HJ & Lurie HI (1971) Histopathological observations in experimental 
cryptococcosis caused by a hypha-producing strain of Cryptococcus neoformans 
(Coward strain) in mice. Sabouraudia 9(1):6-9. 
 
86. Zimmer BL, Hempel HO, & Goodman NL (1983) Pathogenicity of the hyphae of 
Filobasidiella neoformans. Mycopathologia 81(2):107-110. 
 
87. Fromtling RA, Blackstock R, Hall NK, & Bulmer GS (1979) Kinetics of 
lymphocyte transformation in mice immunized with viable avirulent forms of 
Cryptococcus neoformans. Infect Immun 24(2):449-453. 
 
88. Wang L, Tian X, Gyawali R, & Lin X (2013) Fungal adhesion protein guides 
community behaviors and autoinduction in a paracrine manner. Proc Natl Acad 
Sci U S A 110(28):11571-11576. 
 
89. Antachopoulos C & Walsh TJ (2012) Immunotherapy of Cryptococcus 
infections. Clin Microbiol Infect 18(2):126-133. 
 
90. Casadevall A, Feldmesser M, & Pirofski LA (2002) Induced humoral immunity 
and vaccination against major human fungal pathogens. Curr Opin Microbiol 
5(4):386-391. 
 
91. Casadevall A & Pirofski LA (2006) A reappraisal of humoral immunity based on 
mechanisms of antibody-mediated protection against intracellular pathogens. Adv 
Immunol 91:1-44. 
 
92. Larsen RA, et al. (2005) Phase I evaluation of the safety and pharmacokinetics of 
murine-derived anticryptococcal antibody 18B7 in subjects with treated 
cryptococcal meningitis. Antimicrob Agents Chemother 49(3):952-958. 
 
93. Dadachova E, Nakouzi A, Bryan RA, & Casadevall A (2003) Ionizing radiation 
delivered by specific antibody is therapeutic against a fungal infection. Proc Natl 
Acad Sci U S A 100(19):10942-10947. 
 
94. Dadachova E, et al. (2004) Evaluation of acute hematologic and long-term 
pulmonary toxicities of radioimmunotherapy of Cryptococcus neoformans 
infection in murine models. Antimicrob Agents Chemother 48(3):1004-1006. 
 
95. Saag MS, et al. (2000) Practice guidelines for the management of cryptococcal 
disease. Infectious Diseases Society of America. Clin Infect Dis 30(4):710-718. 
 131 
 
96. Laniado-Laborin R & Cabrales-Vargas MN (2009) Amphotericin B: side effects 
and toxicity. Rev Iberoam Micol 26(4):223-227. 
 
97. Ellis D (2002) Amphotericin B: spectrum and resistance. J Antimicrob 
Chemother 49 Suppl 1:7-10. 
 
98. Baginski M & Czub J (2009) Amphotericin B and its new derivatives - mode of 
action. Curr Drug Metab 10(5):459-469. 
 
99. Deray G (2002) Amphotericin B nephrotoxicity. J Antimicrob Chemother 49 
Suppl 1:37-41. 
 
100. Craddock C, et al. (2010) Best practice guidelines for the management of adverse 
events associated with amphotericin B lipid complex. Expert Opin Drug Saf 
9(1):139-147. 
 
101. Arthur RR, Drew RH, & Perfect JR (2004) Novel modes of antifungal drug 
administration. Expert Opin Invest Drug 13(8):903-932. 
 
102. Robinson PA, et al. (1999) Early mycological treatment failure in AIDS-
associated cryptococcal meningitis. Clin Infect Dis 28(1):82-92. 
 
103. Powderly WG (1996) Recent advances in the management of cryptococcal 
meningitis in patients with AIDS. Clin Infect Dis 22 Suppl 2:S119-123. 
 
104. Vanden Bossche H (1985) Biochemical targets for antifungal azole derivatives: 
hypothesis on the mode of action. Curr Top Med Mycol 1:313-351. 
 
105. Vanden Bossche H, Willemsens G, & Marichal P (1987) Anti-Candida drugs--
the biochemical basis for their activity. Crit Rev Microbiol 15(1):57-72. 
 
106. Pappas PG, et al. (2001) Cryptococcosis in human immunodeficiency virus-
negative patients in the era of effective azole therapy. Clin Infect Dis 33(5):690-
699. 
 
107. van der Horst CM, et al. (1997) Treatment of cryptococcal meningitis associated 
with the acquired immunodeficiency syndrome. National Institute of Allergy and 
Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group. N 
Engl J Med 337(1):15-21. 
 
108. Lutsar I, Roffey S, & Troke P (2003) Voriconazole concentrations in the 
cerebrospinal fluid and brain tissue of guinea pigs and immunocompromised 
patients. Clin Infect Dis 37(5):728-732. 
 132 
 
109. Nau R, Sorgel F, & Eiffert H (2010) Penetration of drugs through the blood-
cerebrospinal fluid/blood-brain barrier for treatment of central nervous system 
infections. Clin Microbiol Rev 23(4):858-883. 
 
110. Paugam A, et al. (1994) Increased fluconazole resistance of Cryptococcus 
neoformans isolated from a patient with AIDS and recurrent meningitis. Clin 
Infect Dis 19(5):975-976. 
 
111. Birley HD, et al. (1995) Azole drug resistance as a cause of clinical relapse in 
AIDS patients with cryptococcal meningitis. International journal of STD & 
AIDS 6(5):353-355. 
 
112. Berg J, Clancy CJ, & Nguyen MH (1998) The hidden danger of primary 
fluconazole prophylaxis for patients with AIDS. Clin Infect Dis 26(1):186-187. 
 
113. Armengou A, Porcar C, Mascaro J, & Garcia-Bragado F (1996) Possible 
development of resistance to fluconazole during suppressive therapy for AIDS-
associated cryptococcal meningitis. Clin Infect Dis 23(6):1337-1338. 
 
114. Cheong JW & McCormack J (2013) Fluconazole resistance in cryptococcal 
disease: emerging or intrinsic? Med Mycol 51(3):261-269. 
 
115. Cowen LE, Anderson JB, & Kohn LM (2002) Evolution of drug resistance in 
Candida albicans. Annu Rev Microbiol 56:139-165. 
 
116. Lupetti A, Danesi R, Campa M, Del Tacca M, & Kelly S (2002) Molecular basis 
of resistance to azole antifungals. Trend Mol Med 8(2):76-81. 
 
117. Marichal P, et al. (1999) Contribution of mutations in the cytochrome P450 
14alpha-demethylase (Erg11p, Cyp51p) to azole resistance in Candida albicans. 
Microbiol 145 ( Pt 10):2701-2713. 
 
118. Sanglard D, Ischer F, Monod M, & Bille J (1997) Cloning of Candida albicans 
genes conferring resistance to azole antifungal agents: characterization of CDR2, 
a new multidrug ABC transporter gene. Microbiol 143 ( Pt 2):405-416. 
 
119. Sanglard D, et al. (1995) Mechanisms of resistance to azole antifungal agents in 
Candida albicans isolates from AIDS patients involve specific multidrug 
transporters. Antimicrob Agents Chemother 39(11):2378-2386. 
 
120. Kuhn DM, George T, Chandra J, Mukherjee PK, & Ghannoum MA (2002) 
Antifungal susceptibility of Candida biofilms: unique efficacy of amphotericin B 
lipid formulations and echinocandins. Antimicrob Agents Chemother 46(6):1773-
1780. 
 133 
 
121. Blankenship JR & Mitchell AP (2006) How to build a biofilm: a fungal 
perspective. Curr Opin Microbiol 9(6):588-594. 
 
122. Sionov E, Chang YC, Garraffo HM, & Kwon-Chung KJ (2009) Heteroresistance 
to fluconazole in Cryptococcus neoformans is intrinsic and associated with 
virulence. Antimicrob Agents Chemother 53(7):2804-2815. 
 
123. Sionov E, Chang YC, & Kwon-Chung KJ (2013) Azole heteroresistance in 
Cryptococcus neoformans: emergence of resistant clones with chromosomal 
disomy in the mouse brain during fluconazole treatment. Antimicrob Agents 
Chemother 57(10):5127-5130. 
 
124. Sionov E, Lee H, Chang YC, & Kwon-Chung KJ (2010) Cryptococcus 
neoformans overcomes stress of azole drugs by formation of disomy in specific 
multiple chromosomes. PLoS Pathog 6(4):e1000848. 
 
125. Andes D (2013) Optimizing antifungal choice and administration. Curr Med Res 
Opin 29 Suppl 4:13-18. 
 
126. Sucher AJ, Chahine EB, & Balcer HE (2009) Echinocandins: the newest class of 
antifungals. Annals Pharmacother 43(10):1647-1657. 
 
127. Krishnarao TV & Galgiani JN (1997) Comparison of the in vitro activities of the 
echinocandin LY303366, the pneumocandin MK-0991, and fluconazole against 
Candida species and Cryptococcus neoformans. Antimicrob Agents Chemother 
41(9):1957-1960. 
 
128. Malhotra P, Shah SS, Kaplan M, & McGowan JP (2005) Cryptococcal fungemia 
in a neutropenic patient with AIDS while receiving caspofungin. J Infect 
51(3):e181-183. 
 
129. Maligie MA & Selitrennikoff CP (2005) Cryptococcus neoformans resistance to 
echinocandins: (1,3)beta-glucan synthase activity is sensitive to echinocandins. 
Antimicrob Agents Chemother 49(7):2851-2856. 
 
130. Thompson JR, et al. (1999) A glucan synthase FKS1 homolog in cryptococcus 
neoformans is single copy and encodes an essential function. J bacteriol 
181(2):444-453. 
 
131. Gallis HA, Drew RH, & Pickard WW (1990) Amphotericin B: 30 years of 
clinical experience. Rev Infect Dis 12(2):308-329. 
 
 134 
 
132. Vermes A, Guchelaar HJ, & Dankert J (2000) Flucytosine: a review of its 
pharmacology, clinical indications, pharmacokinetics, toxicity and drug 
interactions. J Antimicrob Chemother 46(2):171-179. 
 
133. Bachmann SP, et al. (2003) Antifungal combinations against Candida albicans 
biofilms in vitro. Antimicrob Agents Chemother 47(11):3657-3659. 
 
134. Sarkar S, Uppuluri P, Pierce CG, & Lopez-Ribot JL (2014) In vitro study of 
sequential fluconazole and caspofungin treatment against Candida albicans 
biofilms. Antimicrob Agents Chemother 58(2):1183-1186. 
 
135. Mitsuyama J, et al. (2008) In vitro and in vivo antifungal activities of T-2307, a 
novel arylamidine. Antimicrob Agents Chemother 52(4):1318-1324. 
 
136. Yamada E, Nishikawa H, Nomura N, & Mitsuyama J (2010) T-2307 shows 
efficacy in a murine model of Candida glabrata infection despite in vitro trailing 
growth phenomena. Antimicrob Agents Chemother 54(9):3630-3634. 
 
137. Nishikawa H, et al. (2010) Uptake of T-2307, a novel arylamidine, in Candida 
albicans. J Antimicrob Chemother 65(8):1681-1687. 
 
138. Shibata T, et al. (2012) T-2307 causes collapse of mitochondrial membrane 
potential in yeast. Antimicrob Agents Chemother 56(11):5892-5897. 
 
139. Hata K, et al. (2011) Efficacy of oral E1210, a new broad-spectrum antifungal 
with a novel mechanism of action, in murine models of candidiasis, aspergillosis, 
and fusariosis. Antimicrob Agents Chemother 55(10):4543-4551. 
 
140. Miyazaki M, et al. (2011) In vitro activity of E1210, a novel antifungal, against 
clinically important yeasts and molds. Antimicrob Agents Chemother 
55(10):4652-4658. 
 
141. Lu SE, et al. (2009) Occidiofungin, a unique antifungal glycopeptide produced 
by a strain of Burkholderia contaminans. Biochemistry 48(35):8312-8321. 
 
142. Tan W, et al. (2012) Nonclinical toxicological evaluation of occidiofungin, a 
unique glycolipopeptide antifungal. Int J Toxicol 31(4):326-336. 
 
143. Emrick D, et al. (2013) The antifungal occidiofungin triggers an apoptotic 
mechanism of cell death in yeast. J Nat Prod 76(5):829-838. 
 
144. Butts A & Krysan DJ (2012) Antifungal drug discovery: something old and 
something new. PLoS Pathog 8(9):e1002870. 
 135 
 
145. Rudin CM, et al. (2013) Phase 2 study of pemetrexed and itraconazole as second-
line therapy for metastatic nonsquamous non-small-cell lung cancer. J Thorac 
Oncol 8(5):619-623. 
 
146. Weiss VC, West DP, & Mueller CE (1981) Topical minoxidil in alopecia areata. 
J Am Acad Dermatol 5(2):224-226. 
 
147. Del Poeta M, Cruz MC, Cardenas ME, Perfect JR, & Heitman J (2000) 
Synergistic antifungal activities of bafilomycin A(1), fluconazole, and the 
pneumocandin MK-0991/caspofungin acetate (L-743,873) with calcineurin 
inhibitors FK506 and L-685,818 against Cryptococcus neoformans. Antimicrob 
Agents Chemother 44(3):739-746. 
 
148. Dolan K, et al. (2009) Antifungal activity of tamoxifen: in vitro and in vivo 
activities and mechanistic characterization. Antimicrob Agents Chemother 
53(8):3337-3346. 
 
149. Breger J, et al. (2007) Antifungal chemical compounds identified using a C. 
elegans pathogenicity assay. PLoS Pathog 3(2):e18. 
 
150. Spitzer M, et al. (2011) Cross-species discovery of syncretic drug combinations 
that potentiate the antifungal fluconazole. Mol Syst Biol 7:499. 
 
151. Heitman J, Allen B, Alspaugh JA, & Kwon-Chung KJ (1999) On the origins of 
congenic MATalpha and MATa strains of the pathogenic yeast Cryptococcus 
neoformans. Fungal Genet Biol 28(1):1-5. 
 
152. Lin X, et al. (2007) alpha AD alpha hybrids of Cryptococcus neoformans: 
evidence of same-sex mating in nature and hybrid fitness. PLoS Genet 
3(10):1975-1990. 
 
153. Barchiesi F, et al. (2005) Comparative analysis of pathogenicity of Cryptococcus 
neoformans serotypes A, D and AD in murine cryptococcosis. J Infect 51(1):10-
16. 
 
154. Lin X, Nielsen K, Patel S, & Heitman J (2008) Impact of mating type, serotype, 
and ploidy on the virulence of Cryptococcus neoformans. Infect Immun 
76(7):2923-2938. 
 
155. Litvintseva AP & Mitchell TG (2009) Most environmental isolates of 
Cryptococcus neoformans var. grubii (serotype A) are not lethal for mice. Infect 
Immun 77(8):3188-3195. 
 136 
 
156. Nielsen K, et al. (2005) Cryptococcus neoformans {alpha} strains preferentially 
disseminate to the central nervous system during coinfection. Infect Immun 
73(8):4922-4933. 
 
157. Zhu P, Zhai B, Lin X, & Idnurm A (2013) Congenic strains for genetic analysis 
of virulence traits in Cryptococcus gattii. Infect Immun 81(7):2616-2625. 
 
158. Ni M, et al. (2013) Unisexual and heterosexual meiotic reproduction generate 
aneuploidy and phenotypic diversity de novo in the yeast Cryptococcus 
neoformans. PLoS Biol 11(9):e1001653. 
 
159. Marra RE, et al. (2004) A genetic linkage map of Cryptococcus neoformans 
variety neoformans serotype D (Filobasidiella neoformans). Genet 167(2):619-
631. 
 
160. Hsueh YP, Xue C, & Heitman J (2009) A constitutively active GPCR governs 
morphogenic transitions in Cryptococcus neoformans. EMBO J 28(9):1220-1233. 
 
161. Lee SC & Heitman J (2012) Function of Cryptococcus neoformans KAR7 
(SEC66) in karyogamy during unisexual and opposite-sex mating. Eukaryot Cell 
11(6):783-794. 
 
162. Magditch DA, Liu TB, Xue C, & Idnurm A (2012) DNA mutations mediate 
microevolution between host-adapted forms of the pathogenic fungus 
Cryptococcus neoformans. PLoS Pathog 8(10):e1002936. 
 
163. Crabtree JN, et al. (2012) Titan cell production enhances the virulence of 
Cryptococcus neoformans. Infect Immun 80(11):3776-3785. 
 
164. Ngamskulrungroj P, Chang Y, Sionov E, & Kwon-Chung KJ (2012) The primary 
target organ of Cryptococcus gattii is different from that of Cryptococcus 
neoformans in a murine model. mBio 3(3). 
 
165. Molina J, Cordero E, & Pachon J (2009) New information about the 
polymyxin/colistin class of antibiotics. Exp Opin Pharmacother 10(17):2811-
2828. 
 
166. Brown JM, Dorman DC, & Roy LP (1970) Acute renal failure due to overdosage 
of colistin. Med J Aust 2(20):923-924. 
 
167. Koch-Weser J, et al. (1970) Adverse effects of sodium colistimethate. 
Manifestations and specific reaction rates during 317 courses of therapy. Ann 
Intern Med 72(6):857-868. 
 137 
 
168. Falagas ME & Kasiakou SK (2006) Toxicity of polymyxins: a systematic review 
of the evidence from old and recent studies. Crit care 10(1):R27. 
 
169. Zavascki AP, Goldani LZ, Li J, & Nation RL (2007) Polymyxin B for the 
treatment of multidrug-resistant pathogens: a critical review. J Antimicrob 
Chemother 60(6):1206-1215. 
 
170. Evans ME, Feola DJ, & Rapp RP (1999) Polymyxin B sulfate and colistin: old 
antibiotics for emerging multiresistant gram-negative bacteria. Ann 
Pharmacother 33(9):960-967. 
 
171. Hancock RE & Chapple DS (1999) Peptide antibiotics. Antimicrob Agents 
Chemother 43(6):1317-1323. 
 
172. Nosanchuk JD & Casadevall A (1997) Cellular charge of Cryptococcus 
neoformans: contributions from the capsular polysaccharide, melanin, and 
monoclonal antibody binding. Infect Immun 65(5):1836-1841. 
 
173. Fritsche TR, Rhomberg PR, Sader HS, & Jones RN (2008) Antimicrobial activity 
of omiganan pentahydrochloride against contemporary fungal pathogens 
responsible for catheter-associated infections. Antimicrob Agents Chemother 
52(3):1187-1189. 
 
174. Ben-Ami R, Lewis RE, Tarrand J, Leventakos K, & Kontoyiannis DP (2010) 
Antifungal activity of colistin against mucorales species in vitro and in a murine 
model of Rhizopus oryzae pulmonary infection. Antimicrob Agents Chemother 
54(1):484-490. 
 
175. Sarria JC, Angulo-Pernett F, Kimbrough RC, McVay CS, & Vidal AM (2004) 
Use of intravenous polymyxin B during continuous venovenous hemodialysis. 
Eur J Clin Microbiol Infect Dis 23(4):340-341. 
 
176. Litvintseva AP, Thakur R, Vilgalys R, & Mitchell TG (2006) Multilocus 
sequence typing reveals three genetic subpopulations of Cryptococcus 
neoformans var. grubii (serotype A), including a unique population in Botswana. 
Genet 172(4):2223-2238. 
 
177. Neuville S, et al. (2003) Primary cutaneous cryptococcosis: a distinct clinical 
entity. Clin Infect Dis 36(3):337-347. 
 
178. Miller JL, et al. (2004) In vitro and in vivo efficacies of the new triazole 
albaconazole against Cryptococcus neoformans. Antimicrob Agents Chemother 
48(2):384-387. 
 138 
 
179. Chaturvedi V, et al. (2002) Molecular genetic analyses of mating pheromones 
reveal intervariety mating or hybridization in Cryptococcus neoformans. Infect 
Immun 70(9):5225-5235. 
 
180. Winzeler EA, et al. (1999) Functional characterization of the S. cerevisiae 
genome by gene deletion and parallel analysis. Science 285(5429):901-906. 
 
181. Chong CR, Chen X, Shi L, Liu JO, & Sullivan DJ, Jr. (2006) A clinical drug 
library screen identifies astemizole as an antimalarial agent. Nat Chem Biol 
2(8):415-416. 
 
182. Berenbaum MC (1978) A method for testing for synergy with any number of 
agents. J Infect Dis 137(2):122-130. 
 
183. Falla TJ, Karunaratne DN, & Hancock RE (1996) Mode of action of the 
antimicrobial peptide indolicidin. J Biol Chem 271(32):19298-19303. 
 
184. Moneib NA (1995) In-vitro activity of commonly used antifungal agents in the 
presence of rifampin, polymyxin B and norfloxacin against Candida albicans. J 
Chemother 7(6):525-529. 
 
185. Schwartz SN, Medoff G, Kobayashi GS, Kwan CN, & Schlessinger D (1972) 
Antifungal properties of polymyxin B and its potentiation of tetracycline as an 
antifungal agent. Antimicrob Agents Chemother 2(1):36-40. 
 
186. Kwa A, Kasiakou SK, Tam VH, & Falagas ME (2007) Polymyxin B: similarities 
to and differences from colistin (polymyxin E). Exp Rev Anti Infect Ther 
5(5):811-821. 
 
187. Srimal S, Surolia N, Balasubramanian S, & Surolia A (1996) Titration 
calorimetric studies to elucidate the specificity of the interactions of polymyxin B 
with lipopolysaccharides and lipid A. Biochem J 315 ( Pt 2):679-686. 
 
188. Storm DR, Rosenthal KS, & Swanson PE (1977) Polymyxin and related peptide 
antibiotics. Ann Rev Biochem 46:723-763. 
 
189. HsuChen CC & Feingold DS (1973) The mechanism of polymyxin B action and 
selectivity toward biologic membranes. Biochemistry 12(11):2105-2111. 
 
190. Teuber M & Miller IR (1977) Selective binding of polymyxin B to negatively 
charged lipid monolayers. Biochim Biophys Acta 467(3):280-289. 
 
 139 
 
191. Jandrositz A, Turnowsky F, & Hogenauer G (1991) The gene encoding squalene 
epoxidase from Saccharomyces cerevisiae: cloning and characterization. Gene 
107(1):155-160. 
 
192. Anderson JB (2005) Evolution of antifungal-drug resistance: mechanisms and 
pathogen fitness. Nat Rev Microbiol 3(7):547-556. 
 
193. Odds FC, Brown AJ, & Gow NA (2003) Antifungal agents: mechanisms of 
action. Trends Microbiol 11(6):272-279. 
 
194. Garcia-Rivera J, Chang YC, Kwon-Chung KJ, & Casadevall A (2004) 
Cryptococcus neoformans CAP59 (or Cap59p) is involved in the extracellular 
trafficking of capsular glucuronoxylomannan. Eukaryot Cell 3(2):385-392. 
 
195. Hermsen ED, Sullivan CJ, & Rotschafer JC (2003) Polymyxins: pharmacology, 
pharmacokinetics, pharmacodynamics, and clinical applications. Infect Dis Clin 
North Am 17(3):545-562. 
 
196. Li J, et al. (2003) Use of high-performance liquid chromatography to study the 
pharmacokinetics of colistin sulfate in rats following intravenous administration. 
Antimicrob Agents Chemother 47(5):1766-1770. 
 
197. Zaragoza O, Alvarez M, Telzak A, Rivera J, & Casadevall A (2007) The relative 
susceptibility of mouse strains to pulmonary Cryptococcus neoformans infection 
is associated with pleiotropic differences in the immune response. Infect Immun 
75(6):2729-2739. 
 
198. Lass-Florl C, Dierich MP, Fuchs D, Semenitz E, & Ledochowski M (2001) 
Antifungal activity against Candida species of the selective serotonin-reuptake 
inhibitor, sertraline. Clin Infect Dis 33(12):E135-136. 
 
199. Lass-Florl C, et al. (2001) Antifungal properties of selective serotonin reuptake 
inhibitors against Aspergillus species in vitro. J Antimicrob Chemother 
48(6):775-779. 
 
200. Winek CL, Wahba WW, Winek CL, Jr., & Balzer TW (2001) Drug and chemical 
blood-level data 2001. Forensic Sci Int 122(2-3):107-123. 
 
201. Young TJ, Oliver GP, Pryde D, Perros M, & Parkinson T (2003) Antifungal 
activity of selective serotonin reuptake inhibitors attributed to non-specific 
cytotoxicity. J Antimicrob Chemother 51(4):1045-1047. 
 
 140 
 
202. Tremaine LM, Welch WM, & Ronfeld RA (1989) Metabolism and disposition of 
the 5-hydroxytryptamine uptake blocker sertraline in the rat and dog. Drug 
Metab Dispos 17(5):542-550. 
 
203. Cook EH, et al. (2001) Long-term sertraline treatment of children and 
adolescents with obsessive-compulsive disorder. J Am Acad Child Adolesc 
Psychiatry 40(10):1175-1181. 
 
204. Rapaport MH, et al. (2001) Sertraline treatment of panic disorder: results of a 
long-term study. Acta Psychiatr Scand 104(4):289-298. 
 
205. Rasmussen S, et al. (1997) A 2-year study of sertraline in the treatment of 
obsessive-compulsive disorder. Int Clin Psychopharmacol 12(6):309-316. 
 
206. Aberg-Wistedt A (1989) The antidepressant effects of 5-HT uptake inhibitors. Br 
J Psychiatry Suppl (8):32-40. 
 
207. Rainey MM, Korostyshevsky D, Lee S, & Perlstein EO (2010) The 
antidepressant sertraline targets intracellular vesiculogenic membranes in yeast. 
Genetics 185(4):1221-1233. 
 
208. Tuynder M, et al. (2004) Translationally controlled tumor protein is a target of 
tumor reversion. Proc Natl Acad Sci U S A 101(43):15364-15369. 
 
209. Lin CJ, Robert F, Sukarieh R, Michnick S, & Pelletier J (2010) The 
antidepressant sertraline inhibits translation initiation by curtailing mammalian 
target of rapamycin signaling. Cancer Res 70(8):3199-3208. 
 
210. MacDonald ML, et al. (2006) Identifying off-target effects and hidden 
phenotypes of drugs in human cells. Nat Chem Biol 2(6):329-337. 
 
211. Letendre SL, et al. (2007) The role of cohort studies in drug development: 
clinical evidence of antiviral activity of serotonin reuptake inhibitors and HMG-
CoA reductase inhibitors in the central nervous system. J Neuroimmune 
Pharmacol 2(1):120-127. 
 
212. Munoz-Criado S, Munoz-Bellido JL, & Garcia-Rodriguez JA (1996) In vitro 
activity of nonsteroidal anti-inflammatory agents, phenotiazines, and 
antidepressants against Brucella species. Eur J Clin Microbiol Infect Dis 
15(5):418-420. 
 
213. Munoz-Bellido JL, Munoz-Criado S, & Garcia-Rodriguez JA (2000) 
Antimicrobial activity of psychotropic drugs: selective serotonin reuptake 
inhibitors. Int J Antimicrob Agents 14(3):177-180. 
 141 
 
214. Peng Q, et al. (2008) The antidepressant sertraline improves the phenotype, 
promotes neurogenesis and increases BDNF levels in the R6/2 Huntington's 
disease mouse model. Exp Neurol 210(1):154-163. 
 
215. Kumar VS, et al. (2006) The spermicidal and antitrichomonas activities of SSRI 
antidepressants. Bioorg Med Chem Lett 16(9):2509-2512. 
 
216. Wu C, Amrani N, Jacobson A, & Sachs MS (2007) The use of fungal in vitro 
systems for studying translational regulation. Methods Enzymol 429:203-225. 
 
217. Hiemke C & Hartter S (2000) Pharmacokinetics of selective serotonin reuptake 
inhibitors. Pharmacol Ther 85(1):11-28. 
 
218. Heller I, Leitner S, Dierich MP, & Lass-Florl C (2004) Serotonin (5-HT) 
enhances the activity of amphotericin B against Aspergillus fumigatus in vitro. 
Int J Antimicrob Agents 24(4):401-404. 
 
219. Wang Z & Sachs MS (1997) Arginine-specific regulation mediated by the 
Neurospora crassa arg-2 upstream open reading frame in a homologous, cell-free 
in vitro translation system. J Biol Chem 272(1):255-261. 
 
220. Zhai B & Lin X (2011) Recent progress on antifungal drug development. Curr 
Pharm Biotechnol 12(8):1255-1262. 
 
221. Oliver JD (2010) Recent findings on the viable but nonculturable state in 
pathogenic bacteria. FEMS Microbiol Rev 34(4):415-425. 
 
222. Liu Y, Mittal R, Solis NV, Prasadarao NV, & Filler SG (2011) Mechanisms of 
Candida albicans trafficking to the brain. PLoS Pathog 7(10):e1002305. 
 
223. Huang Z, et al. (2013) A functional variomics tool for discovering drug-
resistance genes and drug targets. Cell Rep 3(2):577-585. 
 
224. Pierce CG & Lopez-Ribot JL (2013) Candidiasis drug discovery and 
development: new approaches targeting virulence for discovering and identifying 
new drugs. Expert Opt Drug Discov 8(9):1117-1126. 
 
 
